

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/087399 A1

- (51) International Patent Classification⁷: C12Q 1/26, A61K 31/03, 31/12, A61P 3/10 (74) Agent: HÖGLUND, Lars; Biovitrum AB, S-112 76 Stockholm (SE).
- (21) International Application Number: PCT/SE03/00618 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 16 April 2003 (16.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0201152-6 17 April 2002 (17.04.2002) SE
60/410,626 13 September 2002 (13.09.2002) US
- (71) Applicant (for all designated States except US): BIOVITRUM AB [SE/SE]; S-112 76 Stockholm (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GRÖNBERG, Alvar [SE/SE]; Tuvstarrvägen 7, S-741 42 Knivsta (SE). WIKSTRÖM, Per [SE/SE]; Tegelvägen 1 b, S-194 36 Upplands Väsby (SE).
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/087399 A1

(54) Title: NAD(P)H OXIDASE INHIBITORS FOR INCREASED GLUCOSE UPTAKE AND TREATMENT OF TYPE II DIABETES

(57) Abstract: The present invention relates to the use of NAD(P)H oxidase inhibitors to increase cellular uptake of glucose and in the treatment and/or prevention of diseases caused by insulin resistance or diseases related thereto, such as type II diabetes. Specifically, the invention relates to a method for identifying an agent useful for the treatment or prophylaxis of a medical condition associated with elevated levels of blood glucose, the method comprising (i) contacting a candidate agent with a mammalian NAD(P)H oxidase or NAD(P)H oxidase complex; and (ii) determining whether said candidate agent inhibits the biological activities of the NAD(P)H oxidase or NAD(P)H oxidase complex.

BEST AVAILABLE COPY

NAD(P)H Oxidase inhibitors for increased glucose uptake and treatment of type II diabetes.

TECHNICAL FIELD

The present invention relates to the use of NAD(P)H oxidase inhibitors to
5 increase cellular uptake of glucose and in the treatment and/or prevention of diseases
caused by insulin resistance or diseases related thereto, such as type II diabetes.

BACKGROUND ART

A large number of people suffer, or are predisposed to suffer from disturbances
10 in their metabolism. One such disturbance includes insulin resistance, which is
characteristic of the metabolic syndrome (syndrome X), polycystic ovary syndrome,
obesity and type II diabetes, diseases that are rapidly growing in number in the western
world. These diseases are multi-factorial and their mechanism or physiology are, in the
majority of cases, not well characterized or understood. Type II diabetes includes the
15 most prevalent form of diabetes, which results from insulin resistance with an insulin
secretory defect. Pharmacological treatments such as metformin and rosiglitazone have
an ameliorating effect on insulin resistance and are believed to increase the
effectiveness of endogenous insulin and thereby contribute to the lowering of elevated
blood glucose levels in type II diabetes patients.

20 One mechanism whereby insulin resistance may be induced is via elevation of
reactive oxygen species (ROS). Although contrasting effects of ROS have been reported
on the insulin signal transduction system and glucose transport, it has been shown that
prolonged exposure of cells to ROS causes insulin resistance. Insulinomimetic effects of
ROS have been reported using muscle cells and adipocytes. Acute exposure of
25 adipocytes to H_2O_2 was shown to activate pyruvate dehydrogenase activity and lipid
synthesis [May et al., Journal of Biological Chemistry, 254:9017-21 (1979)]. Some but
not all aspects of insulin signaling appear to be activated by H_2O_2 . Using L6 myocytes it
was shown that H_2O_2 caused a PI3K-dependent activation of PKB and inhibition of
GSK3 within 30 min of treatment [Tirosh et al., Journal of Biological Chemistry,
30 274:10595-602 (1999)]. Prolonged treatment (24 h) of L6 muscle cells and 3T3-L1
adipocytes with a ROS generating system increased the expression of GLUT1 that
resulted in elevated basal glucose transport [Kozlovsky et al., Free Radical Biology &
Medicine, 23:859-69 (1997); Kozlovsky et al., Journal of Biological Chemistry,

272:33367-72 (1997)]. Treatment of these cell lines with H_2O_2 also interferes with insulin signaling [Rudich et al., American Journal of Physiology, 272:E935-40 (1997)]. Simultaneous treatment with insulin and H_2O_2 was shown to inhibit insulin stimulated glucose transport and glycogen synthesis in spite of intact PKB activation [Blair et al.,
5 Journal of Biological Chemistry, 274:36293-9 (1999)]. Pretreatment with ROS inhibited insulin stimulated IRS-1 and PI3K cellular redistribution, PKB serine phosphorylation and glucose transport [Tirosh, Potashnik et al., Journal of Biological Chemistry, 274:10595-602 (1999)]. The antioxidant lipoic acid could prevent these effects [Rudich et al., Diabetologia, 42:949-57 (1999)]. Taken together, these results suggest that insulin
10 signaling involve redox reactions, with some steps that can be mimicked and some that can be inhibited by H_2O_2 . Integrating these findings with the demonstration that insulin can stimulate the production of H_2O_2 , it can be hypothesized that ROS are involved in insulin signaling and may be responsible for the insulin resistance observed after prolonged treatment with insulin and other agents.

15 Oxidative stress is caused by excess free radical production in cellular metabolism. The free radicals derived from reaction products of oxygen are often termed reactive oxygen species (ROS). A reducing environment inside the cell prevents oxidative damage and can be maintained by the action of antioxidant enzymes and substances, such as superoxide dismutase (SOD), catalase, glutathione, selenium-
20 dependent glutathione, thioredoxin hydroperoxidases, thioredoxin, vitamins C and E, and probably more unknown players.

Oxidative stress has been demonstrated in several different diseases and is implicated as an important driving force in the aging process [Finkel et al., Nature, 408:239-47 (2000); Spector, Journal of Ocular Pharmacology & Therapeutics, 16:193-
25 201 (2000)]. A growing body of data demonstrate signs of increased oxidative stress in type II diabetes. It is likely that the oxidative stress is contributing to many of the vascular complications occurring in the late stages of the disease but the evidence for oxidative stress as causative factor in the development of insulin resistance and deterioration of beta cell function is still lacking. An inverse relationship between
30 insulin action on glucose disposal and plasma superoxide ion, and a positive relationship between insulin action on glucose disposal and plasma GSH/GSSG ratio have been observed in type 2 diabetic patients during euglycemic hyperinsulinemic clamp [Paolisso et al., Metabolism: Clinical & Experimental, 43:1426-9 (1994)]. Decreased serum vitamin E content, a marker of impaired oxidant/antioxidant status,

was reported to be associated with increased risk of developing type II diabetes [Salonen et al., *BMJ*, 311:1124-7 (1995)]. In animal experiments it was recently demonstrated that chemically induced oxidative stress exacerbated insulin resistance and hyperglycemia in obese Zucker rats [Laight et al., *British Journal of Pharmacology*, 128:269-71 (1999)]. There are also indications that beta cell toxic agents like alloxan and streptozotocin that are used to induce experimental animal diabetes act via oxidative stress [Davis et al., *Biochemical Pharmacology*, 55:1301-7 (1998); Hotta et al., *Journal of Experimental Medicine*, 188:1445-51 (1998)].

Superoxide can be produced by a number of cellular enzyme systems: NAD(P)H oxidases, xanthine oxidase, lipoxygenases, cyclooxygenase, P-450 monooxygenases, and the enzymes of mitochondrial oxidative phosphorylation. The majority of free radicals are produced by the mitochondria as unwanted by-products of the respiratory chain but the cell also purposely generates free radicals. The cellular defense system of the body utilizes oxygen radicals to kill invading microorganisms and the vascular system uses the nitric oxide radicals as an intermediate in the regulation of vascular tone. Originally, the NAD(P)H oxidase system responsible for production of superoxide that participates in bacterial killing was demonstrated in neutrophils and other phagocyte cells [Segal et al., *Annals of the New York Academy of Sciences*, 832:215-22 (1997)]. A growing number of experimental data from endothelial cells and other cell types show that ROS can be produced through activation of NAD(P)H-oxidase [Jones et al., *American Journal of Physiology*, 271:H1626-34 (1996); Krieger-Brauer et al., *Journal of Biological Chemistry*, 272:10135-43 (1997); Bayraktutan et al., *Cardiovascular Research*, 38:256-62 (1998)]. When activated, the NAD(P)H oxidase assembles at the plasma membrane and catalyses the single electron reduction of molecular O_2 to superoxide (O_2^-). In the presence of superoxide dismutase, O_2^- dismutates to hydrogen peroxide (H_2O_2) that can be converted to a hydroxyl radical (OH^\cdot) in the presence of ferrous ions. The list of other free radicals originating from O_2^- that can be formed in the cell is longer, and will not be further discussed here. At least five proteins are required for the formation of an active NAD(P)H oxidase complex: the membrane bound cytochrome b558 and the cytosolic proteins, p47^{phox}, p67^{phox}, p40^{phox} and a small GTP-binding protein, Rac-1 or Rac-2 [Abo et al., *Journal of Biological Chemistry*, 267:16767-70 (1992); Babior, *Advances in Enzymology & Related Areas of Molecular Biology*, 65:49-95 (1992); Knaus et al., *Journal of Biological Chemistry*, 267:23575-82 (1992)]. Cytochrome b558 is a flavoprotein with an NAD(P)H-binding

site and consists of two subunits, gp91^{phox} and p22^{phox} [Sumimoto et al., Biochemical & Biophysical Research Communications, 186:1368-75 (1992)].

The hypoglycemic agent diphenylene iodonium (DPI) has been shown to diminish the rate of mitochondrial respiration by inhibiting NADH dehydrogenase.

- 5 Holland et al. (1973; J. Biol. Chem. 248: 6050-6056) discloses that the enzyme inhibition causes the hypoglycemic action by decreasing mitochondrial oxidation and the hepatic and whole body ATP content (See also Gatley, S.J. & Martin, J.L. (1979) Xenobiotica 9: 539-546). However, it has not been previously shown that agents which inhibit NAD(P)H oxidase would be useful for increasing the activity of the insulin
10 receptor and/or the intracellular insulin-signaling pathway, and thereby be useful against insulin resistance.

BRIEF DESCRIPTION OF THE DRAWINGS

- Fig. 1 is a graph depicting the effect of DPI on insulin stimulated glucose
15 transport in L6 cells when treated with different concentrations (0.1–10 μ M) of DPI alone for 30 min or together with insulin (200 or 1000 nM) for additional 30 min.

- Fig. 2 is a graph depicting the effect of H₂O₂ generated by glucose oxidase (GO) DPI stimulated glucose transport. Differentiated L6 cells were treated with 25 mU/ml GO for 30 min before addition of DPI. After additional 30 min, 200 nM insulin was
20 added and glucose transport was measured after 30 min.

Fig. 3 is a graph depicting blood glucose concentrations during an insulin tolerance test in ob/ob mice treated for 4 days with daily i.p. injections of DPI, 1 mg/kg (n=7), or vehicle (n=8).

25 DISCLOSURE OF THE INVENTION

- It has surprisingly been found that inhibition of NAD(P)H oxidase stimulates glucose uptake in rat skeletal muscle cells. A NAD(P)H oxidase complex is putatively involved in down-regulation of insulin signaling via generation of ROS. Thus, pharmacological inhibition of NAD(P)H oxidase activity should increase insulin
30 signaling and restore insulin sensitivity. This surprising effect has not been seen previously and demonstrates the utility of the entire, or parts of, NAD(P)H oxidase complex, which generates ROS, as a tool for finding drugs that can be used for treating type II diabetes, specifically insulin resistance.

Consequently, in a first aspect this invention provides a method for identifying an agent useful for the treatment or prophylaxis of a medical condition associated with elevated levels of blood glucose, said method comprising

- (i) contacting a candidate agent with a mammalian NAD(P)H oxidase or
5 NAD(P)H oxidase complex; and
- (ii) determining whether said candidate agent inhibits the biological activities of the NAD(P)H oxidase or NAD(P)H oxidase complex.

The said medical condition is preferably associated with insulin resistance, such as, in particular, type II diabetes. One clinical definition of diabetes is the so-called
10 fasting glucose level. A patient is diagnosed with diabetes if the amount of glucose is above 126 milligrams per deciliter (mg/dl) measured on two occasions. Impaired fasting glucose and impaired glucose tolerance are associated with the insulin resistance syndrome. An individual can be insulin resistant in the absence of fasting hyperglycemia if an oral glucose tolerance test with 75 g anhydrous glucose dissolved
15 in water gives a 2 h plasma glucose value ≥ 200 mg/dl in a test performed as described by WHO [World Health Organization, Tech. Rep. Ser., no. 727, (1985)].

In one embodiment of the invention, cells containing the NAD(P)H oxidase or the NAD(P)H oxidase complex may be brought into contact with inhibitors of the NAD(P)H oxidase or the NAD(P)H oxidase complex, followed by monitoring the
20 glucose uptake by these cells, and comparing this activity with that of a the NAD(P)H oxidase or the NAD(P)H oxidase complex in the absence of inhibitor. Compounds that affect the glucose uptake of these cells are to be considered as potential drug candidates.

The NAD(P)H oxidase or NAD(P)H oxidase complex is preferably selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1,
25 DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, and Rac-2.

The proteins may be of any mammalian species, however, a preferred species is *Homo sapiens*. The nucleotide and amino acid sequences from *Homo sapiens* are disclosed in the enclosed sequence listing.

In one embodiment, the invention includes a method for identifying an agent
30 that increases glucose uptake by a cell. The method includes the following steps: contacting a cell with a candidate agent that inhibits the activity of an NAD(P)H oxidase or an NAD(P)H oxidase complex; measuring glucose uptake by the cell in the presence of the candidate agent; and determining whether the candidate agent increases glucose uptake by the cell.

The method can optionally include an additional step of comparing glucose uptake by the cell in the presence of the candidate agent with glucose uptake by a cell in the absence of the candidate agent.

The method can optionally include a step of contacting the candidate agent with
5 the NAD(P)H oxidase or the NAD(P)H oxidase complex and determining that the candidate agent inhibits the activity of the NAD(P)H oxidase or the NAD(P)H oxidase complex.

In one example, the NAD(P)H oxidase or the NAD(P)H oxidase complex is a human NAD(P)H oxidase or a human NAD(P)H oxidase complex. The NAD(P)H
10 oxidase or the NAD(P)H oxidase complex can optionally be selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, and Rac-2. The nucleic acid and amino acid sequences of exemplary NAD(P)H oxidases and NAD(P)H oxidase complexes are described herein.

15 The cell can be, for example, a muscle cell or an adipocyte.

In some embodiments, the candidate agent is selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate, chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride acetovanillone, and derivatives thereof.

In another aspect, the invention features a method for increasing glucose uptake
20 in a cell by contacting a cell with an amount of an inhibitor of an NAD(P)H oxidase or an NAD(P)H oxidase complex effective to increase glucose uptake by the cell. The cell can be, for example, a muscle cell or an adipocyte. The method can optionally include an additional step of detecting an increase in glucose uptake by the cell in response to the contacting of the cell with the inhibitor.

25 In one example, the NAD(P)H oxidase or the NAD(P)H oxidase complex is a human NAD(P)H oxidase or a human NAD(P)H oxidase complex. The NAD(P)H oxidase or the NAD(P)H oxidase complex can optionally be selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, and Rac-2. The nucleic acid and
30 amino acid sequences of exemplary NAD(P)H oxidases and NAD(P)H oxidase complexes are described herein.

In some embodiments, the inhibitor is selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate, chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride acetovanillone, and derivatives thereof.

In another aspect, the invention provides a method for the treatment of a medical condition associated with elevated levels of blood glucose, comprising administering to a patient in need thereof an effective amount of an inhibitor or antagonist of NAD(P)H oxidase or NAD(P)H oxidase complex.

5 In one embodiment, the invention features a method for the treatment of a medical condition, including the following steps: selecting an individual diagnosed as having a medical condition characterized by elevated levels of blood glucose; and administering to the individual an amount of an inhibitor of an NAD(P)H oxidase or an NAD(P)H oxidase complex effective to reduce blood glucose levels in the individual.

10 The medical condition can be characterized by, for example, insulin resistance, a need for increased activity of the insulin receptor, and/or a need for increased activity of the intracellular insulin-signaling pathway.

In one example, the medical condition is diabetes, e.g., type II diabetes.

In some embodiments, the individual does not have and/or has not been
15 diagnosed as having a disorder (e.g., atherosclerosis) characterized by a vascular injury, e.g., vascular hyperpermeability of endothelial cells. In addition, in some embodiments, the method does not include a step of evaluating a vascular injury (if present) in the individual before and/or after the administration of the inhibitor to the individual.

In some embodiments, the method includes an additional step of detecting a
20 reduction in blood glucose levels in the individual in response to the administration of the inhibitor.

In one example, the NAD(P)H oxidase or the NAD(P)H oxidase complex is a human NAD(P)H oxidase or a human NAD(P)H oxidase complex. The NAD(P)H oxidase or the NAD(P)H oxidase complex can optionally be selected from the group
25 consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, and Rac-2. The nucleic acid and amino acid sequences of exemplary NAD(P)H oxidases and NAD(P)H oxidase complexes are described herein.

In some embodiments, the inhibitor is selected from the group consisting of
30 pyridine, imidazole, diethyl pyrocarbonate, chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride acetovanillone, and derivatives thereof.

The inhibitor or antagonist can be identified according to the method as described above. Examples of known inhibitors or antagonists are those selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate,

chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride and acetovanillone, including derivatives thereof. The said inhibitor or antagonist is e.g. a compound having an inhibitory effect on the ROS generating activity of the NAD(P)H oxidase or the NAD(P)H oxidase complex. The inhibitor or antagonist could exert its effect by
5 interacting with the active site or a regulatory site, or both sites, of the NAD(P)H oxidase.

A compound that shows the desirable characteristics with regards to inhibiting the activity of the NAD(P)H oxidase or the NAD(P)H oxidase complex will be further tested in an assay of insulin stimulated glucose uptake in differentiated L6-K1 cells or
10 other skeletal muscle cells, muscle tissue biopsies, adipocytes or adipocyte cell lines. An active compound should stimulate basal and insulin stimulated glucose uptake in a manner similar to the NAD(P)H oxidase inhibitor diphenylene iodonium (DPI). The compounds will preferably be of such nature that they are suited for oral administration, but any route of administration, such as, intravenous, suppository or parental routes will
15 be considered.

In yet another aspect, the invention provides the use of an NAD(P)H oxidase- or NAD(P)H oxidase complex inhibitor or antagonist, as described above, in the manufacture of a medicament for the treatment and/or prevention of a medical condition connected with elevated levels of blood glucose.

20 As defined herein, the term "prevent" or "treat" is not intended to exclusively mean the complete abolishment of the disease or condition, but is meant that there is complete or some amelioration, so that an improvement over the expected symptomology is clinically observed. An example of one such criterion could be the lowering of blood glucose levels by more than 25%. Other such criteria, well known in
25 the art, could be envisioned.

As defined herein, the term "reactive oxygen species" means compounds selected from the group comprising compounds or compound species such as H_2O_2 , OH^- and O_2^- . Compounds such as these will be referred to as "ROS".

As defined herein, the term "NAD(P)H oxidase" or "NAD(P)H oxidase
30 complex" means one of the proteins or any combination of two or more of the proteins selected from the group comprising the membrane bound cytochrome b558 consisting of gp91^{phox} (nucleotide sequence according to SEQ ID NO:1, amino acid sequence according to SEQ ID NO:2), p22^{phox} (nucleotide sequence according to SEQ ID NO:3, amino acid sequence according to SEQ ID NO:4), Mox2 (nucleotide sequence

according to SEQ ID NO:5, amino acid sequence according to SEQ ID NO:6), Nox4 (nucleotide sequence according to SEQ ID NO:7, amino acid sequence according to SEQ ID NO:8), Nox5 (nucleotide sequence according to SEQ ID NO:9, amino acid sequence according to SEQ ID NO:10), DUOX1 (nucleotide sequence according to SEQ ID NO:11, amino acid sequence according to SEQ ID NO:12), p138Tox (DUOX2) (nucleotide sequence according to SEQ ID NO:13, amino acid sequence according to SEQ ID NO:14), (b5+b5R) oxidoreductase (nucleotide sequence according to SEQ ID NO:15, amino acid sequence according to SEQ ID NO:16), and the cytosolic proteins, p47^{phox} (nucleotide sequence according to SEQ ID NO:17, amino acid sequence according to SEQ ID NO:18), p67^{phox} (nucleotide sequence according to SEQ ID NO:19, amino acid sequence according to SEQ ID NO:20), p40^{phox} (nucleotide sequence according to SEQ ID NO:21, amino acid sequence according to SEQ ID NO:22), and a small GTP-binding protein, Rac-1, (which has two different amino acid variants), (nucleotide sequence according to SEQ ID NO:23, amino acid sequence according to SEQ ID NO:24 and SEQ ID NO:25, respectively), or Rac-2, (nucleotide sequence according to SEQ ID NO:26, amino acid sequence according to SEQ ID NO:27), which combination gives rise to reactive oxygen species, or other proteins or assemblies of proteins which essentially have NAD(P)H oxidase activity. Preferably, these enzymes contain consensus sequences for FAD- and/or NAD(P)H-binding sites.

In addition to the specific NAD(P)H oxidase amino acid and nucleotide sequences described herein, fragments or variants thereof that retain NAD(P)H oxidase activity (or fragments or variants thereof that encode polypeptides that retain such activity) can be used in the methods of the invention (e.g., screening methods).

In some embodiments, a polypeptide used in a method of the invention differs from an NAD(P)H oxidase amino acid sequence described herein at one or more residues and yet retains NAD(P)H oxidase activity. The differences are, preferably, differences or changes at a non-essential residue or a conservative substitution. In one embodiment, a polypeptide includes an amino acid sequence that is at least about 60% identical to an NAD(P)H oxidase amino acid sequence described herein or a fragment thereof. Preferably, the polypeptide is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more identical to an NAD(P)H oxidase amino acid sequence described herein. Preferred polypeptide fragments are at least 10%, preferably at least 20%, 30%, 40%, 50%, 60%, 70%, or more, of the length of an NAD(P)H oxidase amino acid sequence described herein.

As used herein, "% identity" of two amino acid sequences, or of two nucleic acid sequences, is determined using the algorithm of Karlin and Altschul (PNAS USA 87:2264-2268, 1990), modified as in Karlin and Altschul, PNAS USA 90:5873-5877, 1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al. (J. Mol. Biol. 215:403-410, 1990). BLAST nucleotide searches are performed with the NBLAST program, score = 100, wordlength = 12. BLAST protein searches are performed with the XBLAST program, score = 50, wordlength = 3. To obtain gapped alignment for comparison purposes GappedBLAST is utilized as described in Altschul et al (Nucleic Acids Res. 25:3389-3402, 1997). When utilizing BLAST and GappedBLAST programs the default parameters of the respective programs (e.g., XBLAST and NBLAST) are used to obtain nucleotide sequences homologous to a nucleic acid molecule described herein.

The term "NAD(P)H oxidase activity", as described herein, refers to enzymatic activity of either the NAD(P)H oxidase or the NAD(P)H oxidase complex, as defined herein, whereby reactive oxygen species (ROS) are produced. Such enzymatic activity is readily established and procedures for this are well known to a skilled person. This activity is well known in the art and methods whereby this can be monitored are well known.

The term "inhibiting" with regards to ROS generating activity of the NAD(P)H oxidase or the NAD(P)H oxidase complex is meant the lowering of said activity to the range between 20%-100% of normal activity when measured with said methods. A preferred value of the inhibitory constant K_i is $<10 \mu\text{M}$, or more preferably $<1 \mu\text{M}$.

As defined herein, the term "NAD(P)H oxidase inhibitor" means any compound capable of lowering the activity of the NAD(P)H oxidase or the NAD(P)H oxidase complex, according to the above mentioned definition.

When activated, the NAD(P)H oxidase complex assembles at the plasma membrane and catalyses the single electron reduction of molecular O_2 to superoxide (O_2^-). In the presence of superoxide dismutase, O_2^- dismutates to hydrogen peroxide (H_2O_2) that can be converted to a hydroxyl radical (OH^\cdot) in the presence of ferrous ions. The list of other free radicals originating from O_2^- that can be formed in the cell is longer, and will not be further discussed here. Several proteins are required for the formation of an active NAD(P)H oxidase complex and may include: p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, Rac-2 [Lambeth et al. (2000) Trends Biochem. Sci. 25: 459-461].

A fully active complex producing oxygen radicals in the presence of NAD(P)H, FAD, GTP and amphiphilic compounds can be reconstituted *in vitro* with individual recombinant proteins [Rotrosen et al., Journal of Biological Chemistry, 268:14256-60 (1993)].

5 The invention will now be demonstrated by the following examples. These examples are for the purpose of illustration only and are not intended to limit the scope of the invention in any way. The information necessary for carrying out these experiments is supplied in the references. Any variations and adjustments that need to be made for correct function of these assays (variations in pH, concentration ranges, etc) will be apparent for a skilled person.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Suitable methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

EXAMPLES

EXAMPLE 1: The NAD(P)H oxidase inhibitor DPI increases glucose uptake in rat skeletal muscle cells

25 Cell culture medium, fetal bovine serum, antibiotics, trypsin-EDTA were purchased from Life Technologies. Diphenylene iodonium (DPI), cytidine, bovine insulin, bovine serum albumin, and glucose oxidase were purchased from Sigma. 2-Deoxy-[³H] glucose (specific activity 1102.6 GBq/mmol) was purchased from NEN Life Science Products and 2-Deoxy-[¹⁴C] glucose from Amersham Pharmacia Biotech. Tissue culture plastics were purchased from Becton Dickinson.

30 Rat skeletal muscle L6-K cells were grown in minimal essential medium (α -MEM Glutamax I) containing 10% fetal bovine serum at 37°C, 5% CO₂. The cells were passaged twice weekly by treatment with trypsin-EDTA and transfer of 1/3 of the cells to new flasks with fresh culture medium. For differentiation into myotubes, 30,000 cells

were seeded in 1 ml in 24-well plates. When the cells were confluent, usually after 3 days, the medium was replaced by differentiation medium consisting of α -MEM, 2% fetal bovine serum and penicillin/streptomycin at a concentration of 100 U/ml and 100 μ g/ml, respectively. The medium was replaced every 2-3 days. Between days 4-7, differentiation medium containing 1 mM cytidine was used. The cells were differentiated for 8-10 days before being used in experiments.

On the day before the glucose transport assay, the wells of the culture plate were emptied and 1 ml serum free DMEM containing 5 mM glucose and penicillin/streptomycin was added. In some experiments the cells were treated over night with test compounds in 1 ml and additional treatments were added the next day to give a total volume of 2 ml. In these experiments, insulin (100-1000 nM) was added in 0.2 ml. When all treatments were performed after 20-24 h in serum free medium, a total volume of 1 ml was used. The wells were emptied and 0.5 ml prewarmed PBS without $\text{Ca}^{2+}/\text{Mg}^{2+}$ containing 1 μ Ci/ml radioactive 2-deoxy-glucose added. After 10 min at 37°C, the wells were emptied and washed three times with cold PBS. The cell monolayer was solubilized in 0.5 ml 0.5 M NaOH for 3 h at room temperature. 400 μ l was mixed with 8 ml scintillation fluid (Optiphase, Wallac) and counted in a scintillation counter (Packard TriCarb). Two 10- μ l aliquots were used for determination of protein concentration using the method according to Bradford (Anal. Biochem., 1976, 72:248-54) from BioRad.

When differentiated L6 cells are incubated with the NAD(P)H oxidase inhibitor DPI [O'Donnell V.B. et al. (1993) Biochem. J. 290: 41-49] a significant increase in glucose uptake can be observed (Fig. 1). This increase is comparable to or greater than that caused by insulin. This effect is seen when cells are stimulated with 0.1-10 μ M DPI for 1 h. A bell-shaped dose response curve for DPI with an optimum at 1 μ M is recorded. The effect of suboptimal concentrations of DPI during a 1 h treatment could be stimulated further if insulin is added 30 min after DPI. However, insulin has little additional effect when the maximum effect of DPI is reached in the 1 h protocol (Fig. 1). The effective concentrations at which DPI stimulates glucose transport corresponds well to the concentrations inhibiting NAD(P)H oxidase activity in cell free systems [O'Donnell et al., Biochemical Journal, 290:41-9 (1993)]. These results suggest that DPI stimulates glucose transport via activation of the same mechanism as insulin. On the basis of the above results it is postulated that DPI enhances a constitutive activity of the insulin receptor and/or the intracellular insulin-signaling pathway. The existence of such

a constitutive activity is suggested from experiments in which adipocytes have been transfected with the tyrosine phosphatase PTP1B [Chen et al., Journal of Biological Chemistry, 272:8026-31 (1997)]. These data are compatible with DPI augmenting constitutive intracellular signaling via the same pathway that is used by insulin.

5
EXAMPLE 2: Glucose oxidase reduces the effect of DPI on glucose uptake

Assuming that the enhancing effect of DPI on insulin signaling was due to inhibition of ROS production, it was investigated whether an exogenous source of H_2O_2 could counteract the effect of DPI. To this end, L6 cells were treated with 25 mU/ml of glucose oxidase for 30 min before addition of DPI. Such a treatment has previously
10 been shown to result in a steady production of micromolar concentrations of H_2O_2 that can freely pass the cell membrane and cause inhibition of insulin signaling [Tirosh, Potashnik et al., Journal of Biological Chemistry, 274:10595-602 (1999)].

It was found that glucose oxidase reduced the stimulatory effect of DPI by 68%
15 and insulin stimulated glucose transport by 65% (Fig. 2). The available results suggest that H_2O_2 can counteract the effect of DPI in addition to inducing insulin resistance. This further strengthens the similarity between the effects of insulin and DPI and shows that DPI acts by inhibiting H_2O_2 production. In spite of superoxide being the primary product of NAD(P)H oxidase, H_2O_2 is the main effector in the cell since superoxide is
20 converted to H_2O_2 by superoxide dismutase.

EXAMPLE 3: DPI decreases blood glucose levels in ob/ob mice

Studies were conducted *in vivo*, in an animal model of obesity characterized by insulin resistance. Eight-month old C57BL/6J ob/ob mice (M&B A/S, Denmark) were
25 matched for sex, weight and fasting blood glucose concentrations. The animals were injected intraperitoneally once daily with DPI (1 mg/kg) or water for 4 days. On day 5, the animals were fasted for 2.5 h and then given an i.p. injection of human insulin 0.5 U/kg (Actrapid, Novo Nordisk, Denmark) and their blood glucose levels were monitored for 4 h by sampling from the tail. The glucose concentration was determined
30 using a Glucometer Accutrend Sensor (Roche).

Without any overt side effects of the DPI treatment, the treated animals exhibited significantly lower blood glucose levels than the control group 1-4 h after injection of insulin, suggesting a decreased insulin resistance (Fig. 3).

EXAMPLE 4: Identification of agents inhibiting NAD(P)H oxidase

Methods to be used for identifying compounds that inhibit the activity of the NAD(P)H oxidase complex are illustrated.

(A) Neutrophil membrane and cytosol assay for superoxide mediated cytochrome c reduction (Diatchuk, V. et al. (1997) J. Biol. Chem. 272: 13292-13301). Sources of neutrophil membranes and cytosol from buffy coats of normal donors are obtainable from the Blood Bank. Enzyme cofactors and cytochrome c for detection of superoxide-mediated reduction are commercially available. The assay is based on a color change that occurs upon reduction of cytochrome c. This change can be measured as a change in light absorbance using a standard microplate spectrophotometer.

(B) Neutrophil membrane + recombinant p47^{phox}, p67^{phox} and rac1 for superoxide-mediated cytochrome c reduction (absorbance) (Nisimoto, Y. et al. (1997) J. Biol. Chem. 272: 18834-18841).

(C) Fully recombinant NAD(P)H oxidase assay for superoxide mediated cytochrome c reduction [Rotrosen, D. et al, (1993) J. Biol. Chem. 268: 14256-14260].

(D) Fluorescence assay, which measures the interaction between rac and p67^{phox} [Nisimoto, Y. et al. (1997) J. Biol. Chem. 272: 18834-18841]. This assay would limit the screening to detection of compounds interfering with this particular step in the activation of the oxidase. The fluorescent GTP analog 2'-(or-3')-O-(N-methylanthraniloyl)- β - γ -imidoguanosine 5'-triphosphate (MANT-GMPPNP, available from Molecular Probes), binds tightly to Rac, and shows an increase in fluorescence when p67^{phox} is added, indicating complex formation. Rac1 and Rac2 bind to p67^{phox} with a 1:1 stoichiometry and with K_d values of 120 nM and 60 nM, respectively.

(E) Binding assay utilizing ¹²⁵I- or fluorescence labeled mastoparan. Mastoparan is a peptide present in wasp venom that has been shown to inhibit NAD(P)H oxidase activation, most likely via its ability to bind to p67^{phox} [Tisch-Idelson, D., et al.(2001) Biochemical Pharmacology 61: 1063-1071].

(F) Test compounds can be analyzed in a nitroblue tetrazolium reduction assay utilizing a thioredoxin-gp91^{phox} fusion protein. This protein has weak diaphorase activity in the presence of NAD(P)H and FAD and is inhibited by DPI.

(G) Test compounds can be added in appropriate amounts to cultured cells. The reactive oxygen species released from said cells may be measured with the use of a probe, resorufin, which becomes fluorescent in the presence of hydrogen peroxide and a peroxidase [Zhou, M. et al., (1997) Anal. Biochem., 253: 162-168].

Intracellular production of ROS can be measured with the use of various cell permeable analogs of dichlorofluorescein acetate as described by Xie, J.I. et al. [(1999) J. Biol. Chem. 274: 19323-19328].

CLAIMS

1. A method for identifying an agent that increases glucose uptake by a cell, the method comprising:
 - 5 contacting a cell with a candidate agent that inhibits the activity of an NAD(P)H oxidase or an NAD(P)H oxidase complex;
 measuring glucose uptake by the cell in the presence of the candidate agent; and
 determining whether the candidate agent increases glucose uptake by the cell.
- 10 2. The method of claim 1, wherein the NAD(P)H oxidase or the NAD(P)H oxidase complex is a human NAD(P)H oxidase or a human NAD(P)H oxidase complex.
3. The method of claim 1, wherein the cell is a muscle cell.
- 15 4. The method of claim 1, wherein the cell is an adipocyte.
5. The method of claim 1, wherein the NAD(P)H oxidase or the NAD(P)H oxidase complex is selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox,
20 p40phox, Rac-1, and Rac-2.
6. The method of claim 1, wherein the candidate agent is selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate, chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride acetovanillone, and derivatives thereof.
25
7. The method of claim 1, further comprising comparing glucose uptake by the cell in the presence of the candidate agent with glucose uptake by a cell in the absence of the candidate agent.
- 30 8. The method of claim 1, further comprising contacting the candidate agent with the NAD(P)H oxidase or the NAD(P)H oxidase complex and determining that the candidate agent inhibits the activity of the NAD(P)H oxidase or the NAD(P)H oxidase complex.

9. A method for increasing glucose uptake in a cell, the method comprising contacting a cell with an amount of an inhibitor of an NAD(P)H oxidase or an NAD(P)H oxidase complex effective to increase glucose uptake by the cell.

5 10. The method of claim 9, further comprising detecting an increase in glucose uptake by the cell in response to the contacting of the cell with the inhibitor.

11. The method of claim 9, wherein the cell is a muscle cell.

10 12. The method of claim 9, wherein the cell is an adipocyte.

13. The method of claim 9, wherein the NAD(P)H oxidase or the NAD(P)H oxidase complex is selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox,
15 p40phox, Rac-1, and Rac-2.

14. The method of claim 9, wherein the NAD(P)H oxidase or the NAD(P)H oxidase complex is a human NAD(P)H oxidase or a human NAD(P)H oxidase complex.

20 15. The method of claim 9, wherein the inhibitor is selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate, chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride acetovanillone, and derivatives thereof.

25 16. A method for the treatment of a medical condition, the method comprising:
selecting an individual diagnosed as having a medical condition characterized by elevated levels of blood glucose; and
administering to the individual an amount of an inhibitor of an NAD(P)H oxidase or an NAD(P)H oxidase complex effective to reduce blood glucose levels in the individual.

30 17. The method of claim 16, further comprising detecting a reduction in blood glucose levels in the individual in response to the administration of the inhibitor.

18. The method of claim 16, wherein the medical condition is characterized by insulin resistance.

19. The method of claim 16, wherein the medical condition is characterized by a need for increased activity of the insulin receptor.

20. The method of claim 16, wherein the medical condition is characterized by a need for increased activity of the intracellular insulin-signaling pathway.

21. The method of claim 16, wherein the medical condition is diabetes.

22. The method of claim 21, wherein the medical condition is type II diabetes.

23. The method of claim 16, wherein the NAD(P)H oxidase or the NAD(P)H oxidase complex is selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, and Rac-2.

24. The method of claim 16, wherein the NAD(P)H oxidase or the NAD(P)H oxidase complex is a human NAD(P)H oxidase or a human NAD(P)H oxidase complex.

25. The method of claim 16, wherein the inhibitor is selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate, chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride acetovanillone, and derivatives thereof.

26. Use of an inhibitor of an NAD(P)H oxidase or an NAD(P)H oxidase complex, effective to increase glucose uptake by the cell, in the manufacture of a medicament for increasing glucose uptake in a cell.

Fig. 1




Fig. 2





Fig. 3



SEQUENCE LISTING

<110> Biovitrum AB
 <120> New use
 <130> BV-1000
 <160> 27
 <170> PatentIn version 3.1

<210> 1
 <211> 4266
 <212> DNA
 <213> Homo sapiens

<400> 1
 cttcctctgc caŕcatgggg aactgggctg tgaatgaggg gctctccatt tttgtcattc 60
 tggtttggtt ggggttgaac gtcttcctct ttgtctggta ttaccgggtt tatgatattc 120
 cacctaagtt cttttacaca agaaaacttc ttgggtcagc actggcactg gccagggccc 180
 ctgcagcctg cctgaatttc aactgcatgc tgattctctt gccagtctgt cgaaatctgc 240
 tgtccttctt caggggttcc agtgctgct gctcaacaag agttcgaaga caactggaca 300
 ggaatctcac ctttcataaa atggtggcat ggatgattgc acttcactct gcgattcaca 360
 ccattgcaca tctatttaat gtggaatggt gtgtgaatgc ccgagtcaat aattctgatc 420
 cttattcagt agcactctct gaacttggag acaggcaaaa tgaaagttat ctcaattttg 480
 ctcgaaagag aataaagaac cctgaaggag gcctgtacct ggctgtgacc ctggtggcag 540
 gcatactgg agttgtcatc acgctgtgcc tcatattaat tatcacttcc tccacaaaaa 600
 ccatccggag gtcttacttt gaagtctttt ggtacacaca tcatctcttt gtgatcttct 660
 tcattggcct tgccatccat ggagctgaac gaattgtacg tgggcagacc gcagagagtt 720
 tggctgtgca taatataaca gtttgtgaac aaaaaatctc agaatgggga aaaataaagg 780
 aatgcccaat ccctcagttt gctggaaacc ctctatgac ttggaaatgg atagtgggtc 840
 ccatgtttct gtatctctgt gagaggttgg tgcggttttg gcgatctcaa cagaagggtg 900
 tcatcaccaa ggtggtcact caccctttca aaaccatcga gctacagatg aagaagaagg 960
 ggttcaaaat ggaagtggga caatacatth ttgtcaagtg cccaaagggtg tccaagctgg 1020
 agtggcaccc ttttactg acatccgccc ctgaggaaga cttctttagt atccatatcc 1080
 gcacgttggt ggactggaca gaggggctgt tcaatgcttg tggctgtgat aagcaggagt 1140
 ttcaagatgc gtggaaacta cctaagatag cggttgatgg gccctttggc actgccagt 1200
 aagatgtggt cagctatgag gtggtgatgt tagtgggagc agggattggg gtcacaccct 1260

tgcgcatccat tctcaagtca gtctggtaca aatattgcaa taacgccacc aatctgaagc 1320
tcaaaaagat ctactttctac tggctgtgcc gggacacaca tgcctttgag tggtttgag 1380
atctgctgca actgctggag agccagatgc aggaaaggaa caatgccggc ttcctcagct 1440
acaacatcta cctcactggc tgggatgagt ctcaggccaa tcactttgct gtgcaccatg 1500
atgaggagaa agatgtgatc acaggcctga aacaaaagac tttgtatgga cggcccaact 1560
gggataatga attcaagaca attgcaagtc aacaccctaa taccagaata ggagttttcc 1620
tctgtggacc tgaagccttg gctgaaaccc tgagtaaaca aagcatctcc aactctgagt 1680
ctggccctcg gggagtgcac ttcattttca acaaggaaaa cttctaactt gtctcttcca 1740
tgaggaaata aatgtgggtt gtgctgccaa atgctcaaata aatgctaatt gataatataa 1800
ataccccctg cttaaaaatg gacaaaaaga aactataatg taatggtttt cccttaaagg 1860
aatgtcaaag attgtttgat agtgataagt tacatttatg tggagctcta tggttttgag 1920
agcactttta caaacattat ttcatttttt ttcctctcagt aatgtcagtg gaagttaggg 1980
aaaagattct tggactcaat tttagaatca aaagggaag gatcaaaagg ttcagtaact 2040
tccctaagat tatgaaactg tgaccagatc tagcccatct tactccaggt ttgatactct 2100
ttccacaata ctgagctgcc tcagaatcct caaaatcagt ttttatattc cccaaaagaa 2160
gaaggaaacc aaggagtagc tatatatttc tactttgtgt catttttgcc atcattatta 2220
tcatactgaa ggaaattttc cagatcatta ggacataata catgttgaga gtgtctcaac 2280
acttattagt gacagtattg acatctgagc atactccagt ttactaatac agcagggtaa 2340
ctgggccaga tgttctttct acagaagaat attggattga ttggagttaa tgtaatactc 2400
atcatttacc actgtgcttg gcagagagcg gatactcaag taagttttgt taaatgaatg 2460
aatgaattta gaaccacaca atgccaagat agaattaatt taaagcctta aacaaaattt 2520
atctaaagaa ataacttcta ttactgtcat agaccaaagg aatctgattc tccctaggg 2580
caagaacagg ctaaggatac taaccaatag gattgcctga agggttctgc acattcttat 2640
ttgaagcatg aaaaaagagg gttggagggtg gagaattaac ctcttgccat gactctggct 2700
catctagtcc tgctccttgt gctataaaat aaatgcagac taatttcctg cccaaagtgg 2760
tcttctccag ctagccctta tgaatattga acttaggaat tgtgacaaat atgtatctga 2820
tatggtcatt tgttttaaat aacccccacc cttattttc cgtaaataca cacacaaaat 2880
ggatcgcatc tgtgtgacta atggtttatt tgtattatat catcatcatc atcctaaaat 2940
taacaacca gaaacaaaaa tctctataca gagatcaaat tcacactcaa tagtatgttc 3000
tgaatatatg ttcaagagag agtctctaaa tcactgttag tgtggccaag agcagggttt 3060

3/61

```

tctttttgtt cttagaactg ctcccatttc tgggaactaa aaccagtttt atttgcccca 3120
cccttgagg ccacaaatgt ttagaactct tcaacttcgg taatgaggaa gaaggagaaa 3180
gagctggggg aagggcagaa gactggttta ggagggaaaag gaaataagga gaaaagagaa 3240
tgaggagagt agagaaaata aaaaaggcaa aaggggagaga gaggggaagg ggggtctcata 3300
ttggtcattc cctgccccag atttcttaaa gtttgatatg tatagaatat aattgaagga 3360
gggtatacaca tactgatgtt gttttgatta tctatggat tgaatctttt aaaatctggg 3420
cacaaatttt gatgctgagg gggattattc aagggactag gatgaactaa ataagaactc 3480
agttgttctt tgtcatacta ctattccttt cgtctcccag aatcctcagg gcactgaggg 3540
taggtctgac aaataaggcc tgctgtgcga atatagcctt tctgaaatgt accaggatgg 3600
tttctgctta gagacactta ggtccagcct gttcacactg cacctcaggt atcaattcat 3660
ctattcaaca gatatttatt gtgttattac tatgagtcag gctctgttta ttgtttcaat 3720
tctttacacc aaagtatgaa ctggagaggg tacctcagtt ataaggagtc tgagaatatt 3780
ggccctttct aacctatgtg cataattaaa accagcttca tttgttgctc cgagagtgtt 3840
tctccaaggt tttctatctt caaaaccaac taagttatga aagtagagag atctgccctg 3900
tgttatccag ttatgagata aaaaatgaat ataagagtgc ttgtcattat aaaagtttcc 3960
tttttatctc tcaagccacc agctgccagc caccacgagc cagctgccag cctagctttt 4020
tttttttttt ttttttttagc acttagtatt tagcatttat taacaggtac tctaagaatg 4080
atgaagcatt gtttttaatc ttaagactat gaaggttttt cttagttctt ctgcttttgc 4140
aattgtgttt gtgaaatttg aatacttgca ggctttgtat gtgaataatt ctagcggggg 4200
acctgggaga taattctacg gggaattctt aaaactgtgc tcaactatta aaatgaatga 4260
gctttc 4266

```

<210> 2
 <211> 570
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Gly Asn Trp Ala Val Asn Glu Gly Leu Ser Ile Phe Val Ile Leu
 1 5 10 15
 Val Trp Leu Gly Leu Asn Val Phe Leu Phe Val Trp Tyr Tyr Arg Val
 20 25 30
 Tyr Asp Ile Pro Pro Lys Phe Phe Tyr Thr Arg Lys Leu Leu Gly Ser
 35 40 45
 Ala Leu Ala Leu Ala Arg Ala Pro Ala Ala Cys Leu Asn Phe Asn Cys
 50 55 60

4/61

Met Leu Ile Leu Leu Pro Val Cys Arg Asn Leu Leu Ser Phe Leu Arg
 65 70 75 80
 Gly Ser Ser Ala Cys Cys Ser Thr Arg Val Arg Arg Gln Leu Asp Arg
 85 90 95
 Asn Leu Thr Phe His Lys Met Val Ala Trp Met Ile Ala Leu His Ser
 100 105 110
 Ala Ile His Thr Ile Ala His Leu Phe Asn Val Glu Trp Cys Val Asn
 115 120 125
 Ala Arg Val Asn Asn Ser Asp Pro Tyr Ser Val Ala Leu Ser Glu Leu
 130 135 140
 Gly Asp Arg Gln Asn Glu Ser Tyr Leu Asn Phe Ala Arg Lys Arg Ile
 145 150 155 160
 Lys Asn Pro Glu Gly Gly Leu Tyr Leu Ala Val Thr Leu Leu Ala Gly
 165 170 175
 Ile Thr Gly Val Val Ile Thr Leu Cys Leu Ile Leu Ile Ile Thr Ser
 180 185 190
 Ser Thr Lys Thr Ile Arg Arg Ser Tyr Phe Glu Val Phe Trp Tyr Thr
 195 200 205
 His His Leu Phe Val Ile Phe Phe Ile Gly Leu Ala Ile His Gly Ala
 210 215 220
 Glu Arg Ile Val Arg Gly Gln Thr Ala Glu Ser Leu Ala Val His Asn
 225 230 235 240
 Ile Thr Val Cys Glu Gln Lys Ile Ser Glu Trp Gly Lys Ile Lys Glu
 245 250 255
 Cys Pro Ile Pro Gln Phe Ala Gly Asn Pro Pro Met Thr Trp Lys Trp
 260 265 270
 Ile Val Gly Pro Met Phe Leu Tyr Leu Cys Glu Arg Leu Val Arg Phe
 275 280 285
 Trp Arg Ser Gln Gln Lys Val Val Ile Thr Lys Val Val Thr His Pro
 290 295 300
 Phe Lys Thr Ile Glu Leu Gln Met Lys Lys Lys Gly Phe Lys Met Glu
 305 310 315 320
 Val Gly Gln Tyr Ile Phe Val Lys Cys Pro Lys Val Ser Lys Leu Glu
 325 330 335
 Trp His Pro Phe Thr Leu Thr Ser Ala Pro Glu Glu Asp Phe Phe Ser
 340 345 350
 Ile His Ile Arg Ile Val Gly Asp Trp Thr Glu Gly Leu Phe Asn Ala
 355 360 365
 Cys Gly Cys Asp Lys Gln Glu Phe Gln Asp Ala Trp Lys Leu Pro Lys
 370 375 380

5/61

Ile Ala Val Asp Gly Pro Phe Gly Thr Ala Ser Glu Asp Val Phe Ser
 385 390 395 400

Tyr Glu Val Val Met Leu Val Gly Ala Gly Ile Gly Val Thr Pro Phe
 405 410 415

Ala Ser Ile Leu Lys Ser Val Trp Tyr Lys Tyr Cys Asn Asn Ala Thr
 420 425 430

Asn Leu Lys Leu Lys Lys Ile Tyr Phe Tyr Trp Leu Cys Arg Asp Thr
 435 440 445

His Ala Phe Glu Trp Phe Ala Asp Leu Leu Gln Leu Leu Glu Ser Gln
 450 455 460

Met Gln Glu Arg Asn Asn Ala Gly Phe Leu Ser Tyr Asn Ile Tyr Leu
 465 470 475 480

Thr Gly Trp Asp Glu Ser Gln Ala Asn His Phe Ala Val His His Asp
 485 490 495

Glu Glu Lys Asp Val Ile Thr Gly Leu Lys Gln Lys Thr Leu Tyr Gly
 500 505 510

Arg Pro Asn Trp Asp Asn Glu Phe Lys Thr Ile Ala Ser Gln His Pro
 515 520 525

Asn Thr Arg Ile Gly Val Phe Leu Cys Gly Pro Glu Ala Leu Ala Glu
 530 535 540

Thr Leu Ser Lys Gln Ser Ile Ser Asn Ser Glu Ser Gly Pro Arg Gly
 545 550 555 560

Val His Phe Ile Phe Asn Lys Glu Asn Phe
 565 570

<210> 3

<211> 687

<212> DNA

<213> Homo sapiens

<400> 3

gcagtgtccc agccgggttc gtgtcgccat ggggcagatc gagtgggcca tgtggggcaa 60

cgagcaggcg ctggcgctccg gctgatacct catcaccggg ggcacgtgg ccacagctgg 120

gcgcttcacc cagtgggtact ttggtgccta ctccattgtg gcgggcgtgt ttgtgtgctt 180

gctggagtac ccccggggga agaggaagaa gggctccacc atggagcgct ggggacagaa 240

gcacatgacc gccgtggtga agctgttcgg gccctttacc aggaattact atgttcgggc 300

cgctctgcat ctctgctct cggtgcccgc cggcttcctg ctggccacca tccttgggac 360

cgctgctg gccattgcga gcggcatcta cctactggcg gctgtgcgtg gcgagcagt 420

gacgcccata gagcccaagc cccgggagcg gccgcagatc ggaggcacca tcaagcagcc 480

gcccagcaac cccccgccgc gggccccggc cgaggccgc aagaagccca gcgaggagga 540

6/61

ggctgcggcg gcggcggggg gacccccggg aggtccccag gtcaaccca tcccgggtgac 600
 cgacgaggtc gtgtgacctc gccccggacc tgcctccca ccaggtgcac ccacctgcaa 660
 taaacgcagc gaaggccggg aaaaaaa 687

<210> 4
 <211> 195
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Gly Gln Ile Glu Trp Ala Met Trp Ala Asn Glu Gln Ala Leu Ala
 1 5 10 15
 Ser Gly Leu Ile Leu Ile Thr Gly Gly Ile Val Ala Thr Ala Gly Arg
 20 25 30
 Phe Thr Gln Trp Tyr Phe Gly Ala Tyr Ser Ile Val Ala Gly Val Phe
 35 40 45
 Val Cys Leu Leu Glu Tyr Pro Arg Gly Lys Arg Lys Lys Gly Ser Thr
 50 55 60
 Met Glu Arg Trp Gly Gln Lys His Met Thr Ala Val Val Lys Leu Phe
 65 70 75 80
 Gly Pro Phe Thr Arg Asn Tyr Tyr Val Arg Ala Val Leu His Leu Leu
 85 90 95
 Leu Ser Val Pro Ala Gly Phe Leu Leu Ala Thr Ile Leu Gly Thr Ala
 100 105 110
 Cys Leu Ala Ile Ala Ser Gly Ile Tyr Leu Leu Ala Ala Val Arg Gly
 115 120 125
 Glu Gln Trp Thr Pro Ile Glu Pro Lys Pro Arg Glu Arg Pro Gln Ile
 130 135 140
 Gly Gly Thr Ile Lys Gln Pro Pro Ser Asn Pro Pro Pro Arg Pro Pro
 145 150 155 160
 Ala Glu Ala Arg Lys Lys Pro Ser Glu Glu Glu Ala Ala Ala Ala Ala
 165 170 175
 Gly Gly Pro Pro Gly Gly Pro Gln Val Asn Pro Ile Pro Val Thr Asp
 180 185 190
 Glu Val Val
 195

<210> 5
 <211> 2044
 <212> DNA
 <213> Homo sapiens

<400> 5
 caaagacaaa ataatttact aggaagccc ttactaacga cccaacatcc agacacaggt 60

gagggagaag aaatttctctg acagccgaag agcaacaagt atcatgatgg ggtgctggat 120
tttgaatgag ggtctctcca ccatattagt actctcatgg ctgggaataa atttttatct 180
gtttattgac acgttctact ggtatgaaga ggaggagtct ttccattaca cagagttat 240
tttgggttca aacttggtt gggcacgagc atccgactg tgcctgaatt ttaactgcat 300
gctaattcta atacctgtca gtcgaaacct tatttcattc ataagaggaa caagtatttg 360
ctgcagagga ccgtggagga ggcaattaga caaaaacctc agatttcaca aactggctgc 420
ctatgggata gctgttaatg caaccatcca catcgtggcg catttcttca acctggaacg 480
ctaccactgg agccagtccg aggaggccca gggacttctg gccgcacttt ccaagctggg 540
caacacctt aacgagagct acctcaacct tgtccggacc ttccccacaa acacaaccac 600
tgaattgcta aggacaatag caggcgtcac cggctctggg atctctctgg cttagtctt 660
gatcatgacc tcgtcaactg agttcatcag acaggcctcc tatgagttgt tctggtacac 720
acaccatgtt ttcactgtct tctttctcag cctggccatc catgggacgg gtcggattgt 780
tcgaggccaa acccaagaca gtctctctct gcacaacatc accttctgta gagaccgcta 840
tgcagaatgg cagacagtgg cccaatgcc cgtgcctcaa ttttctggca aggaacctc 900
ggcttggaag tggatttttag gccctgtggg cttgtatgca tgtgaaagaa taattaggtt 960
ctggcgattt caacaagaag ttgtcattac caagggtgta agccacctt ctggagtctt 1020
ggaacttcac atgaaaaagc gtggctttta aatggcgcca gggcagtaca tcttggtgca 1080
gtgcccagcc atatcttcgc tggagtggca ccccttcacc cttacctctg cccccagga 1140
agactttttc agcgtgcaca tccgggcagc aggagactgg acagcagcgc tactggaggc 1200
ctttggggca gaggacagg ccctccagga gccctggagc ctgccaaggc tggcagtgga 1260
cgggcccttt ggaactgcc tgacagatgt atttcactac ccagtgtgtg tgtgcgttgc 1320
cgcggggatc ggagtcactc cttctgctgc tcttctgaaa tctatatggt acaaatgcag 1380
tgaggcacag accccactga agctgagcaa ggtgtatttc tactggattt gccgggatgc 1440
aagagctttt gagtggtttg ctgatctctt actctccctg gaaacacgga tgagtgcag 1500
ggggaaaact cactttctga gttatcatat atttcttacc ggctgggatg aaaatcaggc 1560
tcttcacata gctttactt gggacgaaaa tactgacgtg attacaggct taaagcagaa 1620
gaccttctat gggaggccca actggaacaa tgagttcaag cagattgcct acaatcacc 1680
cagcagcagt attggcgtgt tcttctgtgg acctaaagct ctctcgagga cacttcaaaa 1740
gatgtgccac ttgtattcat cagctgacct cagaggtgtt catttctatt acaacaagga 1800
gagcttctag actttggagg tcaagtcag gcattgtgtt ttcaatcaag ttattgattc 1860
caaagaactc caccaggaat tcctgtgacg gcctgttgat atgagctccc agttgggaac 1920

tggtgaataa taattaacta ttgtgaacag tacactatac cataacttcoct tagcttataa 1980
 ataacatgtc atatacaaca gaacaaaaac atttactgaa attaaaaatat attatgtttc 2040
 tcca 2044

<210> 6
 <211> 568
 <212> PRT
 <213> Homo sapiens

<400> 6
 Met Met Gly Cys Trp Ile Leu Asn Glu Gly Leu Ser Thr Ile Leu Val
 1 5 10 15
 Leu Ser Trp Leu Gly Ile Asn Phe Tyr Leu Phe Ile Asp Thr Phe Tyr
 20 25 30
 Trp Tyr Glu Glu Glu Ser Phe His Tyr Thr Arg Val Ile Leu Gly
 35 40 45
 Ser Thr Leu Ala Trp Ala Arg Ala Ser Ala Leu Cys Leu Asn Phe Asn
 50 55 60
 Cys Met Leu Ile Leu Ile Pro Val Ser Arg Asn Leu Ile Ser Phe Ile
 65 70 75 80
 Arg Gly Thr Ser Ile Cys Cys Arg Gly Pro Trp Arg Arg Gln Leu Asp
 85 90 95
 Lys Asn Leu Arg Phe His Lys Leu Val Ala Tyr Gly Ile Ala Val Asn
 100 105 110
 Ala Thr Ile His Ile Val Ala His Phe Phe Asn Leu Glu Arg Tyr His
 115 120 125
 Trp Ser Gln Ser Glu Glu Ala Gln Gly Leu Leu Ala Ala Leu Ser Lys
 130 135 140
 Leu Gly Asn Thr Pro Asn Glu Ser Tyr Leu Asn Pro Val Arg Thr Phe
 145 150 155 160
 Pro Thr Asn Thr Thr Thr Glu Leu Leu Arg Thr Ile Ala Gly Val Thr
 165 170 175
 Gly Leu Val Ile Ser Leu Ala Leu Val Leu Ile Met Thr Ser Ser Thr
 180 185 190
 Glu Phe Ile Arg Gln Ala Ser Tyr Glu Leu Phe Trp Tyr Thr His His
 195 200 205
 Val Phe Ile Val Phe Phe Leu Ser Leu Ala Ile His Gly Thr Gly Arg
 210 215 220
 Ile Val Arg Gly Gln Thr Gln Asp Ser Leu Ser Leu His Asn Ile Thr
 225 230 235 240
 Phe Cys Arg Asp Arg Tyr Ala Glu Trp Gln Thr Val Ala Gln Cys Pro
 245 250 255

9/61

Val Pro Gln Phe Ser Gly Lys Glu Pro Ser Ala Trp Lys Trp Ile Leu
 260 265 270
 Gly Pro Val Val Leu Tyr Ala Cys Glu Arg Ile Ile Arg Phe Trp Arg
 275 280 285
 Phe Gln Gln Glu Val Val Ile Thr Lys Val Val Ser His Pro Ser Gly
 290 295 300
 Val Leu Glu Leu His Met Lys Lys Arg Gly Phe Lys Met Ala Pro Gly
 305 310 315 320
 Gln Tyr Ile Leu Val Gln Cys Pro Ala Ile Ser Ser Leu Glu Trp His
 325 330 335
 Pro Phe Thr Leu Thr Ser Ala Pro Gln Glu Asp Phe Phe Ser Val His
 340 345 350
 Ile Arg Ala Ala Gly Asp Trp Thr Ala Ala Leu Leu Glu Ala Phe Gly
 355 360 365
 Ala Glu Gly Gln Ala Leu Gln Glu Pro Trp Ser Leu Pro Arg Leu Ala
 370 375 380
 Val Asp Gly Pro Phe Gly Thr Ala Leu Thr Asp Val Phe His Tyr Pro
 385 390 395 400
 Val Cys Val Cys Val Ala Ala Gly Ile Gly Val Thr Pro Phe Ala Ala
 405 410 415
 Leu Leu Lys Ser Ile Trp Tyr Lys Cys Ser Glu Ala Gln Thr Pro Leu
 420 425 430
 Lys Leu Ser Lys Val Tyr Phe Tyr Trp Ile Cys Arg Asp Ala Arg Ala
 435 440 445
 Phe Glu Trp Phe Ala Asp Leu Leu Leu Ser Leu Glu Thr Arg Met Ser
 450 455 460
 Glu Gln Gly Lys Thr His Phe Leu Ser Tyr His Ile Phe Leu Thr Gly
 465 470 475 480
 Trp Asp Glu Asn Gln Ala Leu His Ile Ala Leu His Trp Asp Glu Asn
 485 490 495
 Thr Asp Val Ile Thr Gly Leu Lys Gln Lys Thr Phe Tyr Gly Arg Pro
 500 505 510
 Asn Trp Asn Asn Glu Phe Lys Gln Ile Ala Tyr Asn His Pro Ser Ser
 515 520 525
 Ser Ile Gly Val Phe Phe Cys Gly Pro Lys Ala Leu Ser Arg Thr Leu
 530 535 540
 Gln Lys Met Cys His Leu Tyr Ser Ser Ala Asp Pro Arg Gly Val His
 545 550 555 560
 Phe Tyr Tyr Asn Lys Glu Ser Phe
 565

<210> 7
<211> 2232
<212> DNA
<213> Homo sapiens

<400> 7
ccgcacaact gtaaccgctg ccccgccgc cgcgcgctcc ttctcgggcc ggcgggcaca 60
gagcgagcg cggcggggcc ggcggcatgg ctgtgtcctg gaggagctgg ctgcaccaacg 120
aaggggttaa acacctctgc ctgttcatct ggctctccat gaatgtcctg cttttctgga 180
aaaccttctt gctgtataac caagggccag agtatcacta cctccaccag atgttggggc 240
taggattgtg tctaagcaga gcctcagcat ctgttcttaa cctcaactgc agccttatcc 300
ttttacccat gtgccgaaca ctcttggtt acctccgagg atcacagaag gttccaagca 360
ggagaaccag gagattgttg gataaaagca gaacattcca tattacctgt ggtgttacta 420
tctgtatctt ctgaggcgtg catgtggctg cccatctggt gaatgccctc aacttctcag 480
tgaattacag tgaagacttt gttgaactga atgcagcaag ataccgagat gaggatccta 540
gaaaacttct cttcacaact gttcctggcc tgacaggggt ctgcatggtg gtggtgctat 600
tctcatgat cacagcctct acatatgcaa taagagtttc taactatgat atcttctggt 660
atactcataa cctcttcttt gtcttctaca tgctgctgac gttgcatggt tcaggagggc 720
tgctgaagta tcaaactaat ttagataccc acctcccggt ctgcatcagt ctttaaccgaa 780
ccagctctca gaatatttcc ttaccagagt atttctcaga acattttcat gaacctttcc 840
ctgaaggatt ttcaaaaccg gcagagttaa ccagcacaa atttgtgaag atttgtatgg 900
aagagcccag attccaagct aattttccac agacttggct ttggatttct ggacctttgt 960
gcctgtactg tgccgaaaga ctttacaggt atatccggag caataagcca gtcaccatca 1020
tttcgggtcat aagtcatccc tcagatgtca tggaaatccg aatggtcaaa gaaaatttta 1080
aagcaagacc tggtcagtat attactctac attgtcccag tgtatctgca ttagaaaatc 1140
atccatttac cctcacaatg tgtccaactg aaaccaaagc aacatttggg gttcatctta 1200
aaatagtagg agactggaca gaacgatttc gagatttact actgcctcca tctagtcaag 1260
actccgaaat tctgcccttc attcaatcta gaaattatcc caagctgtat attgatggtc 1320
cttttggaag tccatttgag gaatcactga actatgaggt cagcctctgc gtggctggag 1380
gcattggagt aactccattt gcatcaatac tcaacaccct gttggatgac tggaaaccat 1440
acaagcttag aagactatac tttatttggg tatgcagaga tatccagtcc ttccgttgggt 1500
ttgcagattt actctgtatg ttgcataaca agttttggca agagaacaga cctgactatg 1560
tcaacatcca gctgtacctc agtcaaacag atgggataca gaagataatt ggagaaaaat 1620

atcatgcact gaattcaaga ctgtttatag gacgtcctcg gtggaaactt ttgtttgatg 1680
 aaatagcaaa atataacaga ggaaaaacag ttggtgtttt ctgttggtga cccaattcac 1740
 tatccaagac ttttcataaa ctgagtaacc agaacaactc atatgggaca agatttgaat 1800
 acaataaaga gtctttcagc tgaaaacttt tgccatgaag caggactcta aagaaggaat 1860
 gagtgcaatt tctaagactt tgaaactcag cggaatcaat cagctgtgtt atgccaaaga 1920
 atagtaaggt tttcttattt atgattattt gaaaatggaa atgtgagaat gtggcaacat 1980
 gaccgtcaca ttacatgttt aatctggaaa ccaaagagac cctgaagaat atttgatgtg 2040
 atgattcatt ttcagttctc aaattaaaag aaaactgtta gatgcacact gttgattttc 2100
 atggtggatt caagaactcc ctagtgagga gctgaacttg ctcaatctaa ggctgattgt 2160
 cgtgttcctc tttaaattgt ttttggttga acaaatgcaa gattgaacaa aattaaaaat 2220
 tcattgaagc tg- 2232

<210> 8
 <211> 578
 <212> PRT
 <213> Homo sapiens

<400> 8
 Met Ala Val Ser Trp Arg Ser Trp Leu Ala Asn Glu Gly Val Lys His
 1 5 10 15
 Leu Cys Leu Phe Ile Trp Leu Ser Met Asn Val Leu Leu Phe Trp Lys
 20 25 30
 Thr Phe Leu Leu Tyr Asn Gln Gly Pro Glu Tyr His Tyr Leu His Gln
 35 40 45
 Met Leu Gly Leu Gly Leu Cys Leu Ser Arg Ala Ser Ala Ser Val Leu
 50 55 60
 Asn Leu Asn Cys Ser Leu Ile Leu Leu Pro Met Cys Arg Thr Leu Leu
 65 70 75 80
 Ala Tyr Leu Arg Gly Ser Gln Lys Val Pro Ser Arg Arg Thr Arg Arg
 85 90 95
 Leu Leu Asp Lys Ser Arg Thr Phe His Ile Thr Cys Gly Val Thr Ile
 100 105 110
 Cys Ile Phe Ser Gly Val His Val Ala Ala His Leu Val Asn Ala Leu
 115 120 125
 Asn Phe Ser Val Asn Tyr Ser Glu Asp Phe Val Glu Leu Asn Ala Ala
 130 135 140
 Arg Tyr Arg Asp Glu Asp Pro Arg Lys Leu Leu Phe Thr Thr Val Pro
 145 150 155 160
 Gly Leu Thr Gly Val Cys Met Val Val Val Leu Phe Leu Met Ile Thr
 165 170 175

Ala Ser Thr Tyr Ala Ile Arg Val Ser Asn Tyr Asp Ile Phe Trp Tyr
 180 185 190
 Thr His Asn Leu Phe Phe Val Phe Tyr Met Leu Leu Thr Leu His Val
 195 200 205
 Ser Gly Gly Leu Leu Lys Tyr Gln Thr Asn Leu Asp Thr His Pro Pro
 210 215 220
 Gly Cys Ile Ser Leu Asn Arg Thr Ser Ser Gln Asn Ile Ser Leu Pro
 225 230 235 240
 Glu Tyr Phe Ser Glu His Phe His Glu Pro Phe Pro Glu Gly Phe Ser
 245 250 255
 Lys Pro Ala Glu Phe Thr Gln His Lys Phe Val Lys Ile Cys Met Glu
 260 265 270
 Glu Pro Arg Phe Gln Ala Asn Phe Pro Gln Thr Trp Leu Trp Ile Ser
 275 280 285
 Gly Pro Leu Cys Leu Tyr Cys Ala Glu Arg Leu Tyr Arg Tyr Ile Arg
 290 295 300
 Ser Asn Lys Pro Val Thr Ile Ile Ser Val Ile Ser His Pro Ser Asp
 305 310 315 320
 Val Met Glu Ile Arg Met Val Lys Glu Asn Phe Lys Ala Arg Pro Gly
 325 330 335
 Gln Tyr Ile Thr Leu His Cys Pro Ser Val Ser Ala Leu Glu Asn His
 340 345 350
 Pro Phe Thr Leu Thr Met Cys Pro Thr Glu Thr Lys Ala Thr Phe Gly
 355 360 365
 Val His Leu Lys Ile Val Gly Asp Trp Thr Glu Arg Phe Arg Asp Leu
 370 375 380
 Leu Leu Pro Pro Ser Ser Gln Asp Ser Glu Ile Leu Pro Phe Ile Gln
 385 390 395 400
 Ser Arg Asn Tyr Pro Lys Leu Tyr Ile Asp Gly Pro Phe Gly Ser Pro
 405 410 415
 Phe Glu Glu Ser Leu Asn Tyr Glu Val Ser Leu Cys Val Ala Gly Gly
 420 425 430
 Ile Gly Val Thr Pro Phe Ala Ser Ile Leu Asn Thr Leu Leu Asp Asp
 435 440 445
 Trp Lys Pro Tyr Lys Leu Arg Arg Leu Tyr Phe Ile Trp Val Cys Arg
 450 455 460
 Asp Ile Gln Ser Phe Arg Trp Phe Ala Asp Leu Leu Cys Met Leu His
 465 470 475 480
 Asn Lys Phe Trp Gln Glu Asn Arg Pro Asp Tyr Val Asn Ile Gln Leu
 485 490 495

13/61

Tyr Leu Ser Gln Thr Asp Gly Ile Gln Lys Ile Ile Gly Glu Lys Tyr
 500 505 510

His Ala Leu Asn Ser Arg Leu Phe Ile Gly Arg Pro Arg Trp Lys Leu
 515 520 525

Leu Phe Asp Glu Ile Ala Lys Tyr Asn Arg Gly Lys Thr Val Gly Val
 530 535 540

Phe Cys Cys Gly Pro Asn Ser Leu Ser Lys Thr Leu His Lys Leu Ser
 545 550 555 560

Asn Gln Asn Asn Ser Tyr Gly Thr Arg Phe Glu Tyr Asn Lys Glu Ser
 565 570 575

Phe Ser

<210> 9
 <211> 2223
 <212> DNA
 <213> Homo sapiens

<400> 9
 gccgacgcgg acggcaacgg ggccatcacc ttcgaggagc tccgggacga gctgcagcgc 60
 ttccccggag tcatggagaa cctgaccatc agcactgccc actggctgac ggcccccgcc 120
 ccccgccac gccgcgccc gccgcgccag ctgacccgcg cctactggca caaccaccgc 180
 agccagctgt tctgcctggc cacctatgca ggccctccag tgctgtctt cgggctggcg 240
 gccagcgcgc accgggacct cggcgccagc gtcattggtg ccaagggctg tggccagtgc 300
 ctcaacttcg actgcagctt catcgcggtg ctgatgtca gacgtgcct cacctggctg 360
 cgggccacgt ggctggctca agtcctacca ctggaccaga acatccagtt ccaccagctt 420
 atgggctacg tggtagtggg gctgtccctc gtgcacactg tggtcacac tgtgaacttt 480
 gtactccagg ctcaggcgga ggccagccct ttocagttct gggagctgct gctcaccacg 540
 aggctggca ttggctgggt acacggttcg gcctccccga cagggtgctc tctgtgtctg 600
 ctgtctctcc tcatgttcat ctgtccagt tcctgcatcc gcaggagtgg ccactttgag 660
 gtgttctatt ggactcacct gtcctacctc ctctgtggc ttctgtcat ctttcatggg 720
 cccaacttct ggaagtggct gctggtgcct ggaatctgt ttttctgga gaaggccatc 780
 ggactggcag tgtcccgcat ggcagccgtg tgcattcatg aagtcaacct cctcccctcc 840
 aaggtcactc atctcctcat caagcgcccc cctttttttc actatagacc tggtgactac 900
 ttgtatctga acatccccac cattgctcgc tatgagtggc accccttcac catcagcagt 960
 gctcctgagc agaaagacac tatctggctg cacattcggc cccaaggcca gtggacaaac 1020
 aggctgtatg agtccttcaa ggcacagac ccactgggc gtggttctaa gaggctgtcg 1080
 aggagtgtga caatgagaaa gagtcaaagg tcgtccaagg gctctgagat acttttggag 1140

```

aaacacaaat tctgtaacat caagtgtac atcgatgggc cttatgggac cccacccgc 1200
aggatctttg cctctgagca tgccgtgctc atcggggcag gcatcgcat caccctttt 1260
gcttccattc tgcagagtat catgtacagg caccagaaaa gaaagcatac ttgccccagc 1320
tgccagcact cctggatcga aggtgtccaa gacaacatga agctccataa ggtggacttt 1380
atctggatca acagagacca gcggtctttc gagtggtttg tgagcctgct gactaaactg 1440
gagatggacc aggccgagga ggctcaatac ggccgcttcc tggagctgca tatgtacatg 1500
acatctgcac tgggcaagaa tgacatgaag gccattggcc tgcagatggc ccttgacctc 1560
ctggccaaca aggagaagaa agactccatc acggggctgc agacgcgcac ccagcctggg 1620
cggcctgact ggagcaaggt gttccagaaa gtggctgctg agaagaaggg caaggtgcag 1680
gtcttcttct gtggctcccc agctctggcc aaggtgctga agggccattg tgagaagttc 1740
ggcttcagat tttccaaga gaatttctag cctcacctct ccaagctctg cccaagtcc 1800
acaccatggg tctgcttcat cgcattagta taaatgcccc cacagggacc agcctcagat 1860
gaccaccca ataagacaaa gcctagggac ccctaatacc tgctcaacag agagaacagg 1920
agacccaag gggcagatga acttctctta gaaccaggg gaaggggcag tgccttgctc 1980
agtctgctgt agattctggg gtttctgtga aagtgaggga accagaggct ggtcacggga 2040
gcttgggggt ggggttcgag ggggcagagg gcaaccactc ctccaaacat tttccgacgg 2100
agccttcccc cacatccatg gtccaaacc tgcccaatca tcacagtcac ttggaagctt 2160
atttctccgg catcttataa aattgttcaa acctacagta aaaaaaaaaa aaaaaaaaaa 2220
aaa
2223

```

```

<210> 10
<211> 565
<212> PRT
<213> Homo sapiens

```

```

<400> 10
Met Glu Asn Leu Thr Ile Ser Thr Ala His Trp Leu Thr Ala Pro Ala
1          5          10          15
Pro Arg Pro Arg Pro Arg Arg Pro Arg Gln Leu Thr Arg Ala Tyr Trp
20          25          30
His Asn His Arg Ser Gln Leu Phe Cys Leu Ala Thr Tyr Ala Gly Leu
35          40          45
His Val Leu Leu Phe Gly Leu Ala Ala Ser Ala His Arg Asp Leu Gly
50          55          60
Ala Ser Val Met Val Ala Lys Gly Cys Gly Gln Cys Leu Asn Phe Asp
65          70          75          80

```

15/61

Cys Ser Phe Ile Ala Val Leu Met Leu Arg Arg Cys Leu Thr Trp Leu
 85 90 95
 Arg Ala Thr Trp Leu Ala Gln Val Leu Pro Leu Asp Gln Asn Ile Gln
 100 105 110
 Phe His Gln Leu Met Gly Tyr Val Val Val Gly Leu Ser Leu Val His
 115 120 125
 Thr Val Ala His Thr Val Asn Phe Val Leu Gln Ala Gln Ala Glu Ala
 130 135 140
 Ser Pro Phe Gln Phe Trp Glu Leu Leu Leu Thr Thr Arg Pro Gly Ile
 145 150 155 160
 Gly Trp Val His Gly Ser Ala Ser Pro Thr Gly Val Ala Leu Leu Leu
 165 170 175
 Leu Leu Leu Leu Met Phe Ile Cys Ser Ser Ser Cys Ile Arg Arg Ser
 180 185 190
 Gly His Phe Glu Val Phe Tyr Trp Thr His Leu Ser Tyr Leu Leu Val
 195 200 205
 Trp Leu Leu Leu Ile Phe His Gly Pro Asn Phe Trp Lys Trp Leu Leu
 210 215 220
 Val Pro Gly Ile Leu Phe Phe Leu Glu Lys Ala Ile Gly Leu Ala Val
 225 230 235 240
 Ser Arg Met Ala Ala Val Cys Ile Met Glu Val Asn Leu Leu Pro Ser
 245 250 255
 Lys Val Thr His Leu Leu Ile Lys Arg Pro Pro Phe Phe His Tyr Arg
 260 265 270
 Pro Gly Asp Tyr Leu Tyr Leu Asn Ile Pro Thr Ile Ala Arg Tyr Glu
 275 280 285
 Trp His Pro Phe Thr Ile Ser Ser Ala Pro Glu Gln Lys Asp Thr Ile
 290 295 300
 Trp Leu His Ile Arg Ser Gln Gly Gln Trp Thr Asn Arg Leu Tyr Glu
 305 310 315 320
 Ser Phe Lys Ala Ser Asp Pro Leu Gly Arg Gly Ser Lys Arg Leu Ser
 325 330 335
 Arg Ser Val Thr Met Arg Lys Ser Gln Arg Ser Ser Lys Gly Ser Glu
 340 345 350
 Ile Leu Leu Glu Lys His Lys Phe Cys Asn Ile Lys Cys Tyr Ile Asp
 355 360 365
 Gly Pro Tyr Gly Thr Pro Thr Arg Arg Ile Phe Ala Ser Glu His Ala
 370 375 380
 Val Leu Ile Gly Ala Gly Ile Gly Ile Thr Pro Phe Ala Ser Ile Leu
 385 390 395 400

Gln Ser Ile Met Tyr Arg His Gln Lys Arg Lys His Thr Cys Pro Ser
 405 410 415

Cys Gln His Ser Trp Ile Glu Gly Val Gln Asp Asn Met Lys Leu His
 420 425 430

Lys Val Asp Phe Ile Trp Ile Asn Arg Asp Gln Arg Ser Phe Glu Trp
 435 440 445

Phe Val Ser Leu Leu Thr Lys Leu Glu Met Asp Gln Ala Glu Glu Ala
 450 455 460

Gln Tyr Gly Arg Phe Leu Glu Leu His Met Tyr Met Thr Ser Ala Leu
 465 470 475 480

Gly Lys Asn Asp Met Lys Ala Ile Gly Leu Gln Met Ala Leu Asp Leu
 485 490 495

Leu Ala Asn Lys Glu Lys Lys Asp Ser Ile Thr Gly Leu Gln Thr Arg
 500 505 510

Thr Gln Pro Gly Arg Pro Asp Trp Ser Lys Val Phe Gln Lys Val Ala
 515 520 525

Ala Glu Lys Lys Gly Lys Val Gln Val Phe Phe Cys Gly Ser Pro Ala
 530 535 540

Leu Ala Lys Val Leu Lys Gly His Cys Glu Lys Phe Gly Phe Arg Phe
 545 550 555 560

Phe Gln Glu Asn Phe
 565

<210> 11

<211> 5494

<212> DNA

<213> Homo sapiens

<400> 11

gcagagctgc agaggcaccg gacgagagag ggctccgcgg gccagctgg cagccaggcc 60

ggagacaagt tgcagtcccg ggctctggtg acgccgtggc cgcagggtct ccattttggg 120

acattctaatt ccttgagccc ctattatttt catcatgggc ttctgcctgg ctctagcatg 180

gacacttctg gttggggcat ggacccctct gggagctcag aacccattt cgtgggaggt 240

gcagcgattt gatgggtggt acaacaacct catggagcac agatggggca gcaaaggctc 300

ccggctgcag cgcttggtcc cagccagcta tgcagatggc gtgtaccagc ccttgggaga 360

acccacctg cccaaccccc gagaccttag caacaccatc tcaaggggcc ctgcagggtc 420

ggcctccctg agaaaccgca cagtgttggg ggtcttcttt ggctatcacg tgctttcaga 480

cctggtgagc gtggaaactc ccggctgccc cgccgagttc ctcaacattc gcatcccgc 540

cggagacccc atgttcgacc ccgaccagcg cggggacgtg gtgctgccct tccagagaag 600
ccgctgggac cccgagaccg gacggagtcc cagcaatccc cgggacccgg ccaaccaggt 660
gacgggctgg ctggacggca gcgccatcta tggttcctcg cattcctgga gcgacgcgt 720
gcggagcttc tccaggggac agctggcgtc ggggcccgcac cccgcttttc cccgagactc 780
gcagaacccc ctgctcatgt gggcggcgcc cgaccccgcc accgggcaga acgggccccg 840
ggggctgtac gccttcgggg cagagagagg gaaccgggaa cccttcctgc aggcgctggg 900
cctgctctgg ttccgctacc acaacctgtg ggcgcagagg ctggccccgc agcaccacaga 960
ctgggaggac gaggagctgt tccagcacgc acgcaagagg gtcacgcga cctaccagaa 1020
catcgtctgt tatgagtggc tgcccagctt cctgcagaaa aactccccg agtatacagg 1080
ataccggcca tttctggacc ccagcatctc ctgagagttc gtggcggcct ctgagcagtt 1140
cctgtccacc atggtgcccc ctggcgctca catgagaaat gccagctgcc acttccaggg 1200
ggtcatcaat cggaactcaa gtgtctccag agctctccgg gtctgcaaca gctactggag 1260
ccgtgagcac ccaagcctac aaagtgtga agatgtggat gcactgctgc tgggcatggc 1320
ctcccagatc gcagagcgag aggacctgt gttggttga gatgtgcggg atttctggcc 1380
tgggccactg aagttttccc gcacagacca cctggccagc tgctgcagc ggggcccggga 1440
tctgggcctg ccctcttaca ccaaggccag ggcagcactg ggcttgtctc ccattacccg 1500
ctggcaggac atcaaccctg cactctcccg gagcaatgac actgtactgg aggccacagc 1560
tgccctgtac aaccaggact tctcctggct agagctgtc cctgggggac tcctggagag 1620
ccaccgggac cctggacctc tgttcagcac catcgtcctt gaacaatttg tgcggtacg 1680
ggatggtgac cgctactggt ttgagaacac caggaatggg ctgttctcca agaaggagat 1740
tgaagaaatc cgaaatacca ccctgcagga cgtgctggtc gctgttatca acattgaccc 1800
cagtgtctg cagcccaatg tctttgtctg gcataaagga gaccctgtc cgcagccgag 1860
acagctcagc actgaaggcc tgccagcgtg tgctccctct gttgttcgtg actattttga 1920
gggcagtgga tttggcttcg gggtcaccat cgggacctc tgttgcttcc ctttggtag 1980
cctgctcagt gcctggattg ttgccggct ccgatgaga aatttcaaga ggctccaggg 2040
ccaggaccgc cagagcatcg tgtctgagaa gctcgtggga ggcattggaag ctttggaatg 2100
gcaaggccac aaggagccct gccggccgt gcttgtgtac ctgcagcccg ggcagatccg 2160
tgtggtagat ggcaggctca ccgtgtccg caccatccag ctgcagcctc cacagaaggt 2220
caacttcgtc ctgtccagca accgtggacg ccgactctg ctgctcaaga tcccaagga 2280
gtatgacctg gtgctgctgt ttaacttga ggaagagcg caggcgtgg tggaaaatct 2340

ccggggagct ctgaaggaga gcggttgag catccaggag tgggagctgc gggagcagga	2400
gctgatgaga gcagctgtga cacgggagca gcgaggcac ctcttgaga ctttttcag	2460
gcaccttttc tcccaggtgc tggacatcaa ccaggccgac gcagggaccc tgcccctgga	2520
ctctcccag aaggtgcggg aggcctgac ctgtgagctg agcaggccg agtttgccga	2580
gtcccctgggc ctcaagcccc aggacatggt tgtggagtcc atgttctctc tggctgacaa	2640
ggatggcaat ggctacctgt ccttccgaga gttcctggac atcctggtgg tcttcatgaa	2700
aggctctcct gaggaaggt ctgccttat gttccgcatg tacgactttg atgggaatgg	2760
cctcatttcc aaggatgagt tcatcaggat gctgagatcc ttcacgaga tctccaacaa	2820
ctgcctgtcc aaggcccagc tggctgaggt ggtggagtcc atgttccggg agtcgggatt	2880
ccaggacaag gaggaactga catgggaaga ttttctctc atgctgcggg accacaatag	2940
cgagctccgc ttacgcagc tctgtgtcaa aggggtggag gtgcctgaag tcatcaagga	3000
cctctgcgg cgagcctcct acatcagcca ggatatgac tgtccctctc ccagagtga	3060
tgcccgtgt tcccgcagcg acattgagac tgagttgaca cctcagagac tgcagtgcc	3120
catggacaca gacctcccc aggagattcg gcgagggtt ggcaagaagg taacgtcatt	3180
ccagcccttg ctgttctctg aggcgcaccg agagaagtt caacgcagct gtctccacca	3240
gacggtgcaa cagttcaagc gcttcattga gaactaccgg cgccacatcg gctgcgtggc	3300
cgtgttctac gccatcgctg gggggctttt cctggagagg gcctactact acgcctttgc	3360
cgcacatcac acgggcatca cggacaccac ccgcgtggga atcatcctgt cgcggggcac	3420
agcagccagc atctctttca tgttctccta catcttgctc accatgtgcc gcaacctcat	3480
caccttctg cgagaaacct tctcaaccg ctacgtgcc ttcgacgcc cggtggactt	3540
ccatgcctc attgcctcca ccgcatcgt cctcacagtc ttacacagtg tgggccatgt	3600
ggtgaatgtg tacctgttct ccatcagccc cctcagctc ctctcttgcc tcttctctg	3660
cctcttccat gatgatgggt ctgagttccc ccagaagtat tactggtggt tcttccagac	3720
cgtaccaggc ctcacggggg ttgtgctgt cctgatectg gccatcatgt atgtctttgc	3780
ctcccaccac ttccgcgcc gcagtttccg gggcttctg ctgaccacc acctctacat	3840
cctgctctat gtctgtctc tcatccatgg tagctttgcc ctgatccagc tgcccgttt	3900
ccacatcttc ttctgggtcc cagcaatcat ctatggggg gacaagctgg tgagcctgag	3960
ccggaagaag gtggagatca gcgtggtgaa ggcggagctg ctgccctcag gagtgaacca	4020
cctgcggttc cagcggcccc agggctttga gtacaagtca gggcagtggt tgcggatcgc	4080
ttgcctggct ctggggacca ccgagtacca ccccttcaca ctgacctctg cgccccatga	4140
ggacacgctt agcctgcaca tccgggcagc agggccctgg accactcgcc tcaggagat	4200


```

ctactcagcc ccgacgggtg acagatgtgc cagataccca aagctgtacc ttgatggacc 4260
atttgagag gggcaccagg agtggcataa gtttgaggtg tcagtgttag tgggaggggg 4320
cattggggtc accccttttg cctccatcct caaagacctg gtcttcaagt catccgtcag 4380
ctgccaagtg ttctgtaaga agatctactt catctgggtg acgcggaccc agcgtcagtt 4440
tgagtggctg gctgacatca tccgagaggt ggaggagaat gaccaccagg acctgggtgc 4500
tgtgcacatc tacatcacc cagctggctga gaagttagac ctcaggacca ctatgctgta 4560
catctgtgag cggcacttcc agaaggttct gaaccggagt ctattcacag gcctgcgctc 4620
catcaccacac tttggccgtc ccccctttga gcccttcttc aactccctgc aggaggtcca 4680
ccccagggtc cggaagatcg ggggtgttag ctgtggcccc cctggcatga ccaagaatgt 4740
ggaaaaggcc tgtcagctca tcaacaggca ggaccggact cacttctccc accattatga 4800
gaacttctag gccctgccc gggggttctg cccactgtcc agttgagcag aggtttgagc 4860
ccacacctca cctctgttct tcctatttct ggctgcctca gccttctctg atttcccacc 4920
tcccaacctt gttccagggt gccatagtca gtcaccatgt gtgggctcag ggacccccag 4980
gaccaggatg tgtctcagcc tggagaaatg gtgggggggc agtgtctagg gactagagtg 5040
agaagtaggg gagctactga tttggggcaa agtgaaacct ctgcttcaga cttcagaaac 5100
aaatctcaga agacaagctg acctgacaag tactatgtgt gtgcatgtct gtatgtgtgt 5160
tggggcgggt agtgtaagga tgcagtggga gcatggatgc tggcatctta gaaccctccc 5220
tactcccata cctcctctc ttctgggtc cccactgtca gacgggctgg caaatgcctt 5280
gcaggaggtg gaggtggac ccatggcaag ccatttacag aaaccctc ggcacccag 5340
tctaacacca caactaattt cacccaagg ttttaagcacg ttctttcatc agaccctggc 5400
ccaataccta tgtatgcaat gtcctcagc cctcttctcc ctgctccagt agtctccctt 5460
ccaaataaat cacttttctg ccaaaaaaaaa aaaa 5494

```

```

<210> 12
<211> 1551
<212> PRT
<213> Homo sapiens

```

```

<400> 12

```

```

Met Gly Phe Cys Leu Ala Leu Ala Trp Thr Leu Leu Val Gly Ala Trp
1           5           10           15

Thr Pro Leu Gly Ala Gln Asn Pro Ile Ser Trp Glu Val Gln Arg Phe
          20           25           30

```

Asp Gly Trp Tyr Asn Asn Leu Met Glu His Arg Trp Gly Ser Lys Gly
35 40 45

Ser Arg Leu Gln Arg Leu Val Pro Ala Ser Tyr Ala Asp Gly Val Tyr
50 55 60

Gln Pro Leu Gly Glu Pro His Leu Pro Asn Pro Arg Asp Leu Ser Asn
65 70 75 80

Thr Ile Ser Arg Gly Pro Ala Gly Leu Ala Ser Leu Arg Asn Arg Thr
85 90 95

Val Leu Gly Val Phe Phe Gly Tyr His Val Leu Ser Asp Leu Val Ser
100 105 110

Val Glu Thr Pro Gly Cys Pro Ala Glu Phe Leu Asn Ile Arg Ile Pro
115 120 125

Pro Gly Asp Pro Met Phe Asp Pro Asp Gln Arg Gly Asp Val Val Leu
130 135 140

Pro Phe Gln Arg Ser Arg Trp Asp Pro Glu Thr Gly Arg Ser Pro Ser
145 150 155 160

Asn Pro Arg Asp Pro Ala Asn Gln Val Thr Gly Trp Leu Asp Gly Ser
165 170 175

Ala Ile Tyr Gly Ser Ser His Ser Trp Ser Asp Ala Leu Arg Ser Phe
180 185 190

Ser Arg Gly Gln Leu Ala Ser Gly Pro Asp Pro Ala Phe Pro Arg Asp
195 200 205

Ser Gln Asn Pro Leu Leu Met Trp Ala Ala Pro Asp Pro Ala Thr Gly
210 215 220

Gln Asn Gly Pro Arg Gly Leu Tyr Ala Phe Gly Ala Glu Arg Gly Asn
225 230 235 240

Arg Glu Pro Phe Leu Gln Ala Leu Gly Leu Leu Trp Phe Arg Tyr His
245 250 255

Asn Leu Trp Ala Gln Arg Leu Ala Arg Gln His Pro Asp Trp Glu Asp
260 265 270

Glu Glu Leu Phe Gln His Ala Arg Lys Arg Val Ile Ala Thr Tyr Gln
275 280 285

Asn Ile Ala Val Tyr Glu Trp Leu Pro Ser Phe Leu Gln Lys Thr Leu
290 295 300

Pro Glu Tyr Thr Gly Tyr Arg Pro Phe Leu Asp Pro Ser Ile Ser Ser
305 310 315 320

Glu Phe Val Ala Ala Ser Glu Gln Phe Leu Ser Thr Met Val Pro Pro
325 330 335

Gly Val Tyr Met Arg Asn Ala Ser Cys His Phe Gln Gly Val Ile Asn
340 345 350

21/61

Arg Asn Ser Ser Val Ser Arg Ala Leu Arg Val Cys Asn Ser Tyr Trp
 355 360 365
 Ser Arg Glu His Pro Ser Leu Gln Ser Ala Glu Asp Val Asp Ala Leu
 370 375 380
 Leu Leu Gly Met Ala Ser Gln Ile Ala Glu Arg Glu Asp His Val Leu
 385 390 395 400
 Val Glu Asp Val Arg Asp Phe Trp Pro Gly Pro Leu Lys Phe Ser Arg
 405 410 415
 Thr Asp His Leu Ala Ser Cys Leu Gln Arg Gly Arg Asp Leu Gly Leu
 420 425 430
 Pro Ser Tyr Thr Lys Ala Arg Ala Ala Leu Gly Leu Ser Pro Ile Thr
 435 440 445
 Arg Trp Gln Asp Ile Asn Pro Ala Leu Ser Arg Ser Asn Asp Thr Val
 450 455 460
 Leu Glu Ala Thr Ala Ala Leu Tyr Asn Gln Asp Leu Ser Trp Leu Glu
 465 470 475 480
 Leu Leu Pro Gly Gly Leu Leu Glu Ser His Arg Asp Pro Gly Pro Leu
 485 490 495
 Phe Ser Thr Ile Val Leu Glu Gln Phe Val Arg Leu Arg Asp Gly Asp
 500 505 510
 Arg Tyr Trp Phe Glu Asn Thr Arg Asn Gly Leu Phe Ser Lys Lys Glu
 515 520 525
 Ile Glu Glu Ile Arg Asn Thr Thr Leu Gln Asp Val Leu Val Ala Val
 530 535 540
 Ile Asn Ile Asp Pro Ser Ala Leu Gln Pro Asn Val Phe Val Trp His
 545 550 555 560
 Lys Gly Asp Pro Cys Pro Gln Pro Arg Gln Leu Ser Thr Glu Gly Leu
 565 570 575
 Pro Ala Cys Ala Pro Ser Val Val Arg Asp Tyr Phe Glu Gly Ser Gly
 580 585 590
 Phe Gly Phe Gly Val Thr Ile Gly Thr Leu Cys Cys Phe Pro Leu Val
 595 600 605
 Ser Leu Leu Ser Ala Trp Ile Val Ala Arg Leu Arg Met Arg Asn Phe
 610 615 620
 Lys Arg Leu Gln Gly Gln Asp Arg Gln Ser Ile Val Ser Glu Lys Leu
 625 630 635 640
 Val Gly Gly Met Glu Ala Leu Glu Trp Gln Gly His Lys Glu Pro Cys
 645 650 655
 Arg Pro Val Leu Val Tyr Leu Gln Pro Gly Gln Ile Arg Val Val Asp
 660 665 670

Gly Arg Leu Thr Val Leu Arg Thr Ile Gln Leu Gln Pro Pro Gln Lys
675 680 685

Val Asn Phe Val Leu Ser Ser Asn Arg Gly Arg Arg Thr Leu Leu Leu
690 695 700

Lys Ile Pro Lys Glu Tyr Asp Leu Val Leu Leu Phe Asn Leu Glu Glu
705 710 715 720

Glu Arg Gln Ala Leu Val Glu Asn Leu Arg Gly Ala Leu Lys Glu Ser
725 730 735

Gly Leu Ser Ile Gln Glu Trp Glu Leu Arg Glu Gln Glu Leu Met Arg
740 745 750

Ala Ala Val Thr Arg Glu Gln Arg Arg His Leu Leu Glu Thr Phe Phe
755 760 765

Arg His Leu Phe Ser Gln Val Leu Asp Ile Asn Gln Ala Asp Ala Gly
770 775 780

Thr Leu Pro Leu Asp Ser Ser Gln Lys Val Arg Glu Ala Leu Thr Cys
785 790 795 800

Glu Leu Ser Arg Ala Glu Phe Ala Glu Ser Leu Gly Leu Lys Pro Gln
805 810 815

Asp Met Phe Val Glu Ser Met Phe Ser Leu Ala Asp Lys Asp Gly Asn
820 825 830

Gly Tyr Leu Ser Phe Arg Glu Phe Leu Asp Ile Leu Val Val Phe Met
835 840 845

Lys Gly Ser Pro Glu Glu Lys Ser Arg Leu Met Phe Arg Met Tyr Asp
850 855 860

Phe Asp Gly Asn Gly Leu Ile Ser Lys Asp Glu Phe Ile Arg Met Leu
865 870 875 880

Arg Ser Phe Ile Glu Ile Ser Asn Asn Cys Leu Ser Lys Ala Gln Leu
885 890 895

Ala Glu Val Val Glu Ser Met Phe Arg Glu Ser Gly Phe Gln Asp Lys
900 905 910

Glu Glu Leu Thr Trp Glu Asp Phe His Phe Met Leu Arg Asp His Asn
915 920 925

Ser Glu Leu Arg Phe Thr Gln Leu Cys Val Lys Gly Val Glu Val Pro
930 935 940

Glu Val Ile Lys Asp Leu Cys Arg Arg Ala Ser Tyr Ile Ser Gln Asp
945 950 955 960

Met Ile Cys Pro Ser Pro Arg Val Ser Ala Arg Cys Ser Arg Ser Asp
965 970 975

Ile Glu Thr Glu Leu Thr Pro Gln Arg Leu Gln Cys Pro Met Asp Thr
980 985 990

23/61

Asp	Pro	Pro	Gln	Glu	Ile	Arg	Arg	Arg	Phe	Gly	Lys	Lys	Val	Thr	Ser
995								1000					1005		
Phe	Gln	Pro	Leu	Leu	Phe	Thr	Glu	Ala	His	Arg	Glu	Lys	Phe	Gln	
1010						1015					1020				
Arg	Ser	Cys	Leu	His	Gln	Thr	Val	Gln	Gln	Phe	Lys	Arg	Phe	Ile	
1025						1030					1035				
Glu	Asn	Tyr	Arg	Arg	His	Ile	Gly	Cys	Val	Ala	Val	Phe	Tyr	Ala	
1040						1045					1050				
Ile	Ala	Gly	Gly	Leu	Phe	Leu	Glu	Arg	Ala	Tyr	Tyr	Tyr	Ala	Phe	
1055						1060					1065				
Ala	Ala	His	His	Thr	Gly	Ile	Thr	Asp	Thr	Thr	Arg	Val	Gly	Ile	
1070						1075					1080				
Ile	Leu	Ser	Arg	Gly	Thr	Ala	Ala	Ser	Ile	Ser	Phe	Met	Phe	Ser	
1085						1090					1095				
Tyr	Ile	Leu	Leu	Thr	Met	Cys	Arg	Asn	Leu	Ile	Thr	Phe	Leu	Arg	
1100						1105					1110				
Glu	Thr	Phe	Leu	Asn	Arg	Tyr	Val	Pro	Phe	Asp	Ala	Ala	Val	Asp	
1115						1120					1125				
Phe	His	Arg	Leu	Ile	Ala	Ser	Thr	Ala	Ile	Val	Leu	Thr	Val	Leu	
1130						1135					1140				
His	Ser	Val	Gly	His	Val	Val	Asn	Val	Tyr	Leu	Phe	Ser	Ile	Ser	
1145						1150					1155				
Pro	Leu	Ser	Val	Leu	Ser	Cys	Leu	Phe	Pro	Gly	Leu	Phe	His	Asp	
1160						1165					1170				
Asp	Gly	Ser	Glu	Phe	Pro	Gln	Lys	Tyr	Tyr	Trp	Trp	Phe	Phe	Gln	
1175						1180					1185				
Thr	Val	Pro	Gly	Leu	Thr	Gly	Val	Val	Leu	Leu	Leu	Ile	Leu	Ala	
1190						1195					1200				
Ile	Met	Tyr	Val	Phe	Ala	Ser	His	His	Phe	Arg	Arg	Arg	Ser	Phe	
1205						1210					1215				
Arg	Gly	Phe	Trp	Leu	Thr	His	His	Leu	Tyr	Ile	Leu	Leu	Tyr	Val	
1220						1225					1230				
Leu	Leu	Ile	Ile	His	Gly	Ser	Phe	Ala	Leu	Ile	Gln	Leu	Pro	Arg	
1235						1240					1245				
Phe	His	Ile	Phe	Phe	Leu	Val	Pro	Ala	Ile	Ile	Tyr	Gly	Gly	Asp	
1250						1255					1260				
Lys	Leu	Val	Ser	Leu	Ser	Arg	Lys	Lys	Val	Glu	Ile	Ser	Val	Val	
1265						1270					1275				
Lys	Ala	Glu	Leu	Leu	Pro	Ser	Gly	Val	Thr	His	Leu	Arg	Phe	Gln	
1280						1285					1290				

24/61

Arg Pro	Gln Gly Phe Glu Tyr	Lys Ser Gly Gln Trp	Val Arg Ile
1295	1300	1305	
Ala Cys	Leu Ala Leu Gly Thr	Thr Glu Tyr His Pro	Phe Thr Leu
1310	1315	1320	
Thr Ser	Ala Pro His Glu Asp	Thr Leu Ser Leu His	Ile Arg Ala
1325	1330	1335	
Ala Gly	Pro Trp Thr Thr Arg	Leu Arg Glu Ile Tyr	Ser Ala Pro
1340	1345	1350	
Thr Gly	Asp Arg Cys Ala Arg	Tyr Pro Lys Leu Tyr	Leu Asp Gly
1355	1360	1365	
Pro Phe	Gly Glu Gly His Gln	Glu Trp His Lys Phe	Glu Val Ser
1370	1375	1380	
Val Leu	Val Gly Gly Gly Ile	Gly Val Thr Pro Phe	Ala Ser Ile
1385	1390	1395	
Leu Lys	Asp Leu Val Phe Lys	Ser Ser Val Ser Cys	Gln Val Phe
1400	1405	1410	
Cys Lys	Lys Ile Tyr Phe Ile	Trp Val Thr Arg Thr	Gln Arg Gln
1415	1420	1425	
Phe Glu	Trp Leu Ala Asp Ile	Ile Arg Glu Val Glu	Glu Asn Asp
1430	1435	1440	
His Gln	Asp Leu Val Ser Val	His Ile Tyr Ile Thr	Gln Leu Ala
1445	1450	1455	
Glu Lys	Phe Asp Leu Arg Thr	Thr Met Leu Tyr Ile	Cys Glu Arg
1460	1465	1470	
His Phe	Gln Lys Val Leu Asn	Arg Ser Leu Phe Thr	Gly Leu Arg
1475	1480	1485	
Ser Ile	Thr His Phe Gly Arg	Pro Pro Phe Glu Pro	Phe Phe Asn
1490	1495	1500	
Ser Leu	Gln Glu Val His Pro	Gln Val Arg Lys Ile	Gly Val Phe
1505	1510	1515	
Ser Cys	Gly Pro Pro Gly Met	Thr Lys Asn Val Glu	Lys Ala Cys
1520	1525	1530	
Gln Leu	Ile Asn Arg Gln Asp	Arg Thr His Phe Ser	His His Tyr
1535	1540	1545	
Glu Asn	Phe		
1550			

<210> 13
 <211> 6375
 <212> DNA
 <213> Homo sapiens

<400> 13
ggctctgtcct gagccgacac ctgcacagtg gcgagaccaa ggacccagag agaaaggtga 60
gagtgcagcc ggggaggctg aggatcgggc gagctggaag agtgaggggtg aaggcaagaa 120
gtagagcaca gaagcaaaga ttttaagagg aaagaagaca tttgaaccca acaccacctt 180
aaaccacagg ctgcaggggtt ggcatgctcc gtgcaagacc agaggcactg atgctcctgg 240
gagctcttct gactggatcc ctgggtccat cgggcagtca ggacgcactc tcaactgccct 300
gggaagtgca gcgctatgac ggctggttta acaacctgag gcaccacgag cgtggtgctg 360
ttggctgccg gttgcagcgc cgcgtaccag ccaattacgc cgacgggtgtg tatcaggctc 420
tggaggagcc gcagctgccc aaccgcgcc ggctcagcaa cgcagccacg cggggcatag 480
ccggcctgcc gtcgctccac aaccgcaccg tactgggggt cttctttggc taccatgttc 540
tttccgacgt ggtgagcgtg gaaacgcccg gttgccccgc cgagttcctc aacatccgca 600
tcccacctgg agacctcgtg ttcgaccccg accagcgccg ggacgtgggtg ctgcccttcc 660
agaggagccg ctgggacccc gagaccggac ggagtcccag caacccccgg gacctggcca 720
accaggtgac gggctggctg gacggcagcg ccatctatgg ctctcgcac tcctggagcg 780
acgcgctgcg gagcttctcg gggggacagc tggcgtcggg gcccgacccc gctttccccc 840
gagactcgca gaacccccctg ctcatgtggg cggcgcccga ccccgccacc gggcagaacg 900
ggccccgggg gctgtacgcc ttcggggcag agagagggaa ccgggaaccc ttcctgcagg 960
cgctgggcct gctctggttc cgctaccaca acctgtgggc gcagaggctg gcccgccagc 1020
accagactg ggaggacgag gagctgttcc agcacgcacg caagaggggc atcgccacct 1080
accagaacat cgctgtgtat gagtggctgc ccagcttcct gcagaaaaca ctcccgaggt 1140
atacaggata ccgtcctttc ctagaccca gcctctcccc ggaatttgtg gtggcctctg 1200
agcagttctt ctctaccatg gtgccccctg gtgtctacat gagaaatgcc agctgtcatt 1260
tccggaaggt cctgaacaag ggttttcaa gctccaagc tctcagggtc tgcaacaact 1320
actggattcg ggagaacccc aatctgaaca gtaccagga ggtgaatgag ctgctgctgg 1380
gaatggcctc ccagatttcg gagtggagg acaacatagt ggttgaagat ctgagggatt 1440
actggcctgg ccctggcaaa ttctcccgta cagactatgt ggccagcagc atccaacgtg 1500
gccgagatat ggggctgccc agctatagcc aggcctgct ggcctttggg ctggacatcc 1560
caaggaactg gagtgatctc aaccctaatt tggaccccca ggtgctggag gccacagctg 1620
ccctgtacaa ccaggaccta tccagctag agctgctcct tggcgggctc ctggagagcc 1680
atggggaccc tggacccctg ttcagtgcc ttgtcctcga ccagtttgta cggctgcggg 1740
atggtgaccg ctactggttt gagaacacca ggaatgggct gttctccaag aaggagattg 1800

aagacatccg aaataccacc ctgcgggacg tgctggctgc tgttatcaac attgacccca	1860
gtgccctgca gccaatgtc tttgtctggc ataaagggtgc accctgccct caacctaagc	1920
agctcacaac tgacggcctg cccagtggtg caccctgac tgtgcttgac ttctttgaag	1980
gcagcagccc tggttttgcc atcaccatca ttgtctctg ctgccttccc ttagtgagtc	2040
tgcttctctc tggagtgggtg gcctatttcc ggggccgaga acacaagaag ctacaaaaga	2100
aactcaaaga gagcgtgaag aaggaagcag ccaaagatgg agtgccagcg atggagtggc	2160
caggcccca ggagaggagc agtcccatca tcatccagct gctgtcagac aggtgtctgc	2220
aggtcctgaa caggcatctc actgtgctcc gtgtgggtcca gctgcagcct ctgcagcagg	2280
tcaacctcat cctgtccaac aaccgaggat gccgcacct gctgctcaag atccctaagg	2340
agtatgacct ggtgctgctg tttagttctg aagaggaacg gggcgcttt gtgcagcagc	2400
tatgggactt ctgcgtgcgc tgggctctgg gcctccatgt ggctgagatg agcgagaagg	2460
agctatttag gaaggctgtg acaaagcagc agcgggaacg catcctggag atcttcttca	2520
gacacctttt tgctcagggtg ctggacatca accaggccga cgcagggacc ctgcccctgg	2580
actcctccca gaagggtgcgg gaggcctga cctgcgagct gagcagggcc gagtttgccg	2640
agtccctggg cctcaagccc caggacatgt ttgtggagtc catgttctct ctggctgaca	2700
aggatggcaa tggctacctg tccttccgag agttcctgga catcctgggtg gtcttcatga	2760
aaggctcccc agaggataag tcccgctctaa tgtttaccat gtatgacctg gatgagaatg	2820
gcttctctc caaggacgaa ttcttcacca tgatgcgatc cttcatcgag atctccaaca	2880
actgcctgtc caaggcccag ctggccgagg tgggtggagtc tatgttccgg gagtcgggat	2940
tccaggacaa ggaggagctg acatgggagg attttctact catgctgcgg gaccatgaca	3000
gcgagctccg cttcacgcag ctctgtgtca aagggtggagg tggaggtgga aatggtatta	3060
gagatatctt taaacaaaac atcagctgtc gagtctcggt catcactcgg acacctgggg	3120
agcgtccca ccccgaggga ctggggcccc ctgtcccaga agccccagag ctgggaggcc	3180
ctggactgaa gaagaggttt ggcaaaaagg cagcagtgcc cactccccgg ctgtacacag	3240
aggcgctgca agagaagatg cagcgaggct tcctagccca aaagctgcag cagtacaagc	3300
gcttcgtgga gaactaccgg aggcacatcg tgtgtgtggc aatcttctcg gccatctgtg	3360
ttggcgtgtt tgcagatcgt gcttactact atggctttgc cttgccacce tcggacattg	3420
cacagaccac cctcgtgggc atcatcctgt cagcaggcac ggcggccagc gtctccttca	3480
tgttctctta tatcttgctc accatgtgcc gcaacctcat aaccttctg cgagagactt	3540
tcctcaaccg ctatgtgcct tttgatgccg cagtggactt ccaccgtgg atcgccatgg	3600
ctgctgttgt cctggccatt ttgcacagt ctggccacgc agtcaatgtc tacatcttct	3660

cagtcagccc actcagcctg ctggcctgca tattcccca	cgtctttgtg aatgatgggt	3720
ccaagcttcc ccagaagttc tattggtggt tcttcagac	cgtcccaggt atgacaggtg	3780
tgcttctgct cctggctcctg gccatcatgt atgtcttcgc	ctcccaccac ttccgcccgc	3840
gcagcttccg gggcttctgg ctgacccacc acctctacat	cctgctctat gccctgctca	3900
tcatccatgg cagctatgct ctgatccagc tgcccacttt	ccacatctac ttccctgggtcc	3960
cggcaatcat ctatggaggt gacaagctgg tgagcctgag	ccggaagaag gtggagatca	4020
gcgtggtgaa ggcggagctg ctgccctcag gagtgaacct	cctgcaattc cagaggcccc	4080
aaggctttga gtacaagtca ggacagtggg tgccgatcgc	ctgcctgggt ctggggacca	4140
ccgagtacca ccccttcaca ctgacctccg cgccccatga	ggacacactc agcctgcaca	4200
tccgggcagt gggggccctgg accactcgcc tcaggagat	ctactcatcc ccaaagggca	4260
atggctgtgc tggataccca aagctgtacc ttgatggacc	gtttggagag ggccatcagg	4320
agtggcataa atttgaggtg tcagtgttgg tgggaggggg	cattgggggtc accccctttg	4380
cctccatcct caaagacctg gtcttcaagt catccttggg	cagccaaatg ctgtgtaaga	4440
agatctactt catctgggtg acacggacc agcgtcagtt	tgagtggctg gctgacatca	4500
tccaagaggt ggaggagaac gaccaccagg acctggtgtc	tgtgcacatt tatgtcacc	4560
agctggctga gaagttcgac ctcaggacca ccattgtata	catctgcgag cggcacttcc	4620
agaaagtgtc gaaccggagt ctgttcacgg gcctgcgtc	catcacccac tttggccgtc	4680
cccccttca gcccttcttc aactccctgc aggaggtcca	cccacaggtg cgcaagatcg	4740
gggtgttcag ctgcggccct ccaggaatga ccaagaatgt	agagaaggcc tgtcagctcg	4800
tcaacaggca ggaccgagcc cacttcatgc accactatga	gaacttctga gcctgtctc	4860
cctggctgct gcttccagta tctgccttc tcttctgtgc	acctaaagttg cccagccctg	4920
ctggcaatct ctccatcaga atccacctta ggctcagct	ggagggctgc agagcccctc	4980
ccaatattgg gagaatattg accagacaa ttatacaaat	gagaaaaggc aggagactat	5040
gttctacaat tgcagtgc atgattata agtcacctg	tttatcaacg gcaccattcc	5100
tgcagccctc cagacttctt gcccttagca agtgcgcaac	cagtcaggat ctcccaaaga	5160
agataaagac cactctcac ccagctcaa gccatggcag	gcgtggcaag caaagtgggg	5220
aggagacagt cctgcttgt gacaagtgtg gaggtgaaaa	ggtcaatagt gcttgtctcc	5280
gatagctccc cacatctcta attgacttcc acaaaatcga	tgcgttgctt tggattttgc	5340
ttggactgac atttgaggga ggaggaggct gggatcctct	ggctgagaat ctctcagag	5400
cccagtgcag aagctgtgat gcttagaacc tggacagccc	gactgcctca actctgtctc	5460

cagggtctatt cctccagct ccaaaaggag cagccctact tctacccctt cccgtcccca 5520
 aagtgtcagc aactttgagg agggcaccag gaaacaaaga tgccttccca gccctgatat 5580
 tcttgatgtc accagtgata cccactgccc tgacccttgg gcaggccccct ctctgcatct 5640
 actggagtgg tccctgggct cttggggctg aaggattcca gcctctctgc cagatattca 5700
 gtactcgatc tcaattcccc tcttcacaa gagttgggtg accagctgtc ctagtttgcc 5760
 caggactctc cctgttttag cactgaaagt ctcttgcccc aggaaacccc atcagtccca 5820
 ggcagattgg gacagctggt caccttacgc aagagccagg ctgaaacatc cctccatac 5880
 tcagctcttt aacttttctt ttcctttttc atcgggctct ttcttaaaaa gctgagctgt 5940
 aaaatatttt acatcgaggt ataataaata atcatgtaca tgttttacca ccaccaggt 6000
 caagacatag aatgtttcaa catttccatc accccagaaa ctccccttgt acccccttcc 6060
 cttcgtctcc cctagctcct agaagcaacc actgatgtga tttctacca atccagtttt 6120
 ggtcctacta aatatactct tttgagactg gcctctttta ctaccataa tgcctttgta 6180
 attcatccat gctggtgtgt gtatcagcag tttgttcctt ttcattgctg agtagtatc 6240
 tattgtagag atgtaccaca gtttgtttat tcttctgttg atggacgttt ggggtgtttc 6300
 taattttgaa tgattataaa taaaaattct gtgagtgttc ttgtaaaaaa aaaaaaaaaa 6360
 aaaaaaaaaa aaaaa 6375

<210> 14
 <211> 1548
 <212> PRT
 <213> Homo sapiens

<400> 14
 Met Leu Arg Ala Arg Pro Glu Ala Leu Met Leu Leu Gly Ala Leu Leu
 1 5 10 15
 Thr Gly Ser Leu Gly Pro Ser Gly Ser Gln Asp Ala Leu Ser Leu Pro
 20 25 30
 Trp Glu Val Gln Arg Tyr Asp Gly Trp Phe Asn Asn Leu Arg His His
 35 40 45
 Glu Arg Gly Ala Val Gly Cys Arg Leu Gln Arg Arg Val Pro Ala Asn
 50 55 60
 Tyr Ala Asp Gly Val Tyr Gln Ala Leu Glu Glu Pro Gln Leu Pro Asn
 65 70 75 80
 Pro Arg Arg Leu Ser Asn Ala Ala Thr Arg Gly Ile Ala Gly Leu Pro
 85 90 95
 Ser Leu His Asn Arg Thr Val Leu Gly Val Phe Phe Gly Tyr His Val
 100 105 110
 Leu Ser Asp Val Val Ser Val Glu Thr Pro Gly Cys Pro Ala Glu Phe
 115 120 125

29/61

Leu Asn Ile Arg Ile Pro Pro Gly Asp Leu Val Phe Asp Pro Asp Gln
 130 135 140
 Arg Gly Asp Val Val Leu Pro Phe Gln Arg Ser Arg Trp Asp Pro Glu
 145 150 155 160
 Thr Gly Arg Ser Pro Ser Asn Pro Arg Asp Leu Ala Asn Gln Val Thr
 165 170 175
 Gly Trp Leu Asp Gly Ser Ala Ile Tyr Gly Ser Ser His Ser Trp Ser
 180 185 190
 Asp Ala Leu Arg Ser Phe Ser Gly Gly Gln Leu Ala Ser Gly Pro Asp
 195 200 205
 Pro Ala Phe Pro Arg Asp Ser Gln Asn Pro Leu Leu Met Trp Ala Ala
 210 215 220
 Pro Asp Pro Ala Thr Gly Gln Asn Gly Pro Arg Gly Leu Tyr Ala Phe
 225 230 235 240
 Gly Ala Glu Arg Gly Asn Arg Glu Pro Phe Leu Gln Ala Leu Gly Leu
 245 250 255
 Leu Trp Phe Arg Tyr His Asn Leu Trp Ala Gln Arg Leu Ala Arg Gln
 260 265 270
 His Pro Asp Trp Glu Asp Glu Glu Leu Phe Gln His Ala Arg Lys Arg
 275 280 285
 Val Ile Ala Thr Tyr Gln Asn Ile Ala Val Tyr Glu Trp Leu Pro Ser
 290 295 300
 Phe Leu Gln Lys Thr Leu Pro Glu Tyr Thr Gly Tyr Arg Pro Phe Leu
 305 310 315 320
 Asp Pro Ser Ile Ser Pro Glu Phe Val Val Ala Ser Glu Gln Phe Phe
 325 330 335
 Ser Thr Met Val Pro Pro Gly Val Tyr Met Arg Asn Ala Ser Cys His
 340 345 350
 Phe Arg Lys Val Leu Asn Lys Gly Phe Gln Ser Ser Gln Ala Leu Arg
 355 360 365
 Val Cys Asn Asn Tyr Trp Ile Arg Glu Asn Pro Asn Leu Asn Ser Thr
 370 375 380
 Gln Glu Val Asn Glu Leu Leu Leu Gly Met Ala Ser Gln Ile Ser Glu
 385 390 395 400
 Leu Glu Asp Asn Ile Val Val Glu Asp Leu Arg Asp Tyr Trp Pro Gly
 405 410 415
 Pro Gly Lys Phe Ser Arg Thr Asp Tyr Val Ala Ser Ser Ile Gln Arg
 420 425 430
 Gly Arg Asp Met Gly Leu Pro Ser Tyr Ser Gln Ala Leu Leu Ala Phe
 435 440 445

Gly Leu Asp Ile Pro Arg Asn Trp Ser Asp Leu Asn Pro Asn Val Asp
 450 455 460

Pro Gln Val Leu Glu Ala Thr Ala Ala Leu Tyr Asn Gln Asp Leu Ser
 465 470 475 480

Gln Leu Glu Leu Leu Leu Gly Gly Leu Leu Glu Ser His Gly Asp Pro
 485 490 495

Gly Pro Leu Phe Ser Ala Ile Val Leu Asp Gln Phe Val Arg Leu Arg
 500 505 510

Asp Gly Asp Arg Tyr Trp Phe Glu Asn Thr Arg Asn Gly Leu Phe Ser
 515 520 525

Lys Lys Glu Ile Glu Asp Ile Arg Asn Thr Thr Leu Arg Asp Val Leu
 530 535 540

Val Ala Val Ile Asn Ile Asp Pro Ser Ala Leu Gln Pro Asn Val Phe
 545 550 555 560

Val Trp His Lys Gly Ala Pro Cys Pro Gln Pro Lys Gln Leu Thr Thr
 565 570 575

Asp Gly Leu Pro Gln Cys Ala Pro Leu Thr Val Leu Asp Phe Phe Glu
 580 585 590

Gly Ser Ser Pro Gly Phe Ala Ile Thr Ile Ile Ala Leu Cys Cys Leu
 595 600 605

Pro Leu Val Ser Leu Leu Leu Ser Gly Val Val Ala Tyr Phe Arg Gly
 610 615 620

Arg Glu His Lys Lys Leu Gln Lys Lys Leu Lys Glu Ser Val Lys Lys
 625 630 635 640

Glu Ala Ala Lys Asp Gly Val Pro Ala Met Glu Trp Pro Gly Pro Lys
 645 650 655

Glu Arg Ser Ser Pro Ile Ile Ile Gln Leu Leu Ser Asp Arg Cys Leu
 660 665 670

Gln Val Leu Asn Arg His Leu Thr Val Leu Arg Val Val Gln Leu Gln
 675 680 685

Pro Leu Gln Gln Val Asn Leu Ile Leu Ser Asn Asn Arg Gly Cys Arg
 690 695 700

Thr Leu Leu Leu Lys Ile Pro Lys Glu Tyr Asp Leu Val Leu Leu Phe
 705 710 715 720

Ser Ser Glu Glu Glu Arg Gly Ala Phe Val Gln Gln Leu Trp Asp Phe
 725 730 735

Cys Val Arg Trp Ala Leu Gly Leu His Val Ala Glu Met Ser Glu Lys
 740 745 750

Glu Leu Phe Arg Lys Ala Val Thr Lys Gln Gln Arg Glu Arg Ile Leu
 755 760 765

31/61

Glu Ile Phe Phe Arg His Leu Phe Ala Gln Val Leu Asp Ile Asn Gln
 770 775 780
 Ala Asp Ala Gly Thr Leu Pro Leu Asp Ser Ser Gln Lys Val Arg Glu
 785 790 795 800
 Ala Leu Thr Cys Glu Leu Ser Arg Ala Glu Phe Ala Glu Ser Leu Gly
 805 810 815
 Leu Lys Pro Gln Asp Met Phe Val Glu Ser Met Phe Ser Leu Ala Asp
 820 825 830
 Lys Asp Gly Asn Gly Tyr Leu Ser Phe Arg Glu Phe Leu Asp Ile Leu
 835 840 845
 Val Val Phe Met Lys Gly Ser Pro Glu Asp Lys Ser Arg Leu Met Phe
 850 855 860
 Thr Met Tyr Asp Leu Asp Glu Asn Gly Phe Leu Ser Lys Asp Glu Phe
 865 870 875 880
 Phe Thr Met Met Arg Ser Phe Ile Glu Ile Ser Asn Asn Cys Leu Ser
 885 890 895
 Lys Ala Gln Leu Ala Glu Val Val Glu Ser Met Phe Arg Glu Ser Gly
 900 905 910
 Phe Gln Asp Lys Glu Glu Leu Thr Trp Glu Asp Phe His Phe Met Leu
 915 920 925
 Arg Asp His Asp Ser Glu Leu Arg Phe Thr Gln Leu Cys Val Lys Gly
 930 935 940
 Gly Gly Gly Gly Gly Asn Gly Ile Arg Asp Ile Phe Lys Gln Asn Ile
 945 950 955 960
 Ser Cys Arg Val Ser Phe Ile Thr Arg Thr Pro Gly Glu Arg Ser His
 965 970 975
 Pro Gln Gly Leu Gly Pro Pro Val Pro Glu Ala Pro Glu Leu Gly Gly
 980 985 990
 Pro Gly Leu Lys Lys Arg Phe Gly Lys Lys Ala Ala Val Pro Thr Pro
 995 1000 1005
 Arg Leu Tyr Thr Glu Ala Leu Gln Glu Lys Met Gln Arg Gly Phe
 1010 1015 1020
 Leu Ala Gln Lys Leu Gln Gln Tyr Lys Arg Phe Val Glu Asn Tyr
 1025 1030 1035
 Arg Arg His Ile Val Cys Val Ala Ile Phe Ser Ala Ile Cys Val
 1040 1045 1050
 Gly Val Phe Ala Asp Arg Ala Tyr Tyr Tyr Gly Phe Ala Leu Pro
 1055 1060 1065
 Pro Ser Asp Ile Ala Gln Thr Thr Leu Val Gly Ile Ile Leu Ser
 1070 1075 1080

Arg Gly	Thr	Ala	Ala	Ser	Val	Ser	Phe	Met	Phe	Ser	Tyr	Ile	Leu	
1085					1090					1095				
Leu	Thr	Met	Cys	Arg	Asn	Leu	Ile	Thr	Phe	Leu	Arg	Glu	Thr	Phe
1100					1105						1110			
Leu	Asn	Arg	Tyr	Val	Pro	Phe	Asp	Ala	Ala	Val	Asp	Phe	His	Arg
1115					1120						1125			
Trp	Ile	Ala	Met	Ala	Ala	Val	Val	Leu	Ala	Ile	Leu	His	Ser	Ala
1130					1135						1140			
Gly	His	Ala	Val	Asn	Val	Tyr	Ile	Phe	Ser	Val	Ser	Pro	Leu	Ser
1145					1150						1155			
Leu	Leu	Ala	Cys	Ile	Phe	Pro	Asn	Val	Phe	Val	Asn	Asp	Gly	Ser
1160					1165						1170			
Lys	Leu	Pro	Gln	Lys	Phe	Tyr	Trp	Trp	Phe	Phe	Gln	Thr	Val	Pro
1175					1180						1185			
Gly	Met	Thr	Gly	Val	Leu	Leu	Leu	Leu	Val	Leu	Ala	Ile	Met	Tyr
1190					1195						1200			
Val	Phe	Ala	Ser	His	His	Phe	Arg	Arg	Arg	Ser	Phe	Arg	Gly	Phe
1205					1210						1215			
Trp	Leu	Thr	His	His	Leu	Tyr	Ile	Leu	Leu	Tyr	Ala	Leu	Leu	Ile
1220					1225						1230			
Ile	His	Gly	Ser	Tyr	Ala	Leu	Ile	Gln	Leu	Pro	Thr	Phe	His	Ile
1235					1240						1245			
Tyr	Phe	Leu	Val	Pro	Ala	Ile	Ile	Tyr	Gly	Gly	Asp	Lys	Leu	Val
1250					1255						1260			
Ser	Leu	Ser	Arg	Lys	Lys	Val	Glu	Ile	Ser	Val	Val	Lys	Ala	Glu
1265					1270						1275			
Leu	Leu	Pro	Ser	Gly	Val	Thr	Tyr	Leu	Gln	Phe	Gln	Arg	Pro	Gln
1280					1285						1290			
Gly	Phe	Glu	Tyr	Lys	Ser	Gly	Gln	Trp	Val	Arg	Ile	Ala	Cys	Leu
1295					1300						1305			
Ala	Leu	Gly	Thr	Thr	Glu	Tyr	His	Pro	Phe	Thr	Leu	Thr	Ser	Ala
1310					1315						1320			
Pro	His	Glu	Asp	Thr	Leu	Ser	Leu	His	Ile	Arg	Ala	Val	Gly	Pro
1325					1330						1335			
Trp	Thr	Thr	Arg	Leu	Arg	Glu	Ile	Tyr	Ser	Ser	Pro	Lys	Gly	Asn
1340					1345						1350			
Gly	Cys	Ala	Gly	Tyr	Pro	Lys	Leu	Tyr	Leu	Asp	Gly	Pro	Phe	Gly
1355					1360						1365			
Glu	Gly	His	Gln	Glu	Trp	His	Lys	Phe	Glu	Val	Ser	Val	Leu	Val
1370					1375						1380			

33/61

Gly Gly 1385	Gly Ile 1390	Gly Val 1395	Thr 1395	Pro Phe Ala Ser Ile 1395	Leu Lys Asp
Leu Val 1400	Phe Lys Ser Ser 1405	Leu 1410	Gly Ser Gln Met 1410	Leu Cys Lys Lys	
Ile Tyr 1415	Phe Ile Trp Val 1420	Thr 1425	Arg Thr Gln Arg 1425	Gln Phe Glu Trp	
Leu Ala 1430	Asp Ile Ile Gln 1435	Glu 1440	Val Glu Glu Asn 1440	Asp His Gln Asp	
Leu Val 1445	Ser Val His Ile 1450	Tyr 1455	Val Thr Gln Leu 1455	Ala Glu Lys Phe	
Asp Leu 1460	Arg Thr Thr Met 1465	Leu 1470	Tyr Ile Cys Glu 1470	Arg His Phe Gln	
Lys Val 1475	Leu Asn Arg Ser 1480	Leu 1485	Phe Thr Gly Leu 1485	Arg Ser Ile Thr	
His Phe 1490	Gly Arg Pro Pro 1495	Phe 1500	Glu Pro Phe Phe 1500	Asn Ser Leu Gln	
Glu Val 1505	His Pro Gln Val 1510	Arg 1515	Lys Ile Gly Val 1515	Phe Ser Cys Gly	
Pro Pro 1520	Gly Met Thr Lys 1525	Asn 1530	Val Glu Lys Ala 1530	Cys Gln Leu Val	
Asn Arg 1535	Gln Asp Arg Ala 1540	His 1545	Phe Met His His 1545	Tyr Glu Asn Phe	

<210> 15
 <211> 1676
 <212> DNA
 <213> Homo sapiens

<400> 15
 agccttatgg attggattcg actgaccaaa agtggaagg atctaacggg attaaaaggc 60
 aggttaattg aagtaactga agaagaactt aagaaacaca acaaaaaaga tgattgttgg 120
 atatgcataa gaggtttcgt ttataatgtc agcccttata tggagtatca tcctggtgga 180
 gaagatgaac taatgagagc agcaggatca gatggtactg aactttttga tcagggttcat 240
 cgttggtgca attatgaatc catgctgaaa gaatgcctgg ttggcagaat ggccattaaa 300
 cctgctgttc tgaaagacta tcgtgaggag gaaaagaaag tcttaaattg catgcttccc 360
 aagagccaag tgacagatac acttgccaaa gaaggtccta gttatccaag ctatgattgg 420
 ttccaaacag actcttttagt caccattgcc atatatacta aacagaagga tatcaattta 480
 gactcaatta tagttgatca tcagaatgat tccttttagag cagaaacaat tattaaggat 540
 tgtttatatc ttatacatat tgggctaagc catgagggtc aggaagattt ttctgtgcgg 600
 gttgttgaga gtgtgggaaa aatagagatt gttctacaaa aaaaagagaa tacttcttgg 660

gactttcttg gccatccct gaagaatcat aattcactta ttccaaggaa agatacaggt 720
 ttgtactaca gaaagtgcc gtttaatttcc aaggaagatg ttactcatga tacgaggctt 780
 ttctgtttga tgctgccacc aagcactcat cttcaagtgc ccattgggca acatgtttac 840
 ctcaagctac ctattacagg tacagaaata gtaaagccat atacacctgt atctggttcc 900
 ttactctcag agttcaagga accagttctt cccaacaata aatacatcta ctttttgata 960
 aaaatctatc ccaactggact cttcacacca gagcttgatc gtcttcagat tggagatttt 1020
 gtttctgtaa gcagtcctga gggcaatttt aaaatatcca agttccaaga attagaagat 1080
 ctctttttgt tggcagctgg aacaggcttc acaccaatgg ttaaaatact gaattatgct 1140
 ttgactgata taccagctct caggaaagtg aagctgatgt tcttcaataa aacagaagat 1200
 gatataattt ggagaagcca attggagaaa ttagcattta aagataaaaag actggatggt 1260
 gaatttggtc tctcagcacc tatttctgaa tggaatggca aacagggaca tatttcacca 1320
 gctcttcttt ctgaattttt gaaaagaaat ttggacaaat ccaaagttct cgtctgcatt 1380
 tgtggaccag tgccatttac agaacaagga gtaaggttgc tgcattgatct caacttttcc 1440
 aaaaatgaga tccatagttt tacagcataa tgaagagctg tcattgtcct ttattcaact 1500
 agtttatcta aatttgtgat tgcttagggg tttttaagag aacatttttg tacataacaa 1560
 aaggttaact agaatccagc cttcagtttc ttaaataaaa tcaaatgttc cttcagtaca 1620
 ggtaacttct tggctttctt ttgtaccaca acttatttta ctactgatat ttgacc 1676

<210> 16
 <211> 487
 <212> PRT
 <213> Homo sapiens

<400> 16
 Met Asp Trp Ile Arg Leu Thr Lys Ser Gly Lys Asp Leu Thr Gly Leu
 1 5 10 15
 Lys Gly Arg Leu Ile Glu Val Thr Glu Glu Glu Leu Lys Lys His Asn
 20 25 30
 Lys Lys Asp Asp Cys Trp Ile Cys Ile Arg Gly Phe Val Tyr Asn Val
 35 40 45
 Ser Pro Tyr Met Glu Tyr His Pro Gly Gly Glu Asp Glu Leu Met Arg
 50 55 60
 Ala Ala Gly Ser Asp Gly Thr Glu Leu Phe Asp Gln Val His Arg Trp
 65 70 75 80
 Val Asn Tyr Glu Ser Met Leu Lys Glu Cys Leu Val Gly Arg Met Ala
 85 90 95
 Ile Lys Pro Ala Val Leu Lys Asp Tyr Arg Glu Glu Glu Lys Lys Val
 100 105 110

35/61

Leu Asn Gly Met Leu Pro Lys Ser Gln Val Thr Asp Thr Leu Ala Lys
 115 120 125
 Glu Gly Pro Ser Tyr Pro Ser Tyr Asp Trp Phe Gln Thr Asp Ser Leu
 130 135 140
 Val Thr Ile Ala Ile Tyr Thr Lys Gln Lys Asp Ile Asn Leu Asp Ser
 145 150 155 160
 Ile Ile Val Asp His Gln Asn Asp Ser Phe Arg Ala Glu Thr Ile Ile
 165 170 175
 Lys Asp Cys Leu Tyr Leu Ile His Ile Gly Leu Ser His Glu Val Gln
 180 185 190
 Glu Asp Phe Ser Val Arg Val Val Glu Ser Val Gly Lys Ile Glu Ile
 195 200 205
 Val Leu Gln Lys Lys Glu Asn Thr Ser Trp Asp Phe Leu Gly His Pro
 210 215 220
 Leu Lys Asn His Asn Ser Leu Ile Pro Arg Lys Asp Thr Gly Leu Tyr
 225 230 235 240
 Tyr Arg Lys Cys Gln Leu Ile Ser Lys Glu Asp Val Thr His Asp Thr
 245 250 255
 Arg Leu Phe Cys Leu Met Leu Pro Pro Ser Thr His Leu Gln Val Pro
 260 265 270
 Ile Gly Gln His Val Tyr Leu Lys Leu Pro Ile Thr Gly Thr Glu Ile
 275 280 285
 Val Lys Pro Tyr Thr Pro Val Ser Gly Ser Leu Leu Ser Glu Phe Lys
 290 295 300
 Glu Pro Val Leu Pro Asn Asn Lys Tyr Ile Tyr Phe Leu Ile Lys Ile
 305 310 315 320
 Tyr Pro Thr Gly Leu Phe Thr Pro Glu Leu Asp Arg Leu Gln Ile Gly
 325 330 335
 Asp Phe Val Ser Val Ser Ser Pro Glu Gly Asn Phe Lys Ile Ser Lys
 340 345 350
 Phe Gln Glu Leu Glu Asp Leu Phe Leu Leu Ala Ala Gly Thr Gly Phe
 355 360 365
 Thr Pro Met Val Lys Ile Leu Asn Tyr Ala Leu Thr Asp Ile Pro Ser
 370 375 380
 Leu Arg Lys Val Lys Leu Met Phe Phe Asn Lys Thr Glu Asp Asp Ile
 385 390 395 400
 Ile Trp Arg Ser Gln Leu Glu Lys Leu Ala Phe Lys Asp Lys Arg Leu
 405 410 415
 Asp Val Glu Phe Val Leu Ser Ala Pro Ile Ser Glu Trp Asn Gly Lys
 420 425 430

36/61

Gln Gly His Ile Ser Pro Ala Leu Leu Ser Glu Phe Leu Lys Arg Asn
 435 440 445

Leu Asp Lys Ser Lys Val Leu Val Cys Ile Cys Gly Pro Val Pro Phe
 450 455 460

Thr Glu Gln Gly Val Arg Leu Leu His Asp Leu Asn Phe Ser Lys Asn
 465 470 475 480

Glu Ile His Ser Phe Thr Ala
 485

<210> 17
 <211> 1340
 <212> DNA
 <213> Homo sapiens

<400> 17
 ccacccagtc atgggggaca ccttcatccg tcacatcgcc ctgctgggct ttgagaagcg 60
 cttcgtaccc agccagcact atgtgtacat gttcctggtg aaatggcagg acctgtcggg 120
 gaagggtggc taccggcgct tcaccgagat ctacgagttc cataaaacct taaaagaaat 180
 gttccctatt gaggcagggg cgatcaatcc agagaacagg atcatcccc acctcccagc 240
 tcccaagtgg ttgacgggc agcggggccg cgagaaccgc cagggcacac ttaccgagta 300
 ctgcagcacg ctcatgagcc tgcccaccaa gatctccgcg tgtccccacc tctctgactt 360
 cttcaagggtg cgccctgatg acctcaagct cccacaggac aaccagacaa aaaagccaga 420
 gacatacttg atgccc aaag atggcaagag taccgcgaca gacatcaccg gccccatcat 480
 cctgcagacg taccgcgcca ttgccgacta cgagaagacc tcgggctccg agatggctct 540
 gtccacgggg gacgtgggtg aggtcgtgga gaagagcgag agcggttggt ggttctgtca 600
 gatgaaagca aagcgaggct ggatcccagc atccttctc gagcccctgg acagtctga 660
 cgagacggaa gaccctgagc ccaactatgc aggtgagcca tacgtcgcca tcaaggccta 720
 cactgctgtg gagggggacg aggtgtccct gctcgagggg gaagctggtg aggtcattca 780
 caagctcctg gacggctggt gggtcacag gaaagacgac gtcacaggct actttccgtc 840
 catgtacctg caaaagtcgg ggcaagacgt gtcccaggcc caacgccaga tcaagcgggg 900
 ggcgcgcgcc cgcaggctcgt ccatccgcaa cgcgcacagc atccatcagc ggtcgcggaa 960
 gcgcctcagc caggacgcct atcgccgcaa cagcgtccgt tttctgcagc agcgacgccg 1020
 ccaggcgcgg ccgggaccgc agagccccgg gagcccgctc gaggaggagc ggcagacgca 1080
 gcgctctaaa ccgcagccgg cggtgcccc gcggccgagc gccgacctca tcctgaaccg 1140
 ctgcagcgag agcaccaagc ggaagctggc gtctgccgct tgaggctgga gcgcagtccc 1200
 cagctagcgt ctcggccctt gccgccccgt gcctgtacat acgtgttcta tagagcctgg 1260
 cgtctggacg ccgagggcag ccccgacccc tgtccagcgc ggctcccgcc acctcaata 1320

aatgttgctt ggagtggaag

1340

<210> 18

<211> 390

<212> PRT

<213> Homo sapiens

<400> 18

Met Gly Asp Thr Phe Ile Arg His Ile Ala Leu Leu Gly Phe Glu Lys
 1 5 10 15

Arg Phe Val Pro Ser Gln His Tyr Val Tyr Met Phe Leu Val Lys Trp
 20 25 30

Gln Asp Leu Ser Glu Lys Val Val Tyr Arg Arg Phe Thr Glu Ile Tyr
 35 40 45

Glu Phe His Lys Thr Leu Lys Glu Met Phe Pro Ile Glu Ala Gly Ala
 50 55 60

Ile Asn Pro Glu Asn Arg Ile Ile Pro His Leu Pro Ala Pro Lys Trp
 65 70 75 80

Phe Asp Gly Gln Arg Ala Ala Glu Asn Arg Gln Gly Thr Leu Thr Glu
 85 90 95

Tyr Cys Ser Thr Leu Met Ser Leu Pro Thr Lys Ile Ser Arg Cys Pro
 100 105 110

His Leu Leu Asp Phe Phe Lys Val Arg Pro Asp Asp Leu Lys Leu Pro
 115 120 125

Thr Asp Asn Gln Thr Lys Lys Pro Glu Thr Tyr Leu Met Pro Lys Asp
 130 135 140

Gly Lys Ser Thr Ala Thr Asp Ile Thr Gly Pro Ile Ile Leu Gln Thr
 145 150 155 160

Tyr Arg Ala Ile Ala Asp Tyr Glu Lys Thr Ser Gly Ser Glu Met Ala
 165 170 175

Leu Ser Thr Gly Asp Val Val Glu Val Val Glu Lys Ser Glu Ser Gly
 180 185 190

Trp Trp Phe Cys Gln Met Lys Ala Lys Arg Gly Trp Ile Pro Ala Ser
 195 200 205

Phe Leu Glu Pro Leu Asp Ser Pro Asp Glu Thr Glu Asp Pro Glu Pro
 210 215 220

Asn Tyr Ala Gly Glu Pro Tyr Val Ala Ile Lys Ala Tyr Thr Ala Val
 225 230 235 240

Glu Gly Asp Glu Val Ser Leu Leu Glu Gly Glu Ala Val Glu Val Ile
 245 250 255

His Lys Leu Leu Asp Gly Trp Trp Val Ile Arg Lys Asp Asp Val Thr
 260 265 270

Gly Tyr Phe Pro Ser Met Tyr Leu Gln Lys Ser Gly Gln Asp Val Ser
 275 280 285
 Gln Ala Gln Arg Gln Ile Lys Arg Gly Ala Pro Pro Arg Arg Ser Ser
 290 295 300
 Ile Arg Asn Ala His Ser Ile His Gln Arg Ser Arg Lys Arg Leu Ser
 305 310 315 320
 Gln Asp Ala Tyr Arg Arg Asn Ser Val Arg Phe Leu Gln Gln Arg Arg
 325 330 335
 Arg Gln Ala Arg Pro Gly Pro Gln Ser Pro Gly Ser Pro Leu Glu Glu
 340 345 350
 Glu Arg Gln Thr Gln Arg Ser Lys Pro Gln Pro Ala Val Pro Pro Arg
 355 360 365
 Pro Ser Ala Asp Leu Ile Leu Asn Arg Cys Ser Glu Ser Thr Lys Arg
 370 375 380
 Lys Leu Ala Ser Ala Val
 385 390

<210> 19
 <211> 2206
 <212> DNA
 <213> Homo sapiens

<400> 19
 ctagtctttc agccttcagg ctgtttttgg cttgaagctc tcttggcctc ctagtcttcta 60
 cctaatacatg tccctgggtgg aggccatcag cctctggaat gaaggggtgc tggcagcgga 120
 caagaaggac tgggaaggag ccctggatgc cttcagtgcc gtccaggacc cccactccccg 180
 gatttgcttc aacattggct gcatgtacac tatcctgaag aacatgactg aagcagagaa 240
 ggccctttacc agaagcatta accgagacaa gcacttggca gtggcttact tccaacgagg 300
 gatgctctac taccagacag agaaatatga tttggctatc aaagacctta aagaagcctt 360
 gattcagctt cgaggggaacc agctgataga ctataagatc ctggggctcc agttcaagct 420
 gtttgctgt gaggtgttat ataacattgc tttcatgtat gccagaagg aggaatggaa 480
 aaaagctgaa gaacagttag cattggccac gagcatgaag tctgagccca gacattccaa 540
 aatcgacaag gcgatggagt gtgtctggaa gcagaagcta tatgagccag tggatgatccc 600
 tgtgggcaag ctgttttcgac caaatgagag acaagtggct cagctggcca agaaggatta 660
 cctaggcaag gcgacggctg tggcatctgt ggtggatcaa gacagtttct ctgggtttgc 720
 ccctctgcaa ccacaggcag ctgagcctcc acccagaccg aaaaccccag agatcttcag 780
 ggctctggaa ggggaggctc accgtgtgct atttgggttt gtgcctgaga caaaagaaga 840
 gctccaggctc atgccaggga acattgtctt tgtcttgaag aagggaatg ataactgggc 900
 cacggtcatg ttcaacgggc agaaggggct tgttccctgc aactaccttg aaccagttga 960

gttgcggatc caccctcagc agcagcccca ggaggaaagc tctccgcagt ccgacatccc 1020
 agctcctcct agttccaaag cccctggaaa accccagctg tcaccaggcc agaaacaaaa 1080
 agaagagcct aaggaagtga agctcagtgt tcccatgccc tacacactca aggtgcacta 1140
 caagtacacg gtagtcatga agactcagcc cgggctcccc tacagccagg tccgggacat 1200
 ggtgtctaag aaactggagc tccggctgga acacactaag ctgagctatc ggcctcggga 1260
 cagcaatgag ctggtgcccc tttcagaaga cagcatgaag gatgcctggg gccagggtgaa 1320
 aaactactgc ctgactctgt ggtgtgagaa cacagtgggt gaccaaggct ttccagatga 1380
 acccaaggaa agtgaaaaag ctgatgctaa taaccagaca acagaacctc agcttaagaa 1440
 aggcagccaa gtggaggcac tcttcagtta tgaggctacc caaccagagg acctggagtt 1500
 tcaggaaggg gatataatcc tgggtgtatc aaagggtgaat gaagaatggc tggaagggga 1560
 gtgcaaaggg aagggtgggca ttttcccaa agtttttgtt gaagactgcg caactacaga 1620
 tttggaaagc actcggagag aagtctagga tgtttcacia actacaaagc tgaagaaaat 1680
 gaagccctat tacttgtttg taagatttag cacccttctg ctgtatactg tactgagaca 1740
 ttacagtttg gaagtgttaa ctatttattc cctgttaaaa tttaacctac tagacaatga 1800
 tgtgagtacc caggatgatt tcctggggca cagtgggtga ggagatgggg acagggtgaat 1860
 ggaggagtta ggggagagga aaagtggatg gaagtgtctg gaaagggcac gagagagtct 1920
 tccagggtact gatcctgttt cttgctctga gtgctagcta gccagctgtg ttcacactgt 1980
 aaacattcat caagctgtac atttggtgca cttttctgtg tcataccaca ataaaaaaaa 2040
 acctatcatc atcttacaaa aacaagacac ccaagtccag gccaaggag taagtacaaa 2100
 tattcctgtt tctgaacat tactgtaatt ggctcttaag gcttgaagta accttatagg 2160
 ttactcataa ggcataata aataaacttg tttgttttct tttttc 2206

<210> 20

<211> 526

<212> PRT

<213> Homo sapiens

<400> 20

Met Ser Leu Val Glu Ala Ile Ser Leu Trp Asn Glu Gly Val Leu Ala
 1 5 10 15

Ala Asp Lys Lys Asp Trp Lys Gly Ala Leu Asp Ala Phe Ser Ala Val
 20 25 30

Gln Asp Pro His Ser Arg Ile Cys Phe Asn Ile Gly Cys Met Tyr Thr
 35 40 45

Ile Leu Lys Asn Met Thr Glu Ala Glu Lys Ala Phe Thr Arg Ser Ile
 50 55 60

Asn Arg Asp Lys His Leu Ala Val Ala Tyr Phe Gln Arg Gly Met Leu
65 70 75 80

Tyr Tyr Gln Thr Glu Lys Tyr Asp Leu Ala Ile Lys Asp Leu Lys Glu
85 90 95

Ala Leu Ile Gln Leu Arg Gly Asn Gln Leu Ile Asp Tyr Lys Ile Leu
100 105 110

Gly Leu Gln Phe Lys Leu Phe Ala Cys Glu Val Leu Tyr Asn Ile Ala
115 120 125

Phe Met Tyr Ala Lys Lys Glu Glu Trp Lys Lys Ala Glu Glu Gln Leu
130 135 140

Ala Leu Ala Thr Ser Met Lys Ser Glu Pro Arg His Ser Lys Ile Asp
145 150 155 160

Lys Ala Met Glu Cys Val Trp Lys Gln Lys Leu Tyr Glu Pro Val Val
165 170 175

Ile Pro Val Gly Lys Leu Phe Arg Pro Asn Glu Arg Gln Val Ala Gln
180 185 190

Leu Ala Lys Lys Asp Tyr Leu Gly Lys Ala Thr Val Val Ala Ser Val
195 200 205

Val Asp Gln Asp Ser Phe Ser Gly Phe Ala Pro Leu Gln Pro Gln Ala
210 215 220

Ala Glu Pro Pro Pro Arg Pro Lys Thr Pro Glu Ile Phe Arg Ala Leu
225 230 235 240

Glu Gly Glu Ala His Arg Val Leu Phe Gly Phe Val Pro Glu Thr Lys
245 250 255

Glu Glu Leu Gln Val Met Pro Gly Asn Ile Val Phe Val Leu Lys Lys
260 265 270

Gly Asn Asp Asn Trp Ala Thr Val Met Phe Asn Gly Gln Lys Gly Leu
275 280 285

Val Pro Cys Asn Tyr Leu Glu Pro Val Glu Leu Arg Ile His Pro Gln
290 295 300

Gln Gln Pro Gln Glu Glu Ser Ser Pro Gln Ser Asp Ile Pro Ala Pro
305 310 315 320

Pro Ser Ser Lys Ala Pro Gly Lys Pro Gln Leu Ser Pro Gly Gln Lys
325 330 335

Gln Lys Glu Glu Pro Lys Glu Val Lys Leu Ser Val Pro Met Pro Tyr
340 345 350

Thr Leu Lys Val His Tyr Lys Tyr Thr Val Val Met Lys Thr Gln Pro
355 360 365

Gly Leu Pro Tyr Ser Gln Val Arg Asp Met Val Ser Lys Lys Leu Glu
370 375 380

41/61

Leu Arg Leu Glu His Thr Lys Leu Ser Tyr Arg Pro Arg Asp Ser Asn
 385 390 395 400
 Glu Leu Val Pro Leu Ser Glu Asp Ser Met Lys Asp Ala Trp Gly Gln
 405 410 415
 Val Lys Asn Tyr Cys Leu Thr Leu Trp Cys Glu Asn Thr Val Gly Asp
 420 425 430
 Gln Gly Phe Pro Asp Glu Pro Lys Glu Ser Glu Lys Ala Asp Ala Asn
 435 440 445
 Asn Gln Thr Thr Glu Pro Gln Leu Lys Lys Gly Ser Gln Val Glu Ala
 450 455 460
 Leu Phe Ser Tyr Glu Ala Thr Gln Pro Glu Asp Leu Glu Phe Gln Glu
 465 470 475 480
 Gly Asp Ile Ile Leu Val Leu Ser Lys Val Asn Glu Glu Trp Leu Glu
 485 490 495
 Gly Glu Cys Lys Gly Lys Val Gly Ile Phe Pro Lys Val Phe Val Glu
 500 505 510
 Asp Cys Ala Thr Thr Asp Leu Glu Ser Thr Arg Arg Glu Val
 515 520 525

<210> 21
 <211> 1301
 <212> DNA
 <213> Homo sapiens

<400> 21
 agactctcca cctgctccct gggaccatcg cccaccatgg ctgtggccca gcagctgcgg 60
 gccgagagtg actttgaaca gcttcgggat gatgttgcca tctcggccaa cattgctgac 120
 atcgaggaga agagaggctt caccagccac tttgttttcg tcatcgaggt gaagacaaaa 180
 ggaggatcca agtacctcat ctaccgccgc taccgccagt tccatgcttt gcagagcaag 240
 ctggaggagc gcttcggggc agacagcaag agcagtgcgc tggcctgtac cctgcccaca 300
 ctcccagcca aagtctacgt ggggtgtgaaa caggagatcg ccgagatgcg gatacctgcc 360
 ctcaacgcct acatgaagag cctgctcagc ctgccggtct ggggtgctgat ggatgaggac 420
 gtccggatct tcttttacca gtgcgcctat gactcagagc aggtgcccga ggcactccgc 480
 cggctccgcc cgcgcacccg gaaagtcaag agcgtgtccc cacagggcaa cagcgttgac 540
 cgcattggcag ctccgagagc agaggctcta tttgacttca ctggaaacag caaactggag 600
 ctgaatttca aagctggaga tgtgatcttc ctctcagtc ggatcaacaa agactggctg 660
 gagggcactg tccggggagc cacgggcata ttccctctct ccttcgtgaa gatcctcaaa 720
 gacttccttg aggaggacga cccaccaaac tggctgcgtt gctactacta cgaagacacc 780
 atcagcacca tcaagtctgt ggctgggag ggaggggcct gtccagcctt cctgccatcc 840

42/61

ctacgaccac cgcccctcac atcaccttct catgggtccc tctcccactc caaagccccc 900
 agtggctccc agatgagcca caatgctgta acaagccatc aacgtccagg gtggcctggc 960
 cagcctcatt cccctttccc ccaccccaca ccccaacttc agcctgatgc ctccttactc 1020
 cagcctgtca ccccttagg gacatcgcg tggaggaaga tctcagcagc actcccctat 1080
 tgaaagacct gctggagctc acaaggcggg agttccagag agaggacata gctctgaatt 1140
 accgggacgc tgagggggat ctggttcggc tgctgtcgga tgaggacgta gcgctcatgg 1200
 tgcggcaggc tcgtggcctc ccctcccaga agcgctctt cccctggaag ctgcacatca 1260
 cgcagaagga caactacagg gtctacaaca cgatgccatg a 1301

<210> 22
 <211> 348
 <212> PRT
 <213> Homo sapiens

<400> 22
 Met Ala Val Ala Gln Gln Leu Arg Ala Glu Ser Asp Phe Glu Gln Leu
 1 5 10 15
 Pro Asp Asp Val Ala Ile Ser Ala Asn Ile Ala Asp Ile Glu Glu Lys
 20 25 30
 Arg Gly Phe Thr Ser His Phe Val Phe Val Ile Glu Val Lys Thr Lys
 35 40 45
 Gly Gly Ser Lys Tyr Leu Ile Tyr Arg Arg Tyr Arg Gln Phe His Ala
 50 55 60
 Leu Gln Ser Lys Leu Glu Glu Arg Phe Gly Pro Asp Ser Lys Ser Ser
 65 70 75 80
 Ala Leu Ala Cys Thr Leu Pro Thr Leu Pro Ala Lys Val Tyr Val Gly
 85 90 95
 Val Lys Gln Glu Ile Ala Glu Met Arg Ile Pro Ala Leu Asn Ala Tyr
 100 105 110
 Met Lys Ser Leu Leu Ser Leu Pro Val Trp Val Leu Met Asp Glu Asp
 115 120 125
 Val Arg Ile Phe Phe Tyr Gln Ser Pro Tyr Asp Ser Glu Gln Val Pro
 130 135 140
 Gln Ala Leu Arg Arg Leu Arg Pro Arg Thr Arg Lys Val Lys Ser Val
 145 150 155 160
 Ser Pro Gln Gly Asn Ser Val Asp Arg Met Ala Ala Pro Arg Ala Glu
 165 170 175
 Ala Leu Phe Asp Phe Thr Gly Asn Ser Lys Leu Glu Leu Asn Phe Lys
 180 185 190
 Ala Gly Asp Val Ile Phe Leu Leu Ser Arg Ile Asn Lys Asp Trp Leu
 195 200 205

43/61

Glu Gly Thr Val Arg Gly Ala Thr Gly Ile Phe Pro Leu Ser Phe Val
 210 215 220
 Lys Ile Leu Lys Asp Phe Pro Glu Glu Asp Asp Pro Thr Asn Trp Leu
 225 230 235 240
 Arg Cys Tyr Tyr Tyr Glu Asp Thr Ile Ser Thr Ile Lys Ser Val Ala
 245 250 255
 Trp Glu Gly Gly Ala Cys Pro Ala Phe Leu Pro Ser Leu Arg Pro Pro
 260 265 270
 Pro Leu Thr Ser Pro Ser His Gly Ser Leu Ser His Ser Lys Ala Pro
 275 280 285
 Ser Gly Ser Gln Met Ser His Asn Ala Val Thr Ser His Gln Arg Pro
 290 295 300
 Gly Trp Pro Gly Gln Pro His Ser Pro Phe Pro His Pro Thr Pro His
 305 310 315 320
 Phe Gln Pro Asp Ala Ser Leu Leu Gln Pro Val Thr Pro Leu Gly Thr
 325 330 335
 Ser Arg Trp Arg Lys Ile Ser Ala Ala Leu Pro Tyr
 340 345

<210> 23
 <211> 28567
 <212> DNA
 <213> Homo sapiens

<400> 23
 gtttcacccat gttggtgagg ctggtctcaa actcctgaac ttgtgatcca cccacctggg 60
 ccgccaacc aaagtgctgg gatgacagac gtgagccact gcgcccagcc accacaggtt 120
 cctctttttt tttttttttt ttgagacggg gtctcgctct gactccaggc tggagtgcag 180
 tggcgccatc tgggctcact gaaaccaccg cctcccagggt tcaagagatt ctctgcctc 240
 aggctcctga gtagctggaa ctacaggcgc gcgcctccac gccctgctaa tctaattttt 300
 gtatttttag tagagacggg gtttcacccat gttggccagg atggtctcga tctcttgacc 360
 ttgtgatccg cctcctcgg cctcccaaag tgctgggttt acaggcttga gccaccgcgc 420
 cctgtctgac aggttcctcg tttttgtttt tgtttttttt tttgagacgg agtttcgctc 480
 ttgtcgccca ggctggagtg caatagcagg atctcggtc actgcaacca ctgcctcccg 540
 ggttgaagtg attcacctgc ctacgcctcc tgagtagctg ggattacagg cgcccaccac 600
 cagccccgt taattttttg tatttttatt agagacagt tttcaccatg ttggccaggc 660
 tggcttgaa ctcgtagcct caggtgatcc gccgcctca gcctcccaaa gtgttgggat 720
 tacggacgtg agccaccgcg ccgagctgac aggttcctct taaagccctg agtcccaggg 780
 aagggacctg caggccccgc cagccccagg ccgcttttagc gcgcaagatg gcggcatgca 840

cgccccgcgg ccggagccga gtgggcccga gcgcttccga gcattcccga agtccagaga	900
aactccggga gcggcgcggg cgggagcggt cggccgggag cggccccgcc cggaacctgg	960
gagcggcggc gccggcgcgg gggaggggag gccggatgtg agtggagcgg ccatttctctg	1020
tttctctgca gttttctctca gctttgggtg gtggccgctg ccgggcatcg gcttccagtc	1080
cgcggagggc gaggcggcgt ggacagcggc cccggcaccc agcgccccgc cgcccgcaag	1140
ccgcgcgccc gtccgcgcgc ccccgagccc gccgcttctt atctcagcgc cctgccgccc	1200
ccgcgcgccc ccagcgagcg gccctgatgc aggccatcaa gtgtgtggtg gtgggagacg	1260
ggtgagtgcg cggccggggc cgggctggag gccgcgggat cgggcgcgga ggggggttgg	1320
gcccgactg gggcccaggc aggcggcgt ccgcgcggtc tcgcgtaggc ggtgggcctg	1380
ggcctgtgtc gcggggcggg ggccgcggcg ggcccccca ccggaccctg acggcccggg	1440
cggcgcggtc ctggttccgg ctctcgatgg aggagggcct cgccgctcgc cggctagagg	1500
gaaaagtga ctccaccctc cggctttctt cccggacgcc gcccgccgcc ctctcggga	1560
gcgctcgtag agcaagcgt cttggagatt ttgaccattt ttccaaaaag ggacccttta	1620
ttttttttgc atgaacctct cgatccccct ttgagaattg ggttgggaac gcggcggtca	1680
agtcgatcat atttgatgca tgcttgattg tacgggccc tttggtgccc ccaaactttt	1740
ctttaaaaaa atttttttt catagacggg gtctcgtgt gttgccagg ccggtctcga	1800
actcctgggt tcaagcaatc ctcccatccc agcctccaaa atgctgggat tacaggcgtg	1860
tgccaccacg cctggctaatt ctttaaaagt tttttgtaga aatggggtct cactgtgttg	1920
tccaggctgg tctcgaattc ctgcgctcaa gtgattctcc tgccctcag cctccaaaag	1980
cgtgggggtg acaccgcgcc cggcctctca acttattttc gacaggtttt ttgacttaca	2040
cttctgccac tgtaggatt cttaaaattg ttttcgccct ttccgtggag aaagttttga	2100
agatgctggc tgggaggagc cggctgtaat gggggactgt tttttctttt ctttctttct	2160
ttttttttt taaacaacgt ggtgtggtca ttgacaaaaa aactgttctt tgcttaacgc	2220
gttaggtatg ggatgtagca gaactggccc cctgtgactc caggcattgc ttttcatgat	2280
tgtccgtgat ggttacaggc cctagaggaa gacaaaactt gtcttatgca gtttttttct	2340
cccatagaaa caagaatctc agtgtaaccc gagcaaaatc gcgcgtctca gcgttgcttg	2400
tataggttag tgtagcgag gaagaattac taccagttaa atcaaactca atgcaactgg	2460
tacatgttgc agtaaagtcc aaggaaagt ctggcatcac ggtaactgg attgatattc	2520
ttcaaactta tcattaggac agattttggg tcttgcaatt cagatgcaag aaggataatt	2580
agacagctga tttttgtaag atgcccactc gtcggatttg tcttggaagt gtgaaggagt	2640
attagagtat gtaggctatt caggctttt tttttttttt tttttttttg agacggagtt	2700

tcactctgtt gccaggctg gaggcagtg gcacgatttc ggctcactac aacctccgcc	2760
ccccagggtc aagcgatcct cctgcctcag tgccttagt agctgggatt acaggcacgc	2820
gccaccgtgt ccggctaatt tttgtatatt ttagtagaga cggggtttca ccatgttggc	2880
ctggctggtc tcgaattcct gacctcaggt gatccacccg cctgggtctc ccagagtgtt	2940
gggattacag gcgtaagcca cggcgcccg cccaattttt tttttttttt ttttcttttt	3000
tttttttttg agacggggtc tcactctgtc gccaggctg gaggcgaatg gcgcgatctc	3060
tgtccttgca acctctgcct cccgggttca agcgattctc gtgccttagt ctcccaagta	3120
gctgggatta caggcgcaag ccaccatgcc cagctaattt gttttttttt tttttttttg	3180
tatttttttg gtggagacgg agtttcacca tgttggtgag gctgggtctca aactcctgac	3240
cctcaagtga tccgcccgc tccgcctgtt tttttttttt ttttttttta agtcatattg	3300
ctgataatta ttgaaaatt tctaaaacta aaacataagc atagcagata cgtttattta	3360
atactaaccg attgtggacc tctgtgttt gaattggctg ttttatctag tcaaataact	3420
tgttgaatgt catggaatct ggaccgtccc ttcaaatccc caccaccgc cttacatggg	3480
gtaaccctaa gcacatcccc cacctcccaa gagaggcgg tcaatgggag gtcaacaaga	3540
ctaaacaaga tgttggttat taactacctc gcagggtccc cttgctgaat gcttagtaaa	3600
tgccaggtag tgttattgag gtttctacta ctgagactct gtgaggaggt attaggctta	3660
aaagtctgtg gccttgagtt ttcagtctgt tttttttttt taattagtta tgagcatttg	3720
aacaagcaca gttatttttt aatactatgt ttagtattga tgttgactac agctaagtga	3780
tattagaagt gaaatgtacc tggccaggtc aggtggctca cacctgtaac ccagcatttt	3840
gggaggccaa ggtgggtgga tcactagagc ttaggagttc aagaccagcc tgggcaacat	3900
ggcgagaccc tgtctctgct aaaaatacaa aaattagcta ggtgtagaca catgtgcctg	3960
tagtcccagc tactcgggag gctaagggtg gaggatcgt tgaaaccag gaggtggagg	4020
ttgtagttag ctgagattgt gccattgcac tccagcccgt gcgacagagt gagacctgt	4080
ctcaaaaaag caaaaacaaa aactattaga gatacgtctt tggccgggca cggtagctca	4140
agcctgtaat cccagcactt tgggaggccg aggtgggagg ttcacctgag gtcaggagtt	4200
tgagaccagt ctggccaata tggcgaaacc tcgtctctac taaaaataga aaaattagct	4260
gggcacgcct gtaatcctag ctattcagga ggttgaggca ggagaatcgc ttgaacttgg	4320
gaggtggagg ttgcagttag ccaagattgt accattgcac tccagcttgg gtgacagagg	4380
gaaactgtct ttttttgttt gtttgtttt aaaggagata catcttcac tgttcctgct	4440
ttgaccttt gcctggacca tggcagtgtc ctttcaggct gtacgtccct ccatcctgcc	4500

ctcctgtgcc tctgcttaca ctgggctctt aaggaaactc ctgctccttg tctcatcatc 4560
cctagggatg gttctgtctt atcatttcta gaattggatg ccttgccatc ttgtttgctc 4620
cttaactctg catacagggc tgtgtaaata attccttcat gaaaatctct atttcaatct 4680
tctgggatga gttttttcct tctgggaccc tgactgatag agactgataa tacacccgta 4740
tgaaaatatg tctgccaggt gcggtggctc atgcctgtaa tctcagcact ttgggaggcc 4800
gaggcaggcg gatcacctga ggtcaggagc tcgagaccag cctggccaac atggcaaac 4860
cctgtctcta ctaaaagtac aaaaattagc cgggcgtggg ggtgggcgcc tgtaatccca 4920
gctactcagg atgctgaggc aggagaatca cttgaacccg gaaggcgga gttgcagtga 4980
gctgagattg tgctactgca ctccagcctg ggcgacaaga gcaaggctct gtcttgaaaa 5040
aaaaagaaaa aaagtcagaa ataatttgca aagcatgtta gaaaattcta gatttctga 5100
atagcaatth aaftgagatt ggccaagaaa tattacatag ggttgatact cttttattct 5160
aagatagtcc tttctgagca tggggctctat aatttttttt tctccacct tactgctgcc 5220
ccacctttta actttcactt agtggacctt tgccccaaga tttctctca gcttttctta 5280
ggtaagacag catcacccgg gcgcgatggc tcatgcctgt aatcccagaa ctttgggagg 5340
ccaaggcagg cggattgcct gaagtcagga gttcgagacc agtctggcca atatggtgaa 5400
accctgtctc tactaaaaat acaaaaaaat tagccaagga tgggtggggg cgctgtaat 5460
cctagctact cgggaggctg aggcagggga attgtttgaa tcaaggaggg tggaagttgc 5520
agtgagccaa tategtgcca ctgcactcca gcctgggtaa cagagtgaga ctccgtctca 5580
aaaaggaaaa aaaagacagc atcttacatt cagggtattta taaacaactt ttattattta 5640
tttgttttta ttttatattg gctcactgca gcctccacct cctgggttca agtgattctc 5700
ctgcgtcagc ctccaagta gctggaacta cacgtgctg ctaccatgcc gaggtaatth 5760
tttttttttt ttttttttg agaaggagtt ttgcctctt ttgcaaagg tggagtgcag 5820
tggtgcgac tcggtcact gcaacctcct cctcctgggt tcaagcgatt ctccgtcctc 5880
agcttgctga gtaggtggga ttacagtcac gctccaccac actgactaat ttcgtattth 5940
taatagagac gaggtttctc cttgttagcc aggttggctc caaacgcctg acctcaggtt 6000
atccacctgc cttagcctct caaaaagtac tgggattaca ggcagtagcc actacgcctg 6060
gcaatttttt gtatttttaa tagagacagg gtttcacat gttgaccagg ttggtttcga 6120
actctgacc ttaggcgac tgccgcctt ggctcccaa agtgctggga ttatgggcgt 6180
gagccatcgt ccctggccta aacaacagtt ttattattth attttttatt tttttattgc 6240
ttattactat tttttgagat ggagtctcgc tctgtcacc aggccggggg gcagtggcat 6300
gatatgggct catggcaacc tctgcctcct gggttcaagc agttctcctg ctttggcctc 6360

ccaaagtgat ggaattacag gcccgagcca ctgcgcccgg ccacaactat tttaatagtg 6420
ttgttttggt gttggttgat taaaggaatg ggaacgaatg acttgaagcc ctctctgttt 6480
cactctttat acaaagtgga gtccagattg ggctagtggc ctgtctagcc caatgtctga 6540
cttggaacata cttactgtc caggagtttc ttagctgaat gtgaaaaatg ccttccgtga 6600
catcatcctt acaggaacat tctttacatt tattctttac ttctgttgaa cgggtggtggc 6660
gtgaaccatg aatttgttta agcttttcag ctgttttgtg tgttttcctc tcaaggcatg 6720
gggtttcata tttttgacct gtggtaaagg tatttgaatt ctgcactggc ctccaaatgt 6780
agggtgtagta tatggctctg atctttgttg atgattttat acataatgtg gtttttttcc 6840
ttgataagcc aaaaaatta tacataatgt gtgtgtgtgt gtgtgtttta atttcaaagt 6900
atagttacag taaaagtttg gagttgggct aagtgggagg agcatcagga agccattttt 6960
agaaacctta aattcacctt ttataacttt ctgtcttttt gcattagtca tctgatacct 7020
tagtactgcc tactttttca catctccatc actacgtagc tcttaaaatt gtagtcttcc 7080
ttgaaaggag atgtttttgt caagagtctt tgccaccaag gcaggattgc atgtgatcag 7140
taggaatatt ttcctgcaat gtcttaatat gaaaaatttc aaacagacta gtggaaagca 7200
ttgtacagtc aacatgcaca taccatggc ctggattcta tgacagtatt ttgctctact 7260
tgttcatttt gctgtatttg ctttatcatg tcttcctgtt atcagaggga accttttaag 7320
aggatttata gaggagtga ttttgttttt tgttttgtt tgttttgctc tttttgaggt 7380
ggagtcttgc tctgttgccc aggetggagt gcaatggcat gatctctgct cactgcaatc 7440
tccgcatccc aggttcaggc gattctcctg cctcagcctc ctgagtagct gggcttacag 7500
gcacccacca ccatgcctgg ctaatttttg tattcttagt tgagacaggt ttcaccatct 7560
tggtccaggct ggtctggaac tctgacctc aggtgatcca cctgcctcgg cctcccaaag 7620
tgatgggatt acaggcgtca gccaccatgc cgggcctgat tttgaaaaag aatagggact 7680
gtgtgcagtt acatataaat tcttattttt gaactcttgt gtgttcagct ggcttgtatc 7740
aactacacca gggttagcct tgattctgga aggggtggatt cagacttcag ctgagttgta 7800
catagtgtct tcagcctaag tgagaaactt tatgcactat cttattttt tgaagcttct 7860
agtggtaata attgctggct tttttttttt ttttttggtg gaaacagagt cttgctctgt 7920
cgccaggctg gagtgcagtg gcacgaaatc agctcactgc aacctctgcc tcccagggtc 7980
aagcaattct cctgcctcag cctcctgagt agctgagatt acaggcgtgt gccaccacac 8040
ccagctaatt tcttttgtat tttagtagag acgggggtttc actgtgctgc ccaggctggt 8100
cttgaactcc taaggtcaga cagtccgccc accttgcct cctaaagtgc taggattaca 8160

ggcatgagcc accgtgcctg gcttatggct agctttcttt acattgattg tgaagtcaga 8220
tattggtagt agaacatcat aatttttagat tgggttttgt gtttatttag cactgcacta 8280
ctctagtggg gtatttttct ggacagattt tatctgcata gttaacgcag ttatatataa 8340
ggcctaccgt tacagaatcc ccataccttg tttgtcagtg taaatcgagg accttcatgc 8400
gagggtcttta atttattcaa taagtaggaa tatatatattg acagttacta aattctactg 8460
ccttgtcctt aagatctaca tacttttttt tgttttttga gtcagagagt ctctgctctgt 8520
tgctcaggct ggagtgcagt gatgcgatct cagctcactg caacctctac cccgtggcct 8580
caagcgatac ttctgcctca gcctcctgag tagctgggat tacaggcgcc tgccaccaca 8640
ctcagctaatt tttttgtatt tttaatagag atgcagtttc gctgtgttgg tcagtctggg 8700
ctcgaactcc tggcctgaag tgatccaccc gccttggcct cttgctggga ttacagggaa 8760
gagccactgc gcctggccaa gatctactca ctttttagaca gcaatatatg ctctgtattt 8820
tggtttgcaa ttgtaattgt cattggaaga gtttggcttt tctgtcctga gatcaacgtg 8880
tctttaaaag aaggcagtg agaaagtgt tattttttga gcttcttggga tcttttattt 8940
ttttaacgtg aggaaattcc tagcgtttct agatttggtg attgtgcttt taagttttgg 9000
tttatagatt tcaggaagta acactaaagt ttaccctact ctctcaaaa agtaagtaaa 9060
aagttctctt ggctgggcgt ggtggctcac gcctgtaacc ccagcacttt gggaggccga 9120
tggggtggat ctctgaggt caggaattcg agaccagtct ggccaacatg gcaaaaccct 9180
gtctctactg aaaatacaac aacaaaaaaa aattagctgg atgtggtggg gcttacgtgt 9240
agtcccagct acttgggagg ctgaggcagg agaattgttc gaaccagca ggcagagggt 9300
gtggttaagcc aggattgcac cattgggctc cagcctggaa gacagagcca agactccgtc 9360
ttaaagttct cttaatggaa aaatgaagaa cataatagca acataagtta tttgctttca 9420
ttgtggttat ttctacagga cagggcaggg gaagcacaga taggttaaaa aaaattgtag 9480
catcatgagc tagggggaaa tccaatgtag aaatggcatg aactttcttc cagccgactc 9540
atgttcgttt cctagagtga tgacattgct cgatgattga aaagagggtg aactgagcag 9600
ttaattatat aaagttagaa attccaaaga agtagtaact accagaaatt ctccagcagt 9660
atcagtcaag acttgtggcc aaatacggct tccattcttc atgagggaaa ggccatggaa 9720
aggctgtcac attgcccagt gcagatgttg acttggtttg tggaagcgca gcgtggacaa 9780
ggaatgaata tacactaata ggagtggaat aacctttttc ttttacctat ttgaataaat 9840
taagtaaaag ttttaatcag aagacttaaa gaggagtcga ttttatcttt tgattgcact 9900
aagcttaaat ataagggtgc actttaagaa ttctgtagtt taataatcat attcttataa 9960
gacatagatt tgtaacaaat agtgattggg aataaaattt cagtcagtat cagattatgc 10020

cagtaccttg aatttcttcc cggttgagcc tttctcagct aaagatgtca ttcaggaaag 10080
gaagtttaga ggattttaga cacagctggt tgcctttata ttagtagttt tgttccctcat 10140
atacatagag acttaggaca gaatagtaaa agaagtgata atgacatttt atcataacag 10200
tcaaaacctt catagcagct tctccttgac actgagtggc aactattggt aaggttttta 10260
cacaaccttt atcttttttt tttttttttt tttttttttt ttttttttga gacggagttt 10320
tgctcttggt gccaggetg gagtgcaatg gcgcaatctc ggctcactgc aacttccgcc 10380
tcccgggttc aagcgactct cctgcttcag cctcccgagt agctgggatt acaggcatgc 10440
acgcccggct aattttgtat ttttagtaga gaggggtttc tccatgttgg tcaggctctt 10500
ctcgaattcc tgacctcagg tgatccgccc gccttggcct cccaaagtgc tgggattaca 10560
tgtgtgagcc accgagccca gccaaccttt atcattttta aaaagggtccc ttagagcctt 10620
aggctccact ttcttctca gctgccacat ccaaaccatg ggtaagcgat gcttgatctg 10680
cctccaagtt caagcagtcc aggaaacagc ccacttatgt tcaactgtcca gtccccattc 10740
ttggtccagg ccaccatgga tggctcctgg actgtagcaa cagcttccat gtgtgtctgc 10800
cttgactgag tccctggcgt cctcaggctt cctgccacac tgcagttgga ggcttcttct 10860
aaaatccagt gctttctggg caatttaaaa cctgtgactt tccaagtagg atctagtccc 10920
catgtcctta acaagaagag gtaacgtatt tccctatgcc actgcccact tattttttta 10980
ttgttgagat gggatcgtgc tttgtcacct aggctgggtg gagtgggtg atcacagctc 11040
actgtgccc tgaattcctg ggctgaaggg atcctcttgc ttcagcctcc tgagtagctg 11100
ggactacagg caagagccac cacttatttt tgaatttttt gtggaaacaa ggtctcccta 11160
tgttgcccag gctggtcttg aactcctggg ctcagcgatc ctcccacctc agggccctgt 11220
gctgggatta tagcctcctg tgctgggatt acaggcctaa gccactgcac caggctttta 11280
ttttttaatt taaaaaatt tatttttttg agacagggtc tcactttgtc cctcagactg 11340
gatgcactgg tgcaatcttg tttcactgca gccttgacct ccctcctggg ttcaagtgat 11400
cctcgtgctt cagcccccca agtagctgag actactgctg cacaccgcca caccaccta 11460
atttttgtat ttttagtaga gaacgggttt ctccatgttg gccagctgg tcttgaactc 11520
ctgggctcaa gcgatccacc cacctcagcc tcccaaagtg ctaggattac aggcattgagc 11580
caccatgcct ggcttaaaaa tatttttttc agctctagaa atgttagctc ttttgctgta 11640
catttccaga gctgctttta taatgacagt tatcacagc ataatttcat gtgatgattg 11700
cattcttaat ttttaaattt aacaactgca cttacttcat gaggtcttgt tcattgatac 11760
atcttttagca cctagtgtgc ttctgggtgta gcacacggtt gatataaatt gaaattgaat 11820

50/61

taatgctcac agtagtttgg ggatggagct ggtagttctg cattaatttt gcaggtgaaa 11880
aaaaaaggca tgaggaagtt gaaacttgcc aaaaaataca gccagtacgt gctagaattg 11940
gccctgggtc tcaaactctgg gcttctgact ccaaagctta ggctcctgct catacaggtt 12000
tattttcaca ttctaagctt ttaacgaaat gtatgtccaa tgagtcattt ctgttttagaa 12060
agccttttagg agttggaagc tacttctctgg tgatgtaatg tttgactctc taaagtcttt 12120
ggaatgggga gttccaactt ttgttaagcc ctcaataatg tcatgagtga atgaatattg 12180
gcaagactgg ctgggcctgt aatctgcctt gagtgtgagg gaaaatggaa aagcgcttaa 12240
ctttatggtg aattctaatt tatagtagtt gagattgaac gacaaaaatc ttaaaattat 12300
gatgctgatg tgtcattgtg accttggtta actgacagca cagcagagag aagggtcat 12360
taaggagagc acttggttaa ctgaaccctc aggatgccag agacttgaat tctcatgtaa 12420
gcccttaagc ttgccttgct aatgctgtaa aaattggaga cttttatgtt ttgctaataa 12480
tgtggtgacc ttagttatta ggtgatagcc tcttgaaaaa cattccaggt ggttgggaga 12540
ctttcagcca ccactcttct gcctggcggc aactggtaa tattaggatt agtctctacc 12600
cattgccagt tgtgcagggt gtgtctcttt ctctgaagta tttctacaca cttctctgtt 12660
tggcaagttt aactcccatc gtctctgagc tgtaattaa atgtctggga tgtattgtga 12720
tagtccctgc ttatagactt atggtgctgt gtgaggattg gggctggggg aggtggcatt 12780
taaatacagc tgaatcaatg tgatggcagt tacgtgtggt agtttattga ctaagcactt 12840
tctctcaaga gaacagtcatt tgctgattgc cataggggag gctgtaggga tgtggtggga 12900
ttttgagctg tcccacttaa ggcagcagaa taagtactt aaagaggaag gctgtgtttg 12960
tatattagtg ttaattaaaa tacctttagg ctgggtgtgg tggctccagc ctgtaatccc 13020
agcactttgg gaggtccagg tgggcggatc acttgaggtc aggagtccga gaccagcctg 13080
gccaacatgg cgaaaaccca tctctactaa aaatacaaaa aaattatcca ggcgtggtgg 13140
tggacagctg taatcccagc tacttgggag gctgaggcag gagaatcgct tgaacctggg 13200
aggcagaggt tgcagtgagc caagatggtg cctctgcact gcaactccagc tggggcgaca 13260
gcacgagact cggctctcaa aaaaaaaaaa aaagaaaaaa aagaaaaaaa gaaaatatct 13320
tcaggatcaa acttaagatt cttgatgaga ggctctacag atgttcacag aagagacgtg 13380
aagttttaaa atcttgtttc tcttgagtct tgtagctagg tgacaactgt ttcttgacta 13440
ttaatgctaa caccgggtac ctaaacagaa tgtgatggct cctgactcta tctttctgag 13500
aaattctagt ttgtttactt taaatttcag ggtaccaatg tgtatgtggt gataaagggt 13560
tatagaaaac attttcttta atgctaagta tgtgatgtat atgccttgat ttttttctc 13620
tagaaattat ttaacttaa tagtgaaagc taagattaca ttcatgttga ctaagcaacc 13680

ttttttctct ttctctttag agctgtaggt aaaacttgcc tactgatcag ttacacaacc 13740
aatgcatttc ctggagaata tateccctact gtgtaagtat cttaaattgg gaattaacct 13800
gtttgtgtta cgggtttcac atttctttga ccatttggtt tgctgtaaag ccattcttaa 13860
tcctcatatg aacagatact aatTTTTTct taaacattca ctgaaaccta attataaggt 13920
atattaggct tttaaaaaat agggctgggg gtggtgatct cagcactttg ggagactgag 13980
gcggttgat caactgaggg tcaggagtcc gagaccagca tggccaacgt gatgaaaccc 14040
catctctact aaaaatacaa aaaattagcc aggtgtggtg gcgggtgcct gtaatccac 14100
atacttggga ggctgaggca ggagaatcac tcgaaccgtg gaggcggagg ttgcagtgag 14160
ccaagatcac gccactgcac tccagcctgg gcaatgagag cgaaactcca tctcaaaaga 14220
aaaaaaaaaa agaaacttag ggtaataata acttttcaca actttgctag ttgattttta 14280
gacatccaga aagcaaactt taactgtctg tgaggtacag agactggatg atgttaaaga 14340
aaaccatagt tggacacaag aactctgacc aaaagtctga tcagaaacag tccttgtcag 14400
tgcacgagtt tcagatacac tggttttctg ggaactggaa agggaaagat tccattacgt 14460
tttaattggc cttttctgat aagtcatcag ttggttacat gtccgcattg aggtgtaggg 14520
ctttggaatt gaaacttggg tgtgtgtgtt gaagggggaa tgggaggggtg gaattggcta 14580
ttgaattgct tactccctat aggcagcaga attgggtgga gacaggaaag tgctgctctg 14640
gtgatgggtt acccgggagc gcacgtagct gagcctcata atgcaccatc ctgcagctgc 14700
tgtgagtctt ccctgtgcag gctggggagg tgctgcctcc tccccacctg tggtcacctc 14760
ctcaggcaca acacacaccc aggtgctctc tgaagtgtcg taccatgtt tttgttgtt 14820
ttgttgttgt tttccttttt tttttttttt ttggagtta gtctctctct cttgccagg 14880
atggagtgtt gtgatgcgat ctgagctcac tgcagcgtct gcctcctggg ttcaagtgt 14940
tctctgcctc agcctcccag gtagctgtga ttacaggcat acaccaccac acctggctaa 15000
tttttgtttc ttttagtagag acgggtttca ccattgtggc caggttggtc tcaaactcct 15060
gacctcaggt gatctgcca cttcagcctc ccaaagtgtt gggattacag gcgtgagcca 15120
cggcaccat tttttactgt aagtgaatc atgtgtccc tgttgtccta aatttatggg 15180
ggagattttc cttatctaca tatgtagata aaggtttaat cattaatgat taatgatttt 15240
gaagtactat aactgattta accactggg cacttggaact cttggtgtta acaaacattg 15300
ctgggttcag tgttgtcctt tatgtcttg tgtacacttg atagattatt agaagcaaaa 15360
tcgtgccaaa tcaaaagaca atggatgttt taaatttttg tagatacagc tgggcgtgat 15420
tgctcacgcc tgtaatccca gcactttggg aggccaaagac ggaaggatca cttgagggtca 15480

52/61

ggagttcgag accaacctgg ccaacatggt aaaaccccca cctctgctaa aaatacagta 15540
gttagccggg tgtggtggtg cactcctgta gtcccagcta ctcaggaggc tgaggcatga 15600
gaattgcttg aaccgaggaa gcagaggttg cagttagcca agattgtgcc actgcacttc 15660
agcctgggta acagagttag actctgtctc ccaaaaaaaaa aaaaaaatta aaaaattatt 15720
ttttggtaga taactaccaa attgctgtct ataaagctgt cactttgctg gccttgactt 15780
aagtggcctc ttagtacaca ctgccattaa cgtgggttga agttatctaa ccgttttcat 15840
ttccaatcac agatgtggtt aaaatctttt gaattttttt tttttttaat taaaaaagtt 15900
tgctcacgcc tgtaatccca gcacttgggg aggctgagct gggcggatca ctgaggtaag 15960
gagtttgaga ccaacttggc caagatggtg aaaccctgtc tctactaaaa atacaaaaat 16020
tagctgggca tgggtggcaca tgactataat ccagctatt cgggaggctg aggcaggagg 16080
attgcttgaa cctgggaggt ggaggttgca gtgagccaag attgtgcctc tgcactccag 16140
cctgggcaac agaacaagac attgtctcca aaaaagaaaa aaaaaatatg tgtttttgta 16200
gagctatggt ttgctatatt gccaggctg gtcttgaaga cctggcctca ggtgattctc 16260
caccttggtc tccgaagtg ttgggattac aggcgtgagc caccacacct ggctcttttg 16320
aatgtttact gtacattttt agtctcttgt gaattgtctg tttaaatctt ttgtattttt 16380
ctactgaaat tttttcttac tgatggaaca tttccttctt tcttccctc cctccctctc 16440
tccctccctt cctcccttcc tttcttccct cctcctcct cctccctcct ctctccctcc 16500
ttccctcctc tctactcct tccctcctc cctcctcct tctcctttct ttccctcc 16560
ctcccttget cctccctcc ctccctttt tttttttttt ttttttgaga tggggtcttg 16620
cagtattgcc caggccggac ttgaagtact ggtccttcca cctcagccta ttgagtagca 16680
tgctccactg cacgtagcct gatggaacgt tttgtaaata atcctcagtc tgtcatttgt 16740
ctttgtactt cattatggtg tcttctgcca tatagaaatt tagcatttaa tgtaaataat 16800
accaccttac ccgggcacgg tggctcacac ctgtaattcc agcactttgg gaagctgagg 16860
tgggcgcatt atgaggtcag gagatcaaga ccagcctgat caacatggtg aaaccccatc 16920
tctactaaaa atacaaaaat taaccgggca tgggtggcgtg cacctgtaat ccagctcct 16980
caggaggctg aggcaggaga atcacttgaa ccaggaggt ggaggttgca gtgagccgag 17040
atgcaccac tgcactccag cctgggtgac agtgagattc tgtctcaaaa aaaaaataat 17100
aataataatg ataataccac ctctccctca gaattgtatg ttgtacttag aaaggccttt 17160
cctacttaaa taatgcaaaa gtatgctcta gtattttttt ctaggatttt tgtggctaaa 17220
atttttatct ttaattcatt taggacttat ttttggtata gaatgaggca aggacctgat 17280
tctttttccc ttatggggaa aaaaagtcac aatactattt atccaataat ttttttctta 17340

tggaatatata attaacatgt ccatcaccat cacacctttt ctttcttctt cttctttttt 17400
cttgagaccg agtttcgcac ttgttgccca ggccggagtg cagtggcgca acttggccca 17460
ctgcaacctc tgcttcccgg gttcaagcga ttctcttgcc tcagcctccc aagtagctgg 17520
gactacaggt gcctgtcacc acgccctggc taatttttgc attttttagta gacacaaagt 17580
ttcgtcatgt tggccaggct ggtctcgaac tcttgacctc aggtgatccg cccacctcgg 17640
cctcccaaag tgctgggatt acaggcgtga gccacctgc ccagcctctg ctttttatta 17700
tatttttctt tttttttttt ttcttttttg ccttcctgtg cagaggaaac actattttct 17760
tctaaagctt ggtttctgct gaccagtagc aatttttaac atcagtctga tttccctctg 17820
tcagcctata ggctttgctg ggttatctct cctgactaat ttgtgtagca acttcacatg 17880
aatttaaaca tttgtatcat cagttaacac tcactttgaa aatgttattg ggaggcttgt 17940
taagtcaggt gtattttgtg tgactgctct acactcaggc cttctggaaa ccctgcagag 18000
ggtagctcta gtggccagct agctctcttg ctgaaaatga gcaacataag tacatgaaaa 18060
acccaacaag taggatttga aagcggggct aattgtaccc ttatttcttc tggggataaa 18120
agtcttaaac tttgtttaaa gtaaaatggt tttatttctg acggtgattt gtttcactta 18180
aatagcttgt tgtttgttct tttcatttct cttaagtttt gggttgggtt tggtttgttt 18240
cccgcaagtt ttgccctgc cgccttctc cttgtgcctg caggacatt tgctgggtgtg 18300
gcagcctcca ggcccgtccc cagcctttt cttggcacac cttctctagg atggctggga 18360
cagtgactta gcttctacac ctgtgactaa ccattttcat tccattctac agctttgaca 18420
attattctgc caatgttatg gtagatggaa aaccggtgaa tctgggctta tgggatacag 18480
ctggacaaga agattatgac agattacgcc ccctatccta tccgcaaaca gtaaggattg 18540
cagctgactt ttaatgtgtc ttttagagta tataattctc gagcgcttaa ttagtgcatg 18600
ttacctatgg acttgcttat attgccatca tttgggtatt gaggtaaag caaacaggg 18660
gggattgggt ccatgtaaac atccccctag atgcaagccc aggggttttg tgttttgagc 18720
gttaccagct gttccattgt tgggcatttt acagtcttcc atttagcttt agaataaccg 18780
tatgaaagag ctactttttg tttttgcaaa ccagttttta acaccaatta gtttgaaggc 18840
aggtttgctg tgtgacattt ttgtaccaca gaatcaaatt aggcagttaa gattcaggtt 18900
tctttaaacc aagttagtaa ctaatctcac aggtttaata cttttttcc cacaaaatac 18960
ataatttgta tggattttgt gaaccatata atagaacct aatttattca atgtagattg 19020
aagttttggt tttgtaaaat gtatccactg tgtctaata gaaaaaaaag tttacttttg 19080
cttctgtatc agacaactaa gtgatttatt taccaaagct aattagagca gtagctgggtg 19140

aaaatgggta cttagaagac attgttgctg ttaaaagtta cttttcttta agcagcggtt 19200
ttacttggt atcatttgct tatcttgta catgttggt cttcattttt aaaagtatct 19260
ttggaagcaa aagttaaata tgcttgagat tccttgggtt gataacctgt gtgcatgtcc 19320
tagctctgtg acttcaggca ggcttcatcc tctctccagt ctttgacctgt ttcctttag 19380
ggtagatga gtacgtgtca cgcacgcata acagtcctgg gcacatagca cacactgtgg 19440
ggccagccgc tgtcagaatt ctctgttcc tcagtgtgcg ggtgggtcgg cctaaagagt 19500
gctgctttcc acgttggtcc caaatgagtg gaagtgtgt ggtgctcagc acacctgggt 19560
tggccggagg gattgggggt ggggttgggt tgaggtcagg aagacatcct agagaaaggc 19620
tggctttgag ccctgattga tgatgaggca gcctgtgatt gattcaacca gtacttcgtt 19680
gtagggggta atatgggtga aataacttag tggttaagtc tgctgtatta aaaatcagtc 19740
tataatcccc agacaattca aattcttcag tatcttagga aactcttcta taccagtggt 19800
atgtttaata attcagattg taaatggatt taaaaacata ctggctggta gagtaggaga 19860
cttcagccca ctggacacat gtggaagggt gtggtgtcat tctgagaaac aagagccacc 19920
ctgtgtgac tcagggggta ccgggcaggg tgaggcctct ctaagggaagg cctcacagta 19980
agtcaagggt gacttggcag gagtcccact ttgtgttctg aggaacacac agataaggaa 20040
agagaactct cctcagcttg aacaaagctg tagagtgtga cgcctggtat caaagtaggt 20100
gttgctctca tagggctaga acttaaactt catgtttcct ctgtgtgaga ctgtggactg 20160
ctttctata aaatatttga ggagcaaggg agggagtggg acatggttct tgcctcagg 20220
tagttcacag aaaagtccca taaactgtgt aagacaccct gtgctagcaa gggggtgagc 20280
cgggcgctta aggagcaaga ggggcgagca cccaccagc agtggaagca ttcctgtctg 20340
gactccttca gagataagga aattatcttg acaactcagg ggcaggccac agatgctcag 20400
ataccagtgt ctggaaggtc tcatccctt gagccacact gtcctaagaa gaactggatc 20460
tggtagtaac atgctggcac ctgggtctct tgttgataaa ggggaaacct ctaaaatttg 20520
tactacatgg aatgtggtcc ctgattgtg gctctgtggt ctgcagacct gttgatgtag 20580
ctcatccaag actgcttaga cactctcctg aaggaccagt tggaagattt cttatctagg 20640
gtgtcctaaa aagagatgtt acatttcttg tggtcattta acattggcat cctctctatt 20700
gggcagctct gtcggctaag tctgttcaga ccattcattt cttcttcgtt ctccaaagat 20760
ggtgagcagg tagtcgcat tcttagttga aattgccctt caggttttta tttcccgaat 20820
tacgtaatcc ttacattatt ttctcttgaa aatctttgct aagtctctgca tactcatctt 20880
cagttgctat gcacagaatc aagtcttgct agagtaacgc tcaagtccag catcttcct 20940
tgtgtagatc acctgtattt atttgctgc ttgtaccagc attggtggtg tgagtggag 21000

cctaagtgac ctgtcagtgt cacagcgagt cctgagccct gtgtgtgtcc tgagactcag 21060
gctgtgcagc ggggttcgctg agatgctgag cctccatggt ggggtcagcc aggaccccag 21120
tgcgtcatgc cagttgtttc attttctctc taggctaaaa gttgttggtg ttgttggtgt 21180
tgtttgagac agagtttcgc tcttggtgcc aggctggagt gcaatgggtg tgatcttggc 21240
tcactgcaac ctccgcttcc caggttcaag tgactttccc gccctagtct ctcaagtagc 21300
tgggactaca ggcattgtgt accatgcctg gctaattttg ttttgtatct tatttttttt 21360
gagacagagc gagactctgt ctcaaaaaaa aaaaagaaaa caaagaaaaa agaaaagctt 21420
gagtggatg aaattaaaat aattttctca ttttgagaca gggctctgct ctgtcaccca 21480
gactggagtg cagtgtcaca atctgcctc actgcaacct ccacctcccg ggttcaagca 21540
gttctctgcc tcagcctccc gagtagctgg gattacaggt gcctgccacc atgcccggt 21600
aattttttgt atttttagta gacacagggt ttcaccatct tggccagggt ggccttgaac 21660
tcctgacctc gtgatccacc tgccctggcc tccaagggtg ttgggattag aggcgtgagc 21720
gcttttctta aaagagttcc agggttctat gttggaagag cgagtttgtc agtttttatt 21780
ggaacaaaga aatgaattga cagcattgtg ataaacactg gaagtgtcac ttctaaaatt 21840
tgtccatggc tgaaagtggg ggctcatgcc tgtaatccca gcacgttggg aagccaagggt 21900
gggtggagca cctgagggtca agagtttgag accagcctgg ccaacatggt gaaacctggt 21960
ctctactaaa aatacaaaaa attagctggg cgtgggtggg tgtgcctgta gtcccagcta 22020
cttgggaggc taaggcagga gaatcgcttg aaccaggag gcagagggtg cagtgagctg 22080
agatctcacc attgcactcc agcctgggca acagagcaag actccgtctc aaaaacgctt 22140
gtccttaagg ggtggcttcc cccagacctc caaagtagcc cagaattgga ggtcttagtg 22200
tcagcaacag tgctgatttt gataatgcaa gtctgtacat tcaaaccagt ctcccagaac 22260
taggtggaag ataggaacat ttctgcatag gagacttgga atgttctggc agcattaaaa 22320
ccctgaggcc cggtatggt ctgggagagc cctttggcag gcatcattta cagacgggtc 22380
cttttctgt atgtgtggc ttcaactagg ctgtgtctga gaactcggat ggagcacttg 22440
aaagtggcg tggtcccgct ctgcctttgc ggtaaggagc agtgcagaac atctccggct 22500
gtgccagctg ttgtagattc tgggtgggtg tgccatggga ggaggagcac gttgttgccc 22560
cccctcagga tctccctgac ctctgtcttc accatcggtg aacttaacgc ctgcttttga 22620
ccaggtagcg tggagtgttt cagtggcatt tgtcatcgaa gatatgttag aatctattgt 22680
atgcttttgg atctctccgg agggtaaga caaaattcta ataaagaatc gataagaggt 22740
tatattgatt tttgtgtcc tcagtctgta ctaaactcaa accaagttct catgcattac 22800

taggttgag aaacgtacgg taaggatata acctccggg gcaaagacaa gccgattgcc 22860
gtatgtaaaa ctttcagtcc acttcagttt caagctttct ctgttctctc atttcacttc 22920
gttttcttag gatTTTTTat taagcctcaa gctccttgag tgttttatat ttaattcact 22980
caaggttggg gttttgcttg atgaaataaa cttcattaga gtgtgatagt ttaccacaccg 23040
gcttgaatta aagcagtttg tgaactgtga tcttctctc ccaagtgaag ggaggggaca 23100
gtgagagggc ccctctctg gctgggtgga gatgcagata tggagactcc tcccggaagc 23160
ccacctggct gtgagccgag ccggagcagg accaaccttg ttgccggggc cttctttctc 23220
cgcttgggtg tcccggttg tgggctgtc tggcggtggc tgtgcagtgc tgctgagcta 23280
acccacccgt gcttgagatg gtgtgctggg tgccgcggtg attcttggac gagcttgtgc 23340
atgcgccagc actcttcaaa tgccagtat aaaaagctgt tgtgtgggat gtttctttcc 23400
ctttcaggta caaggtatca gctggagggg tgaagtgtga gcttgggaat tgtgtgcatt 23460
tcataaagta gcataattgc ctttttccag gagaatatat tagaaatcta gcattttaga 23520
attcttgggc atttttaa acaggtgaat atttgaattt ggtttgacac aaaatacaga 23580
atggatgaag catgcagatg tttggcgtgt gcccgaagc accctctact ctgtcctctg 23640
caccacccct ttgcgcctct gcgtcagcca cagctgcccc gggagcgagt tctctgagg 23700
ccctggctgt gctgactcta gggcagcgtg aggggtggtg tcagctgtga aggtgccact 23760
tacacactaa gtcctccttc cttgtggagg gaagggtca agtagcaaat attggagccc 23820
ccgcttgggtg ctgggagctg tgacaggcag ctctgaaga agcagtttaa ttggaaccag 23880
tgaccatcta aaactgtttg tactctaaac cagattttac agaaatattg gaatcatacc 23940
tttatacttg atttttctt tttagatagt taggcgtaaa ggaagcctcc tgagggtctg 24000
gtctgacct cctgacctt gaagagcttc cagcatcatt ctcccttcat gctccccatt 24060
ttcataagta actggtggct tgacatgctg gggttgggtt gggagccctc tgacaaactg 24120
aaaggggtgga tcaggaagcg tctgaccaca ccaactgtag acacgctctg cgtccaacaa 24180
gtccttccca gcaacatgta gaaagcaaag tgcagcttc attctaaggt tgtgtctaa 24240
atgtttccct gtgttccct tttgtaggat gtgttcttaa tttgcttttc ccttgtgagt 24300
cctgcatcat ttgaaaatgt ccgtgcaaag gtaggtgggg atttaaatg tgtatgtaag 24360
ttatagaatg atcctctcag aaataaatac tttaaaatat cacttagcct aggaattttt 24420
agttatttaa attggtttta gcaatttgc acttaggtac atgattgggt ttttttttt 24480
cttttgagac ggaggtctca ctctgttggt tccaggtgg agttgtactg gtgacatcag 24540
agctcactgt agccttgaac tccgtggctc aaacagttct cctgccccag cctcctgagt 24600
tgctgggacc ataaatgtgc accaccatgc gtggctaac ttaaaagaat tttgtatgg 24660

ctgggttttgt agaccctggc ttgtctcaaa ctcttgggtt gaagtgatct ttcagcttca 24720
gcctcccaaa gtggtgggat tatagctgtg agccactgca tctggcccat cagcagttta 24780
ttttatttat ttatttttga gagagtcttt ttttttgctt ttgttttgt ttttgagatg 24840
gagtttcact cttgttgccc aggtctggagt gcagtgcgc aatcttggct cactgcaact 24900
tccgcctcct gggttcaagt gattctcatg cctcagcctc ccgagtagct gggattacag 24960
gcatgcacca ccacgcccgg ctaattttgt attttttagta gaaatgtggt ttctccacgt 25020
cagtcaggct ggtctcgaac tcccgaacctc aggtgatccg cgcgtctcgg cctcccaaag 25080
tgctgggatt acaggcgtgg gccaccgtgc ccggtgaga cagaatcttg cgctgtcatc 25140
caagctggag tgcagtggca caatcttggg tcaactgcaac ctccccctcc cggttcaage 25200
aattctcctg cctcagcctt cttagtagct gggattacag gtgcccagaca acacacctgg 25260
ctaatttttg tacttttagt agagacgggg tttcaccatg tttgccaggc tgggtctcga 25320
cccctggcct caagtgatcc acccgccgca gactcccaga gtgctgggat ttcaggtgtg 25380
agccactatg cccggcctaa tacgtggatt tttaaagctt caggttcttg ttcagaagtt 25440
tcctgggtct cattaaaata atgaggcact cagaattggt ctaataaaaa taacgaccat 25500
ttctttctac tccagtctct ttcacaaact tcttagtgaa aatgacaagt gaggcccttc 25560
agtaggggca ttttcagtgg agataatagc ggcagacctg agaccttggg ctaggtagtt 25620
tattctcatt tctgaacaga tgatgaattt tctcagatga ccctaagaaa ttgttttacc 25680
aaaaacaaag tgatctattt gctttgggag gaactccctt ccttttgttt ctcttcctt 25740
ccccccctcc cctgcggttg tagagcccgt tctgtccggt cgtggttctg tccagccatg 25800
atccgggagt cctagcttgc taatggaaca cctgagatgt tccttatggc tcaaggcttg 25860
aattgaaggt ggaaccacc tgaagcctcc gtggggaggc cttgcctgag gttaggtgtc 25920
tggcattgagt gccgcccgtt ggggtgtgatt taggtgaagg acatctgtaa aggagcgtgt 25980
cacaacctct gttccttctt cacatctagt ggtatcctga ggtgcggcac cactgtccca 26040
acactcccat catcctagt ggaactaac ttgatcttag ggatgataaa gacacgatcg 26100
agaaactgaa ggagaagaag ctgactccca tcacctatcc gcagggtcta gccatggcta 26160
aggagattgg tatggaatcc tgtgtttttc ctctccttg tacctctttt attgtagtga 26220
cagagactgg agtccagtct gggaaaggag ggtgtgtgtc tcccactcag ggcctgggtg 26280
actcttgggg aaccagctgg caaggccctg tgggtcttaa cgtcagcgtt ggaagggtga 26340
agcagggctg ggagccggca gaaggcggcc gggccccagg agctgcctcc cgctgggtgg 26400
gtgatcagaa gagagtgggg tcgagtgtac attgccgtgt ggtcgtgttt cctgtaggtg 26460

ctgtaaaata cctggagtgc tcggcgctca cacagcgagg cctcaagaca gtgtttgacg 26520
aagcgatccg agcagtcctc tgcccgcctc ccgtgaagaa gaggaagaga aaatgcctgc 26580
tgttgtaaat gtctcagccc ctctgttcttg gtcctgtccc ttggaacctt tgtacgcttt 26640
gctcaaaaaa aaacaaaaaa aaaaaacaaa aaaaaaaaac aacgggtggag ccttcgcact 26700
caatgccaac tttttgttac agattaatth ttccataaaa ccattttttg aaccaatcag 26760
taattttaag gttttgtttg ttctaaatgt aagagttcag actcacattc tattaaaatt 26820
tagccctaaa atgacaagcc ttcttaaagc cttatthttc aaaagcgccc cccccattct 26880
tgttcagatt aagagttgcc aaaatacctt ctgaactaca ctgcattgtt gtgccgagaa 26940
caccgagcac tgaactttgc aaagacctc gtctttgaga agacggtagc ttctgcagtt 27000
aggaggtgca gacacttgct ctctatgta gttctcagat gcgtaaagca gaacagcctc 27060
ccgaatgaag cgttgccatt gaactcacca gtgagttagc agcacgtgtt cccgacataa 27120
cattgtactg taatggagtg agcgtagcag ctacagctctt tggatcagtc tttgtgattt 27180
catagcgagt tttctgacca gcttttgagg agattttgaa cagaactgct atttctctta 27240
atgaagaatt ctgttttagct gtgggtgtgc cgggtggggg gtgtgtgatc aaaggacaaa 27300
gacagtattt tgacaaaata cgaagtggag atttacacta cattgtacaa ggaatgaaag 27360
tgtcacgggt aaaaactcta aaaggttaat ttctgtcaaa tgcagtagat gatgaaagaa 27420
aggttggtat tatcaggaaa tgttttctta agcttttctt ttctcttaca cctgccatgc 27480
ctcccaaat tgggcattta attcatctt aaactgggtg ttctgttagt cgctaactta 27540
gtaagtgtt ttcttataga acccttctg actgagcaat atgcctcctt gtattataaa 27600
atctttctga taatgcatta gaaggttttt ttgtcgatta gtaaaagtgc tttccatgtt 27660
actttattca gagctaataa gtgctttctt tagttttcta gtaactaggt gtaaaaatca 27720
tgtgttgagc ctttatagtt tttaaaatat tttagataat tcttaacta tgaaccttct 27780
taacatcact gtcttgccag attaccgaca ctgtcactg accaatactg accctcttta 27840
cctcgccac gcggacacac gcctcctgta gtcgctttgc ctattgatgt tcctttgggt 27900
ctgtgaggtt ctgtaaactg tgctagtgt gacgatgtt tgtacaactt aactcactgg 27960
cgagaatata gcgtgggacc cttcagccac tacaacagaa ttttttaaat tgacagttgc 28020
agaattgtgg agtgthttta cattgatctt ttgctaagc aattagcatt atgttttgca 28080
tgtatgactt aataaatcct tgaatcatac gactggtaat actgggtgtt ttgagacttg 28140
atgaacaagt tcctgggtg tgthttgtt cttgcttta aagtcctggg ttgttgagaa 28200
cagtcatttt caatgcgtgt ctccacacag gaggacagg gagtgccacc tccaggggag 28260
aactgggtga gcccaaatac ggcaggagt gaggtgacat tcatgtttgg acctgtcgaa 28320

cagtggcgaa gctctgaggg agaagcgct atcgggggtgt gtgtgcacat cctggcccag 28380
 agctaggggc tgaagatgga gatgttggga ccctagactg gccctggaag agtagaggtt 28440
 ggtgaaccac atgcccttaa gatcctttcc agaggctgag tgcgtggctt acgcctctaa 28500
 gcccgcgct ttggggaggct gacacaggag gagcgcttaa gcccaggagt tctagaccag 28560
 cctggac 28567

<210> 24
 <211> 211
 <212> PRT
 <213> homo sapiens

<400> 24
 Met Gln Ala Ile Lys Cys Val Val Val Gly Asp Gly Ala Val Gly Lys
 1 5 10 15
 Thr Cys Leu Leu Ile Ser Tyr Thr Thr Asn Ala Phe Pro Gly Glu Tyr
 20 25 30
 Ile Pro Thr Val Phe Asp Asn Tyr Ser Ala Asn Val Met Val Asp Gly
 35 40 45
 Lys Pro Val Asn Leu Gly Leu Trp Asp Thr Ala Gly Gln Glu Asp Tyr
 50 55 60
 Asp Arg Leu Arg Pro Leu Ser Tyr Pro Gln Thr Val Gly Glu Thr Tyr
 65 70 75 80
 Gly Lys Asp Ile Thr Ser Arg Gly Lys Asp Lys Pro Ile Ala Asp Val
 85 90 95
 Phe Leu Ile Cys Phe Ser Leu Val Ser Pro Ala Ser Phe Glu Asn Val
 100 105 110
 Arg Ala Lys Trp Tyr Pro Glu Val Arg His His Cys Pro Asn Thr Pro
 115 120 125
 Ile Ile Leu Val Gly Thr Lys Leu Asp Leu Arg Asp Asp Lys Asp Thr
 130 135 140
 Ile Glu Lys Leu Lys Glu Lys Lys Leu Thr Pro Ile Thr Tyr Pro Gln
 145 150 155 160
 Gly Leu Ala Met Ala Lys Glu Ile Gly Ala Val Lys Tyr Leu Glu Cys
 165 170 175
 Ser Ala Leu Thr Gln Arg Gly Leu Lys Thr Val Phe Asp Glu Ala Ile
 180 185 190
 Arg Ala Val Leu Cys Pro Pro Pro Val Lys Lys Arg Lys Arg Lys Cys
 195 200 205
 Leu Leu Leu
 210

<210> 25
 <211> 192

<212> PRT
<213> Homo sapiens

<400> 25

Met Gln Ala Ile Lys Cys Val Val Val Gly Asp Gly Ala Val Gly Lys
1 5 10 15
Thr Cys Leu Leu Ile Ser Tyr Thr Thr Asn Ala Phe Pro Gly Glu Tyr
20 25 30
Ile Pro Thr Val Phe Asp Asn Tyr Ser Ala Asn Val Met Val Asp Gly
35 40 45
Lys Pro Val Asn Leu Gly Leu Trp Asp Thr Ala Gly Gln Glu Asp Tyr
50 55 60
Asp Arg Leu Arg Pro Leu Ser Tyr Pro Gln Thr Asp Val Phe Leu Ile
65 70 75 80
Cys Phe Ser Leu Val Ser Pro Ala Ser Phe Glu Asn Val Arg Ala Lys
85 90 95
Trp Tyr Pro Glu Val Arg His His Cys Pro Asn Thr Pro Ile Ile Leu
100 105 110
Val Gly Thr Lys Leu Asp Leu Arg Asp Asp Lys Asp Thr Ile Glu Lys
115 120 125
Leu Lys Glu Lys Lys Leu Thr Pro Ile Thr Tyr Pro Gln Gly Leu Ala
130 135 140
Met Ala Lys Glu Ile Gly Ala Val Lys Tyr Leu Glu Cys Ser Ala Leu
145 150 155 160
Thr Gln Arg Gly Leu Lys Thr Val Phe Asp Glu Ala Ile Arg Ala Val
165 170 175
Leu Cys Pro Pro Pro Val Lys Lys Arg Lys Arg Lys Cys Leu Leu Leu
180 185 190

<210> 26
<211> 579
<212> DNA
<213> Homo sapiens

<400> 26

atgcaggcca tcaagtgtgt ggtggtggga gatggggccg tgggcaagac ctgccttctc 60
atcagctaca ccaccaacgc ctttcccggga gagtacatcc ccaccgtgtt tgacaactat 120
tcagccaatg tgatggtgga cagcaagcca gtgaacctgg ggctgtggga cactgctggg 180
caggaggact acgaccgtct ccggccgctc tcctatccac agacggacgt cttcctcatc 240
tgcttctccc tcgtcagccc agcctcttat gagaacgtcc gcgccaagtg gttcccagaa 300
gtgcggcacc actgccccag cacacccatc atcctggtgg gcaccaagct ggacctgcgg 360
gacgacaagg acaccatcga gaaactgaag gagaagaagc tggtctccat cacctacccg 420

cagggcctgg cactggccaa ggagattgac tcggtgaaat acctggagtg ctcagccctc 480
 acccagagag gcctgaaaac cgtgttcgac gaggccatcc gggccgtgct gtgccctcag 540
 cccacgcggc agcagaagcg cgcctgcagc ctcctctag 579

<210> 27
 <211> 192
 <212> PRT
 <213> Homo sapiens

<400> 27
 Met Gln Ala Ile Lys Cys Val Val Val Gly Asp Gly Ala Val Gly Lys
 1 5 10 15
 Thr Cys Leu Leu Ile Ser Tyr Thr Thr Asn Ala Phe Pro Gly Glu Tyr
 20 25 30
 Ile Pro Thr Val Phe Asp Asn Tyr Ser Ala Asn Val Met Val Asp Ser
 35 40 45
 Lys Pro Val Asn Leu Gly Leu Trp Asp Thr Ala Gly Gln Glu Asp Tyr
 50 55 60
 Asp Arg Leu Arg Pro Leu Ser Tyr Pro Gln Thr Asp Val Phe Leu Ile
 65 70 75 80
 Cys Phe Ser Leu Val Ser Pro Ala Ser Tyr Glu Asn Val Arg Ala Lys
 85 90 95
 Trp Phe Pro Glu Val Arg His His Cys Pro Ser Thr Pro Ile Ile Leu
 100 105 110
 Val Gly Thr Lys Leu Asp Leu Arg Asp Asp Lys Asp Thr Ile Glu Lys
 115 120 125
 Leu Lys Glu Lys Lys Leu Ala Pro Ile Thr Tyr Pro Gln Gly Leu Ala
 130 135 140
 Leu Ala Lys Glu Ile Asp Ser Val Lys Tyr Leu Glu Cys Ser Ala Leu
 145 150 155 160
 Thr Gln Arg Gly Leu Lys Thr Val Phe Asp Glu Ala Ile Arg Ala Val
 165 170 175
 Leu Cys Pro Gln Pro Thr Arg Gln Gln Lys Arg Ala Cys Ser Leu Leu
 180 185 190

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00618

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12Q 1/26, A61K 31/03, A61K 31/12, A61P 3/10
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12Q, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5763496 A (JAMES ARTHUR HOLLAND), 9 June 1998 (09.06.98), column 2, line 4 - line 8; column 10 --	1-26
X	US 5902831 A (JAMES ARTHUR HOLLAND ET AL), 11 May 1999 (11.05.99), column 14"conclusion", column 9 --	1-26
X	Diabetes, Vol. 49, November 2000, Toyoshi Inoguchi et al: "High Glucose Level and Free Fatty Acid Stimulate Reactive Oxygen Species Production Through Protein Kinase C-Dependent Activation of NAD(P)H Oxidase in Cultured Vascular Cells", page 1939 - page 1945, figure 3, page 1940 --	1-26

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier application or patent but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 "&" document member of the same patent family

Date of the actual completion of the international search

21 July 2003

Date of mailing of the international search report

22-07-2003

Name and mailing address of the ISA/

Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Carl-Olof Gustafsson/EÖ
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00618

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 017533 A1 (HENRY FORD HEALTH SYSTEM), 15 March 2001 (15.03.01), pages 6-8, page 8, lines 1-11, claims --	9,16
A	WO 9912539 A1 (THE JOHNS HOPKINS UNIVERSITY SCHOOL O MEDICINE), 18 March 1999 (18.03.99) --	9,16
A	US 2001019832 A1 (MARGUERITE LUTHMAN), 6 Sept 2001 (06.09.01), examples 1-4, claims -- -----	1-26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/00618

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 9-25
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/00618

Claims 9-25 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00618

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
US	5763496	A	09/06/98	AT	189957 T	15/03/00
				AU	1085997 A	19/06/97
				CA	2238098 A,C	05/06/97
				CA	2309881 A	05/06/97
				DE	69606882 D,T	17/08/00
				EP	0861070 A,B	02/09/98
				SE	0861070 T3	
				EP	0914821 A	12/05/99
				ES	2144792 T	16/06/00
				GR	3033067 T	31/08/00
				JP	11507946 T	13/07/99
				US	5902831 A	11/05/99
				WO	9719679 A	05/06/97

US	5902831	A	11/05/99	AT	189957 T	15/03/00
				AU	1085997 A	19/06/97
				CA	2238098 A,C	05/06/97
				CA	2309881 A	05/06/97
				DE	69606882 D,T	17/08/00
				EP	0861070 A,B	02/09/98
				SE	0861070 T3	
				EP	0914821 A	12/05/99
				ES	2144792 T	16/06/00
				GR	3033067 T	31/08/00
				JP	11507946 T	13/07/99
				US	5763496 A	09/06/98
				WO	9719679 A	05/06/97

WO	017533	A1	15/03/01	NONE		

WO	9912539	A1	18/03/99	AU	9226198 A	29/03/99
				US	6090851 A	18/07/00

US	2001019832	A1	06/09/01	AU	4131601 A	12/09/01
				AU	4632100 A	10/11/00
				CA	2399889 A	07/09/01
				EP	1181750 A	27/02/02
				EP	1259232 A	27/11/02
				JP	2002543597 T	17/12/02
				SE	0000718 D	00/00/00
				WO	0164209 A	07/09/01

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)